<?xml version="1.0"?>
<rdf:RDF xmlns="https://bio.scai.fraunhofer.de/ontology/CTO.owl#"
     xml:base="https://bio.scai.fraunhofer.de/ontology/CTO.owl"
     xmlns:dc="http://purl.org/dc/elements/1.1/"
     xmlns:obo="http://purl.obolibrary.org/obo/"
     xmlns:owl="http://www.w3.org/2002/07/owl#"
     xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
     xmlns:xml="http://www.w3.org/XML/1998/namespace"
     xmlns:xsd="http://www.w3.org/2001/XMLSchema#"
     xmlns:foaf="http://xmlns.com/foaf/0.1/"
     xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#"
     xmlns:terms="http://purl.org/dc/terms/"
     xmlns:protege="http://protege.stanford.edu/plugins/owl/protege#"
     xmlns:oboInOwl="http://www.geneontology.org/formats/oboInOwl#"
     xmlns:ncbitaxon="http://purl.obolibrary.org/obo/ncbitaxon#"
     xmlns:statistics="http://purl.org/net/OCRe/statistics.owl#"
     xmlns:study_protocol="http://purl.org/net/OCRe/study_protocol.owl#">
    <owl:Ontology rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO.owl">
        <dc:contributor>Asiyah Yu Lin (CDRH, Food and Drug Administration)</dc:contributor>
        <dc:contributor>Astghik Sargsyan (Fraunhofer SCAI)</dc:contributor>
        <dc:contributor>Geena Mariya Jose (Causality Biomodels)</dc:contributor>
        <dc:contributor>Leon Li (NIH)</dc:contributor>
        <dc:contributor>Oliver He (University of Michigan)</dc:contributor>
        <dc:contributor>Shounak Baksi (Causality Biomodels)</dc:contributor>
        <dc:description rdf:datatype="http://www.w3.org/1999/02/22-rdf-syntax-ns#langString">The core Ontology of Clinical Trials (CTO) will serve as a structured resource integrating basic terms and concepts in the context of clinical trials. Thereby covering clinicaltrails.gov. CoreCTO will serve as a basic ontology to generate extended versions for specific applications such as annotation of variables in study documents from clinical trials.</dc:description>
        <terms:creator>Alpha Tom Kodamullil (Fraunhofer SCAI)</terms:creator>
        <terms:creator>Johannes Darms (Fraunhofer SCAI)</terms:creator>
        <terms:creator>Stephan Gebel (Fraunhofer SCAI)</terms:creator>
        <terms:creator>Sumit Madan (Fraunhofer SCAI)</terms:creator>
        <terms:license>http://creativecommons.org/licenses/by/4.0</terms:license>
        <terms:title>CTO: Core Ontology of Clinical Trials</terms:title>
        <owl:versionInfo>Version Release: 1.0.0</owl:versionInfo>
    </owl:Ontology>
    


    <!-- 
    ///////////////////////////////////////////////////////////////////////////////////////
    //
    // Annotation properties
    //
    ///////////////////////////////////////////////////////////////////////////////////////
     -->

    


    <!-- http://protege.stanford.edu/plugins/owl/protege#readOnly -->

    <owl:AnnotationProperty rdf:about="http://protege.stanford.edu/plugins/owl/protege#readOnly">
        <rdfs:range rdf:resource="http://www.w3.org/2001/XMLSchema#boolean"/>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/BFO_0000179 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/BFO_0000179">
        <obo:IAO_0000111 xml:lang="en">BFO OWL specification label</obo:IAO_0000111>
        <obo:IAO_0000115 xml:lang="en">Relates an entity in the ontology to the name of the variable that is used to represent it in the code that generates the BFO OWL file from the lispy specification.</obo:IAO_0000115>
        <obo:IAO_0000232 xml:lang="en">Really of interest to developers only</obo:IAO_0000232>
        <rdfs:label>BFO OWL specification label</rdfs:label>
        <rdfs:label xml:lang="en">BFO OWL specification label</rdfs:label>
        <rdfs:subPropertyOf rdf:resource="http://www.w3.org/2000/01/rdf-schema#label"/>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/BFO_0000180 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/BFO_0000180">
        <obo:IAO_0000111 xml:lang="en">BFO CLIF specification label</obo:IAO_0000111>
        <obo:IAO_0000115 xml:lang="en">Relates an entity in the ontology to the term that is used to represent it in the the CLIF specification of BFO2</obo:IAO_0000115>
        <obo:IAO_0000119>Person:Alan Ruttenberg</obo:IAO_0000119>
        <obo:IAO_0000232 xml:lang="en">Really of interest to developers only</obo:IAO_0000232>
        <rdfs:label>BFO CLIF specification label</rdfs:label>
        <rdfs:label xml:lang="en">BFO CLIF specification label</rdfs:label>
        <rdfs:subPropertyOf rdf:resource="http://www.w3.org/2000/01/rdf-schema#label"/>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/IAO_0000111 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/IAO_0000111">
        <obo:IAO_0000111>editor preferred label</obo:IAO_0000111>
        <obo:IAO_0000111 xml:lang="en">editor preferred label</obo:IAO_0000111>
        <obo:IAO_0000111>editor preferred term</obo:IAO_0000111>
        <obo:IAO_0000111 xml:lang="en">editor preferred term</obo:IAO_0000111>
        <obo:IAO_0000111>editor preferred term~editor preferred label</obo:IAO_0000111>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000122"/>
        <obo:IAO_0000115 xml:lang="en">The concise, meaningful, and human-friendly name for a class or property preferred by the ontology developers. (US-English)</obo:IAO_0000115>
        <obo:IAO_0000117 xml:lang="en">PERSON:Daniel Schober</obo:IAO_0000117>
        <obo:IAO_0000119 xml:lang="en">GROUP:OBI:&lt;http://purl.obolibrary.org/obo/obi&gt;</obo:IAO_0000119>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/iao.owl"/>
        <rdfs:label>editor preferred label</rdfs:label>
        <rdfs:label xml:lang="en">editor preferred label</rdfs:label>
        <rdfs:label>editor preferred term</rdfs:label>
        <rdfs:label xml:lang="en">editor preferred term</rdfs:label>
        <rdfs:label>editor preferred term~editor preferred label</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/IAO_0000112 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/IAO_0000112">
        <obo:IAO_0000111 xml:lang="en">example</obo:IAO_0000111>
        <obo:IAO_0000111 xml:lang="en">example of usage</obo:IAO_0000111>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000122"/>
        <obo:IAO_0000115 xml:lang="en">A phrase describing how a class name should be used. May also include other kinds of examples that facilitate immediate understanding of a class semantics, such as widely known prototypical subclasses or instances of the class. Although essential for high level terms, examples for low level terms (e.g., Affymetrix HU133 array) are not</obo:IAO_0000115>
        <obo:IAO_0000115 xml:lang="en">A phrase describing how a term should be used and/or a citation to a work which uses it. May also include other kinds of examples that facilitate immediate understanding, such as widely know prototypes or instances of a class, or cases where a relation is said to hold.</obo:IAO_0000115>
        <obo:IAO_0000117 xml:lang="en">PERSON:Daniel Schober</obo:IAO_0000117>
        <obo:IAO_0000119 xml:lang="en">GROUP:OBI:&lt;http://purl.obolibrary.org/obo/obi&gt;</obo:IAO_0000119>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/iao.owl"/>
        <rdfs:label>example of usage</rdfs:label>
        <rdfs:label xml:lang="en">example of usage</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/IAO_0000114 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/IAO_0000114">
        <obo:IAO_0000111 xml:lang="en">has curation status</obo:IAO_0000111>
        <obo:IAO_0000117 xml:lang="en">PERSON:Alan Ruttenberg</obo:IAO_0000117>
        <obo:IAO_0000117 xml:lang="en">PERSON:Bill Bug</obo:IAO_0000117>
        <obo:IAO_0000117 xml:lang="en">PERSON:Melanie Courtot</obo:IAO_0000117>
        <obo:IAO_0000119 xml:lang="en">OBI_0000281</obo:IAO_0000119>
        <rdfs:label>has curation status</rdfs:label>
        <rdfs:label xml:lang="en">has curation status</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/IAO_0000115 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/IAO_0000115">
        <obo:IAO_0000111 xml:lang="en">definition</obo:IAO_0000111>
        <obo:IAO_0000111 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">definition</obo:IAO_0000111>
        <obo:IAO_0000111 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">textual definition</obo:IAO_0000111>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000122"/>
        <obo:IAO_0000115>A property representing the English language definitions of what NCI means by the concept. They may also include information about the definition&apos;s source and attribution in a form that can easily be interpreted by software.</obo:IAO_0000115>
        <obo:IAO_0000115>English language definitions of what NCI means by the concept. These are limited to 1024 characters. They may also include information about the definition&apos;s source and attribution in a form that can easily be interpreted by software.</obo:IAO_0000115>
        <obo:IAO_0000115 xml:lang="en">The official OBI definition, explaining the meaning of a class or property. Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions.</obo:IAO_0000115>
        <obo:IAO_0000115 xml:lang="en">The official definition, explaining the meaning of a class or property. Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions.</obo:IAO_0000115>
        <obo:IAO_0000116 xml:lang="en">2012-04-05:
Barry Smith

The official OBI definition, explaining the meaning of a class or property: &apos;Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions&apos;  is terrible.

Can you fix to something like:

A statement of necessary and sufficient conditions explaining the meaning of an expression referring to a class or property.

Alan Ruttenberg

Your proposed definition is a reasonable candidate, except that it is very common that necessary and sufficient conditions are not given. Mostly they are necessary, occasionally they are necessary and sufficient or just sufficient. Often they use terms that are not themselves defined and so they effectively can&apos;t be evaluated by those criteria.

On the specifics of the proposed definition:

We don&apos;t have definitions of &apos;meaning&apos; or &apos;expression&apos; or &apos;property&apos;. For &apos;reference&apos; in the intended sense I think we use the term &apos;denotation&apos;. For &apos;expression&apos;, I think we you mean symbol, or identifier. For &apos;meaning&apos; it differs for class and property. For class we want documentation that let&apos;s the intended reader determine whether an entity is instance of the class, or not. For property we want documentation that let&apos;s the intended reader determine, given a pair of potential relata, whether the assertion that the relation holds is true. The &apos;intended reader&apos; part suggests that we also specify who, we expect, would be able to understand the definition, and also generalizes over human and computer reader to include textual and logical definition.

Personally, I am more comfortable weakening definition to documentation, with instructions as to what is desirable.

We also have the outstanding issue of how to aim different definitions to different audiences. A clinical audience reading chebi wants a different sort of definition documentation/definition from a chemistry trained audience, and similarly there is a need for a definition that is adequate for an ontologist to work with.  </obo:IAO_0000116>
        <obo:IAO_0000116 xml:lang="en">2012-04-05: 
Barry Smith

The official OBI definition, explaining the meaning of a class or property: &apos;Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions&apos;  is terrible.

Can you fix to something like:

A statement of necessary and sufficient conditions explaining the meaning of an expression referring to a class or property.

Alan Ruttenberg

Your proposed definition is a reasonable candidate, except that it is very common that necessary and sufficient conditions are not given. Mostly they are necessary, occasionally they are necessary and sufficient or just sufficient. Often they use terms that are not themselves defined and so they effectively can&apos;t be evaluated by those criteria. 

On the specifics of the proposed definition:

We don&apos;t have definitions of &apos;meaning&apos; or &apos;expression&apos; or &apos;property&apos;. For &apos;reference&apos; in the intended sense I think we use the term &apos;denotation&apos;. For &apos;expression&apos;, I think we you mean symbol, or identifier. For &apos;meaning&apos; it differs for class and property. For class we want documentation that let&apos;s the intended reader determine whether an entity is instance of the class, or not. For property we want documentation that let&apos;s the intended reader determine, given a pair of potential relata, whether the assertion that the relation holds is true. The &apos;intended reader&apos; part suggests that we also specify who, we expect, would be able to understand the definition, and also generalizes over human and computer reader to include textual and logical definition. 

Personally, I am more comfortable weakening definition to documentation, with instructions as to what is desirable. 

We also have the outstanding issue of how to aim different definitions to different audiences. A clinical audience reading chebi wants a different sort of definition documentation/definition from a chemistry trained audience, and similarly there is a need for a definition that is adequate for an ontologist to work with.  </obo:IAO_0000116>
        <obo:IAO_0000117 xml:lang="en">PERSON:Daniel Schober</obo:IAO_0000117>
        <obo:IAO_0000119 xml:lang="en">GROUP:OBI:&lt;http://purl.obolibrary.org/obo/obi&gt;</obo:IAO_0000119>
        <oboInOwl:hasExactSynonym>DEFINITION</oboInOwl:hasExactSynonym>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/iao.owl"/>
        <rdfs:label xml:lang="en">definition</rdfs:label>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">definition</rdfs:label>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">textual definition</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/IAO_0000116 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/IAO_0000116">
        <obo:IAO_0000111 xml:lang="en">editor note</obo:IAO_0000111>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000122"/>
        <obo:IAO_0000115 xml:lang="en">An administrative note intended for its editor. It may not be included in the publication version of the ontology, so it should contain nothing necessary for end users to understand the ontology.</obo:IAO_0000115>
        <obo:IAO_0000117 xml:lang="en">PERSON:Daniel Schober</obo:IAO_0000117>
        <obo:IAO_0000119 xml:lang="en">GROUP:OBI:&lt;http://purl.obfoundry.org/obo/obi&gt;</obo:IAO_0000119>
        <oboInOwl:hasDbXref rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IAO:0000116</oboInOwl:hasDbXref>
        <oboInOwl:hasOBONamespace rdf:datatype="http://www.w3.org/2001/XMLSchema#string">uberon</oboInOwl:hasOBONamespace>
        <oboInOwl:id rdf:datatype="http://www.w3.org/2001/XMLSchema#string">editor_note</oboInOwl:id>
        <oboInOwl:is_metadata_tag rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</oboInOwl:is_metadata_tag>
        <oboInOwl:shorthand rdf:datatype="http://www.w3.org/2001/XMLSchema#string">editor_note</oboInOwl:shorthand>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/iao.owl"/>
        <rdfs:label>editor note</rdfs:label>
        <rdfs:label xml:lang="en">editor note</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/IAO_0000117 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/IAO_0000117">
        <obo:IAO_0000111 xml:lang="en">definition editor</obo:IAO_0000111>
        <obo:IAO_0000111 xml:lang="en">term editor</obo:IAO_0000111>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000122"/>
        <obo:IAO_0000115 xml:lang="en">Name of editor entering the definition in the file. The definition editor is a point of contact for information regarding the term. The definition editor may be, but is not always, the author of the definition, which may have been worked upon by several people</obo:IAO_0000115>
        <obo:IAO_0000115 xml:lang="en">Name of editor entering the term in the file. The term editor is a point of contact for information regarding the term. The term editor may be, but is not always, the author of the definition, which may have been worked upon by several people</obo:IAO_0000115>
        <obo:IAO_0000116 xml:lang="en">20110707, MC: label update to term editor and definition modified accordingly. See http://code.google.com/p/information-artifact-ontology/issues/detail?id=115.</obo:IAO_0000116>
        <obo:IAO_0000116 xml:lang="en">20110707, MC: label update to term editor and definition modified accordingly. See https://github.com/information-artifact-ontology/IAO/issues/115.</obo:IAO_0000116>
        <obo:IAO_0000117 xml:lang="en">PERSON:Daniel Schober</obo:IAO_0000117>
        <obo:IAO_0000119 xml:lang="en">GROUP:OBI:&lt;http://purl.obolibrary.org/obo/obi&gt;</obo:IAO_0000119>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/iao.owl"/>
        <rdfs:label>definition editor</rdfs:label>
        <rdfs:label xml:lang="en">definition editor</rdfs:label>
        <rdfs:label>term editor</rdfs:label>
        <rdfs:label xml:lang="en">term editor</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/IAO_0000118 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/IAO_0000118">
        <obo:IAO_0000111 xml:lang="en">alternative term</obo:IAO_0000111>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000125"/>
        <obo:IAO_0000115 xml:lang="en">An alternative name for a class or property which means the same thing as the preferred name (semantically equivalent)</obo:IAO_0000115>
        <obo:IAO_0000117 xml:lang="en">PERSON:Daniel Schober</obo:IAO_0000117>
        <obo:IAO_0000119 xml:lang="en">GROUP:OBI:&lt;http://purl.obolibrary.org/obo/obi&gt;</obo:IAO_0000119>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/iao.owl"/>
        <rdfs:label>alternative term</rdfs:label>
        <rdfs:label xml:lang="en">alternative term</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/IAO_0000119 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/IAO_0000119">
        <obo:IAO_0000111 xml:lang="en">definition source</obo:IAO_0000111>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000122"/>
        <obo:IAO_0000115 xml:lang="en">formal citation, e.g. identifier in external database to indicate / attribute source(s) for the definition. Free text indicate / attribute source(s) for the definition. EXAMPLE: Author Name, URI, MeSH Term C04, PUBMED ID, Wiki uri on 31.01.2007</obo:IAO_0000115>
        <obo:IAO_0000117 xml:lang="en">PERSON:Daniel Schober</obo:IAO_0000117>
        <obo:IAO_0000119 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Discussion on obo-discuss mailing-list, see http://bit.ly/hgm99w</obo:IAO_0000119>
        <obo:IAO_0000119 xml:lang="en">GROUP:OBI:&lt;http://purl.obolibrary.org/obo/obi&gt;</obo:IAO_0000119>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/iao.owl"/>
        <rdfs:label>definition source</rdfs:label>
        <rdfs:label xml:lang="en">definition source</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/IAO_0000232 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/IAO_0000232">
        <obo:IAO_0000111 xml:lang="en">curator note</obo:IAO_0000111>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000122"/>
        <obo:IAO_0000115 xml:lang="en">An administrative note of use for a curator but of no use for a user</obo:IAO_0000115>
        <obo:IAO_0000117 xml:lang="en">PERSON:Alan Ruttenberg</obo:IAO_0000117>
        <oboInOwl:hasDbXref rdf:datatype="http://www.w3.org/2001/XMLSchema#string">IAO:0000232</oboInOwl:hasDbXref>
        <oboInOwl:hasOBONamespace rdf:datatype="http://www.w3.org/2001/XMLSchema#string">uberon</oboInOwl:hasOBONamespace>
        <oboInOwl:id rdf:datatype="http://www.w3.org/2001/XMLSchema#string">curator_notes</oboInOwl:id>
        <oboInOwl:is_metadata_tag rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</oboInOwl:is_metadata_tag>
        <oboInOwl:shorthand rdf:datatype="http://www.w3.org/2001/XMLSchema#string">curator_notes</oboInOwl:shorthand>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/iao.owl"/>
        <rdfs:label>curator note</rdfs:label>
        <rdfs:label xml:lang="en">curator note</rdfs:label>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">curator notes</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/IAO_0000233 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/IAO_0000233">
        <obo:IAO_0000111>term tracker item</obo:IAO_0000111>
        <obo:IAO_0000112>the URI for an OBI Terms ticket at sourceforge, such as https://sourceforge.net/p/obi/obi-terms/772/</obo:IAO_0000112>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000125"/>
        <obo:IAO_0000115>An IRI or similar locator for a request or discussion of an ontology term.</obo:IAO_0000115>
        <obo:IAO_0000117>Person: Jie Zheng, Chris Stoeckert, Alan Ruttenberg</obo:IAO_0000117>
        <obo:IAO_0000119>Person: Jie Zheng, Chris Stoeckert, Alan Ruttenberg</obo:IAO_0000119>
        <rdfs:comment>The &apos;tracker item&apos; can associate a tracker with a specific ontology term.</rdfs:comment>
        <rdfs:label xml:lang="en">term tracker item</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/IAO_0000412 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/IAO_0000412">
        <obo:IAO_0000111 xml:lang="en">imported from</obo:IAO_0000111>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000125"/>
        <obo:IAO_0000115 xml:lang="en">For external terms/classes, the ontology from which the term was imported</obo:IAO_0000115>
        <obo:IAO_0000117 xml:lang="en">PERSON:Alan Ruttenberg</obo:IAO_0000117>
        <obo:IAO_0000117 xml:lang="en">PERSON:Melanie Courtot</obo:IAO_0000117>
        <obo:IAO_0000119 xml:lang="en">GROUP:OBI:&lt;http://purl.obolibrary.org/obo/obi&gt;</obo:IAO_0000119>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/iao.owl"/>
        <rdfs:label>imported from</rdfs:label>
        <rdfs:label xml:lang="en">imported from</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/IAO_0000600 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/IAO_0000600">
        <obo:IAO_0000111 xml:lang="en">elucidation</obo:IAO_0000111>
        <obo:IAO_0000117 xml:lang="en">person:Alan Ruttenberg</obo:IAO_0000117>
        <obo:IAO_0000119 xml:lang="en">Person:Barry Smith</obo:IAO_0000119>
        <obo:IAO_0000600 xml:lang="en">Primitive terms in a highest-level ontology such as BFO are terms which are so basic to our understanding of reality that there is no way of defining them in a non-circular fashion. For these, therefore, we can provide only elucidations, supplemented by examples and by axioms</obo:IAO_0000600>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/iao.owl"/>
        <rdfs:label>elucidation</rdfs:label>
        <rdfs:label xml:lang="en">elucidation</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/IAO_0000601 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/IAO_0000601">
        <obo:IAO_0000111 xml:lang="en">has associated axiom(nl)</obo:IAO_0000111>
        <obo:IAO_0000117 xml:lang="en">Person:Alan Ruttenberg</obo:IAO_0000117>
        <obo:IAO_0000119 xml:lang="en">Person:Alan Ruttenberg</obo:IAO_0000119>
        <obo:IAO_0000600 xml:lang="en">An axiom associated with a term expressed using natural language</obo:IAO_0000600>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/iao.owl"/>
        <rdfs:label>has associated axiom(nl)</rdfs:label>
        <rdfs:label xml:lang="en">has associated axiom(nl)</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/IAO_0000602 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/IAO_0000602">
        <obo:IAO_0000111 xml:lang="en">has associated axiom(fol)</obo:IAO_0000111>
        <obo:IAO_0000117 xml:lang="en">Person:Alan Ruttenberg</obo:IAO_0000117>
        <obo:IAO_0000119 xml:lang="en">Person:Alan Ruttenberg</obo:IAO_0000119>
        <obo:IAO_0000600 xml:lang="en">An axiom expressed in first order logic using CLIF syntax</obo:IAO_0000600>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/iao.owl"/>
        <rdfs:label>has associated axiom(fol)</rdfs:label>
        <rdfs:label xml:lang="en">has associated axiom(fol)</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/IAO_0010000 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/IAO_0010000">
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/iao.owl"/>
        <rdfs:label xml:lang="en">has axiom label</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_A11 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/NCIT_A11">
        <obo:IAO_0000115>A property created to allow the source NICHD to assign a parent to each concept with the intent of creating a hierarchy that includes only terms in which they are the contributing source.</obo:IAO_0000115>
        <obo:IAO_0000115>An association created to allow the source NICHD to assign a parent to each concept with the intent of creating a hierarchy that includes only terms in which they are a contributing source.</obo:IAO_0000115>
        <obo:NCIT_NHC0>A11</obo:NCIT_NHC0>
        <obo:NCIT_P106>Conceptual Entity</obo:NCIT_P106>
        <obo:NCIT_P108>Has_NICHD_Parent</obo:NCIT_P108>
        <oboInOwl:hasExactSynonym>Has_NICHD_Parent</oboInOwl:hasExactSynonym>
        <rdfs:label>Has_NICHD_Parent</rdfs:label>
        <rdfs:range rdf:resource="http://www.w3.org/2001/XMLSchema#anyURI"/>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_NHC0 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/NCIT_NHC0">
        <protege:readOnly>true</protege:readOnly>
        <obo:IAO_0000115>A property representing a concept unique identifier within the NCI Enterprise Vocabulary Service&apos;s NCI Thesaurus.</obo:IAO_0000115>
        <obo:NCIT_NHC0>NHC0</obo:NCIT_NHC0>
        <obo:NCIT_P108>code</obo:NCIT_P108>
        <oboInOwl:hasExactSynonym>code</oboInOwl:hasExactSynonym>
        <rdfs:label>code</rdfs:label>
        <rdfs:range rdf:resource="http://www.w3.org/2001/XMLSchema#string"/>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_P106 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/NCIT_P106">
        <obo:IAO_0000115>A property that represents a description of the sort of thing or category to which a concept belongs in the context of the UMLS semantic network.</obo:IAO_0000115>
        <obo:IAO_0000115>The semantic type describes the sort of thing or category to which a concept belongs in the context of the UMLS semantic network.</obo:IAO_0000115>
        <obo:NCIT_NHC0>P106</obo:NCIT_NHC0>
        <obo:NCIT_P106>Conceptual Entity</obo:NCIT_P106>
        <obo:NCIT_P107>Semantic Type</obo:NCIT_P107>
        <obo:NCIT_P108>Semantic_Type</obo:NCIT_P108>
        <obo:NCIT_P98>In general, applying semantic types aids in allowing users (or computer programs) to draw conclusions about concepts by virtue of the categories to which they have been assigned.  We use a set of semantic types developed for the UMLS Metathesaurus. There are currently 134 semantic types in the UMLS.</obo:NCIT_P98>
        <oboInOwl:hasExactSynonym>Semantic_Type</oboInOwl:hasExactSynonym>
        <rdfs:label>Semantic_Type</rdfs:label>
        <rdfs:range rdf:resource="http://purl.obolibrary.org/obo/NCIT_Semantic_Type-enum"/>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_P107 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/NCIT_P107">
        <obo:IAO_0000115>A property representing an alternative Preferred Name for use in some NCI systems.</obo:IAO_0000115>
        <obo:IAO_0000115>Provides an alternative Preferred Name for use in some NCI systems.</obo:IAO_0000115>
        <obo:NCIT_NHC0>P107</obo:NCIT_NHC0>
        <obo:NCIT_P106>Conceptual Entity</obo:NCIT_P106>
        <obo:NCIT_P107>Display Name</obo:NCIT_P107>
        <obo:NCIT_P108>Display_Name</obo:NCIT_P108>
        <oboInOwl:hasExactSynonym>Display Name</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Display_Name</oboInOwl:hasExactSynonym>
        <rdfs:label>Display_Name</rdfs:label>
        <rdfs:range rdf:resource="http://www.w3.org/2001/XMLSchema#string"/>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_P108 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/NCIT_P108">
        <obo:IAO_0000115>A property representing the word or phrase that NCI uses by preference to refer to the concept.</obo:IAO_0000115>
        <obo:IAO_0000115>The word or phrase that NCI uses by preference to refer to the concept.</obo:IAO_0000115>
        <obo:NCIT_NHC0>P108</obo:NCIT_NHC0>
        <obo:NCIT_P106>Conceptual Entity</obo:NCIT_P106>
        <obo:NCIT_P107>Preferred Name</obo:NCIT_P107>
        <obo:NCIT_P108>Preferred_Name</obo:NCIT_P108>
        <oboInOwl:hasExactSynonym>Preferred Name</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Preferred Term</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Preferred_Name</oboInOwl:hasExactSynonym>
        <rdfs:label>Preferred_Name</rdfs:label>
        <rdfs:range rdf:resource="http://www.w3.org/2001/XMLSchema#string"/>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_P207 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/NCIT_P207">
        <obo:IAO_0000115>A property representing the concept unique identifier (CUI) assigned by the National Library of Medicine (NLM). If a concept in any NCI-maintained knowledgebase exists in the NLM Unified Medical Language System (UMLS), NCI includes the NLM CUI among the information we provide about the concept.</obo:IAO_0000115>
        <obo:IAO_0000115>Concept Unique Identifiers, or CUIs, are concept numbers assigned by the National Library of Medicine (NLM). If a concept in any NCI-maintained knowledgebase exists in the NLM Unified Medical Language System (UMLS), NCI includes the NLM CUI among the information we provide about the concept.</obo:IAO_0000115>
        <obo:NCIT_NHC0>P207</obo:NCIT_NHC0>
        <obo:NCIT_P106>Conceptual Entity</obo:NCIT_P106>
        <obo:NCIT_P107>UMLS CUI</obo:NCIT_P107>
        <obo:NCIT_P108>UMLS_CUI</obo:NCIT_P108>
        <oboInOwl:hasExactSynonym>UMLS_CUI</oboInOwl:hasExactSynonym>
        <rdfs:label>UMLS_CUI</rdfs:label>
        <rdfs:range rdf:resource="http://www.w3.org/2001/XMLSchema#string"/>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_P208 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/NCIT_P208">
        <obo:IAO_0000115>A property representing the concept unique identifier (CUI) for those concepts that appear in NCI Metathesaurus but not in the National Library of Medicine Unified Medical Language System (NLM UMLS).</obo:IAO_0000115>
        <obo:NCIT_NHC0>P208</obo:NCIT_NHC0>
        <obo:NCIT_P106>Conceptual Entity</obo:NCIT_P106>
        <obo:NCIT_P107>NCI Metathesaurus CUI</obo:NCIT_P107>
        <obo:NCIT_P108>NCI_META_CUI</obo:NCIT_P108>
        <oboInOwl:hasExactSynonym>NCI_META_CUI</oboInOwl:hasExactSynonym>
        <rdfs:label>NCI_META_CUI</rdfs:label>
        <rdfs:range rdf:resource="http://www.w3.org/2001/XMLSchema#string"/>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_P322 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/NCIT_P322">
        <obo:IAO_0000115>A property is used to indicate when a non-EVS entity has contributed to, and has a stake in, a concept. This is used where such entities, within or outside NCI, have indicated the need to be able to track their own concepts. A single concept can have multiple instances of this property if multiple entities have such a defined stake.</obo:IAO_0000115>
        <obo:IAO_0000115>This property is used to indicate when a non-EVS entity has contributed to, and has a stake in, a concept.  This is used where such entities, within or outside NCI, have indicated the need to be able to track their own concepts. A single concept can have multiple instances of this property if multiple entities have such a defined stake.</obo:IAO_0000115>
        <obo:NCIT_NHC0>P322</obo:NCIT_NHC0>
        <obo:NCIT_P106>Conceptual Entity</obo:NCIT_P106>
        <obo:NCIT_P107>Contributing Source</obo:NCIT_P107>
        <obo:NCIT_P108>Contributing_Source</obo:NCIT_P108>
        <oboInOwl:hasExactSynonym>Contributing_Source</oboInOwl:hasExactSynonym>
        <rdfs:label>Contributing_Source</rdfs:label>
        <rdfs:range rdf:resource="http://purl.obolibrary.org/obo/NCIT_Contributing_Source-enum"/>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_P325 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/NCIT_P325">
        <obo:IAO_0000115>A property representing the English language definition of a concept from a source other than NCI.</obo:IAO_0000115>
        <obo:IAO_0000115>English language definitions of what a source other than NCI means by the concept. These are limited to 1024 characters. They include information about the definition&apos;s source in a form that can easily be interpreted by software.</obo:IAO_0000115>
        <obo:NCIT_NHC0>P325</obo:NCIT_NHC0>
        <obo:NCIT_P106>Conceptual Entity</obo:NCIT_P106>
        <obo:NCIT_P107>[source] Definition</obo:NCIT_P107>
        <obo:NCIT_P108>ALT_DEFINITION</obo:NCIT_P108>
        <oboInOwl:hasExactSynonym>ALT_DEFINITION</oboInOwl:hasExactSynonym>
        <rdfs:label>ALT_DEFINITION</rdfs:label>
        <rdfs:range rdf:resource="http://purl.obolibrary.org/obo/NCIT_textArea"/>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_P366 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/NCIT_P366">
        <protege:readOnly>true</protege:readOnly>
        <obo:IAO_0000115>A property representing a retired unique concept identifier created and stored as Concept Name by legacy EVS software. Use of these values was long discouraged, but continued as late as 2009 when creation of new values ceased and Concept Name was retired. Legacy values are intended solely to help resolve and update earlier coding.</obo:IAO_0000115>
        <obo:IAO_0000115>A retired unique concept identifier created and stored as Concept Name by legacy EVS software.  Use of these values was long discouraged, but continued as late as 2009 when creation of new values ceased and Concept Name was retired.  Legacy values are intended solely to help resolve and update earlier coding.</obo:IAO_0000115>
        <obo:NCIT_NHC0>P366</obo:NCIT_NHC0>
        <obo:NCIT_P106>Conceptual Entity</obo:NCIT_P106>
        <obo:NCIT_P108>Legacy Concept Name</obo:NCIT_P108>
        <oboInOwl:hasExactSynonym>Legacy Concept Name</oboInOwl:hasExactSynonym>
        <rdfs:label>Legacy_Concept_Name</rdfs:label>
        <rdfs:range rdf:resource="http://www.w3.org/2001/XMLSchema#string"/>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_P371 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/NCIT_P371">
        <obo:IAO_0000115>A property representing a term chosen by NICHD to be used in the representation of the NICHD hierarchy.</obo:IAO_0000115>
        <obo:NCIT_NHC0>P371</obo:NCIT_NHC0>
        <obo:NCIT_P106>Conceptual Entity</obo:NCIT_P106>
        <obo:NCIT_P108>NICHD_Hierarchy_Term</obo:NCIT_P108>
        <obo:NCIT_P322>NICHD</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>NICHD_Hierarchy_Term</oboInOwl:hasExactSynonym>
        <rdfs:label>NICHD_Hierarchy_Term</rdfs:label>
        <rdfs:range rdf:resource="http://www.w3.org/2001/XMLSchema#string"/>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_P375 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/NCIT_P375">
        <obo:IAO_0000115>A property representing that a term in another terminology has been mapped to a term in NCIt and describes the relationship between the mapped terms.</obo:IAO_0000115>
        <obo:NCIT_NHC0>P375</obo:NCIT_NHC0>
        <obo:NCIT_P106>Conceptual Entity</obo:NCIT_P106>
        <obo:NCIT_P108>Maps_To</obo:NCIT_P108>
        <oboInOwl:hasExactSynonym>Maps_To</oboInOwl:hasExactSynonym>
        <rdfs:label>Maps_To</rdfs:label>
        <rdfs:range rdf:resource="http://purl.obolibrary.org/obo/NCIT_textArea"/>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_P98 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/NCIT_P98">
        <obo:IAO_0000115>A property representing notations made by NCI vocabulary curators. They are intended to provide supplemental, unstructured information to the user or additional insight about the concept.</obo:IAO_0000115>
        <obo:IAO_0000115>Design notes are notations made by NCI vocabulary curators. They are intended to provide supplemental, unstructured information to the user or additional insight about the concept.</obo:IAO_0000115>
        <obo:NCIT_NHC0>P98</obo:NCIT_NHC0>
        <obo:NCIT_P106>Conceptual Entity</obo:NCIT_P106>
        <obo:NCIT_P107>DesignNote</obo:NCIT_P107>
        <obo:NCIT_P108>DesignNote</obo:NCIT_P108>
        <oboInOwl:hasExactSynonym>DesignNote</oboInOwl:hasExactSynonym>
        <rdfs:label>DesignNote</rdfs:label>
        <rdfs:range rdf:resource="http://www.w3.org/2001/XMLSchema#string"/>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/OBI_0001847 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/OBI_0001847">
        <obo:IAO_0000111 xml:lang="en">ISA alternative term</obo:IAO_0000111>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000122"/>
        <obo:IAO_0000115>An alternative term used by the ISA tools project (http://isa-tools.org).</obo:IAO_0000115>
        <obo:IAO_0000116>Requested by Alejandra Gonzalez-Beltran
https://sourceforge.net/tracker/?func=detail&amp;aid=3603413&amp;group_id=177891&amp;atid=886178</obo:IAO_0000116>
        <obo:IAO_0000117>Person: Alejandra Gonzalez-Beltran</obo:IAO_0000117>
        <obo:IAO_0000117>Person: Philippe Rocca-Serra</obo:IAO_0000117>
        <obo:IAO_0000119>ISA tools project (http://isa-tools.org)</obo:IAO_0000119>
        <rdfs:label xml:lang="en">ISA alternative term</rdfs:label>
        <rdfs:subPropertyOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000118"/>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/OBI_0001886 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/OBI_0001886">
        <obo:IAO_0000111 xml:lang="en">NIAID GSCID-BRC alternative term</obo:IAO_0000111>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000122"/>
        <obo:IAO_0000115>An alternative term used by the National Institute of Allergy and Infectious Diseases (NIAID) Genomic Sequencing Centers for Infectious Diseases (GSCID) and Bioinformatics Resource Centers (BRC).</obo:IAO_0000115>
        <obo:IAO_0000117>PERSON: Chris Stoeckert, Jie Zheng</obo:IAO_0000117>
        <obo:IAO_0000119>NIAID GSCID-BRC metadata working group</obo:IAO_0000119>
        <rdfs:label xml:lang="en">NIAID GSCID-BRC alternative term</rdfs:label>
        <rdfs:subPropertyOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000118"/>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/OPMI_0000364 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/OPMI_0000364">
        <obo:IAO_0000115>An annotation property that refers to a code defined by NCIT</obo:IAO_0000115>
        <rdfs:label xml:lang="en">NCIT code</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/ncbitaxon#has_rank -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/ncbitaxon#has_rank">
        <obo:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A metadata relation between a class and its taxonomic rank (eg species, family)</obo:IAO_0000115>
        <oboInOwl:hasOBONamespace rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ncbi_taxonomy</oboInOwl:hasOBONamespace>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">has_rank</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://purl.org/dc/elements/1.1/contributor -->

    <owl:AnnotationProperty rdf:about="http://purl.org/dc/elements/1.1/contributor"/>
    


    <!-- http://purl.org/dc/elements/1.1/creator -->

    <owl:AnnotationProperty rdf:about="http://purl.org/dc/elements/1.1/creator"/>
    


    <!-- http://purl.org/dc/elements/1.1/description -->

    <owl:AnnotationProperty rdf:about="http://purl.org/dc/elements/1.1/description">
        <dc:description xml:lang="en-us">Description may include but is not limited to: an abstract,
         table of contents, reference to a graphical representation
         of content or a free-text account of the content.</dc:description>
        <rdfs:comment xml:lang="en-us">An account of the content of the resource.</rdfs:comment>
        <rdfs:isDefinedBy rdf:resource="http://purl.org/dc/elements/1.1/"/>
        <rdfs:label>Description</rdfs:label>
        <rdfs:label xml:lang="en-us">Description</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://purl.org/dc/elements/1.1/member -->

    <owl:AnnotationProperty rdf:about="http://purl.org/dc/elements/1.1/member"/>
    


    <!-- http://purl.org/dc/elements/1.1/source -->

    <owl:AnnotationProperty rdf:about="http://purl.org/dc/elements/1.1/source">
        <dc:description xml:lang="en-us">The present resource may be derived from the Source resource
         in whole or in part.  Recommended best practice is to reference
         the resource by means of a string or number conforming to a
         formal identification system.</dc:description>
        <rdfs:comment xml:lang="en-us">A reference to a resource from which the present resource
         is derived.</rdfs:comment>
        <rdfs:isDefinedBy rdf:resource="http://purl.org/dc/elements/1.1/"/>
        <rdfs:label>Source</rdfs:label>
        <rdfs:label xml:lang="en-us">Source</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://purl.org/dc/terms/creator -->

    <owl:AnnotationProperty rdf:about="http://purl.org/dc/terms/creator"/>
    


    <!-- http://purl.org/dc/terms/license -->

    <owl:AnnotationProperty rdf:about="http://purl.org/dc/terms/license"/>
    


    <!-- http://purl.org/dc/terms/title -->

    <owl:AnnotationProperty rdf:about="http://purl.org/dc/terms/title"/>
    


    <!-- http://purl.org/net/OCRe/statistics.owl#curator -->

    <owl:AnnotationProperty rdf:about="http://purl.org/net/OCRe/statistics.owl#curator"/>
    


    <!-- http://purl.org/net/OCRe/study_protocol.owl#develop_comment -->

    <owl:AnnotationProperty rdf:about="http://purl.org/net/OCRe/study_protocol.owl#develop_comment"/>
    


    <!-- http://www.geneontology.org/formats/oboInOwl#hasAlternativeId -->

    <owl:AnnotationProperty rdf:about="http://www.geneontology.org/formats/oboInOwl#hasAlternativeId">
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">has_alternative_id</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://www.geneontology.org/formats/oboInOwl#hasDbXref -->

    <owl:AnnotationProperty rdf:about="http://www.geneontology.org/formats/oboInOwl#hasDbXref">
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">database_cross_reference</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://www.geneontology.org/formats/oboInOwl#hasExactSynonym -->

    <owl:AnnotationProperty rdf:about="http://www.geneontology.org/formats/oboInOwl#hasExactSynonym">
        <obo:IAO_0000115>A property representing a fully qualified synonym, contains the string, term type, source, and an optional source code if appropriate. Each subfield is deliniated to facilitate interpretation by software.</obo:IAO_0000115>
        <obo:IAO_0000115>Fully qualified synonym, contains the string, term type, source, and an optional source code if appropriate. Each subfield is deliniated to facilitate interpretation by software.</obo:IAO_0000115>
        <oboInOwl:hasExactSynonym>FULL_SYN</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Synonym with Source Data</oboInOwl:hasExactSynonym>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">has exact synonym</rdfs:label>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">has_exact_synonym</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://www.geneontology.org/formats/oboInOwl#hasNarrowSynonym -->

    <owl:AnnotationProperty rdf:about="http://www.geneontology.org/formats/oboInOwl#hasNarrowSynonym">
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">has_narrow_synonym</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://www.geneontology.org/formats/oboInOwl#hasOBONamespace -->

    <owl:AnnotationProperty rdf:about="http://www.geneontology.org/formats/oboInOwl#hasOBONamespace">
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">has_obo_namespace</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://www.geneontology.org/formats/oboInOwl#hasRelatedSynonym -->

    <owl:AnnotationProperty rdf:about="http://www.geneontology.org/formats/oboInOwl#hasRelatedSynonym">
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">has_related_synonym</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://www.geneontology.org/formats/oboInOwl#id -->

    <owl:AnnotationProperty rdf:about="http://www.geneontology.org/formats/oboInOwl#id"/>
    


    <!-- http://www.geneontology.org/formats/oboInOwl#inSubset -->

    <owl:AnnotationProperty rdf:about="http://www.geneontology.org/formats/oboInOwl#inSubset">
        <obo:IAO_0000115>An association that connects the concept defining a particular terminology subset with concepts that belong to this subset.</obo:IAO_0000115>
        <obo:IAO_0000115>Used to associate the concept defining a particular terminology subset with concepts that belong to this subset.</obo:IAO_0000115>
        <oboInOwl:hasExactSynonym>Concept_In_Subset</oboInOwl:hasExactSynonym>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">in subset</rdfs:label>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">in_subset</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://www.geneontology.org/formats/oboInOwl#is_metadata_tag -->

    <owl:AnnotationProperty rdf:about="http://www.geneontology.org/formats/oboInOwl#is_metadata_tag"/>
    


    <!-- http://www.geneontology.org/formats/oboInOwl#shorthand -->

    <owl:AnnotationProperty rdf:about="http://www.geneontology.org/formats/oboInOwl#shorthand">
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">shorthand</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://www.w3.org/1999/02/22-rdf-syntax-ns#type -->

    <owl:AnnotationProperty rdf:about="http://www.w3.org/1999/02/22-rdf-syntax-ns#type"/>
    


    <!-- http://www.w3.org/2000/01/rdf-schema#comment -->

    <owl:AnnotationProperty rdf:about="http://www.w3.org/2000/01/rdf-schema#comment"/>
    


    <!-- http://www.w3.org/2000/01/rdf-schema#isDefinedBy -->

    <owl:AnnotationProperty rdf:about="http://www.w3.org/2000/01/rdf-schema#isDefinedBy"/>
    


    <!-- http://www.w3.org/2000/01/rdf-schema#label -->

    <owl:AnnotationProperty rdf:about="http://www.w3.org/2000/01/rdf-schema#label">
        <obo:IAO_0000111>label</obo:IAO_0000111>
        <rdfs:label>label</rdfs:label>
        <rdfs:label xml:lang="en">label</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://www.w3.org/2000/01/rdf-schema#seeAlso -->

    <owl:AnnotationProperty rdf:about="http://www.w3.org/2000/01/rdf-schema#seeAlso"/>
    


    <!-- http://xmlns.com/foaf/0.1/homepage -->

    <owl:AnnotationProperty rdf:about="http://xmlns.com/foaf/0.1/homepage"/>
    


    <!-- http://xmlns.com/foaf/0.1/mbox -->

    <owl:AnnotationProperty rdf:about="http://xmlns.com/foaf/0.1/mbox"/>
    


    <!-- 
    ///////////////////////////////////////////////////////////////////////////////////////
    //
    // Datatypes
    //
    ///////////////////////////////////////////////////////////////////////////////////////
     -->

    


    <!-- http://purl.obolibrary.org/obo/NCIT_Contributing_Source-enum -->

    <rdfs:Datatype rdf:about="http://purl.obolibrary.org/obo/NCIT_Contributing_Source-enum"/>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_Semantic_Type-enum -->

    <rdfs:Datatype rdf:about="http://purl.obolibrary.org/obo/NCIT_Semantic_Type-enum"/>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_textArea -->

    <rdfs:Datatype rdf:about="http://purl.obolibrary.org/obo/NCIT_textArea"/>
    


    <!-- 
    ///////////////////////////////////////////////////////////////////////////////////////
    //
    // Object Properties
    //
    ///////////////////////////////////////////////////////////////////////////////////////
     -->

    


    <!-- http://purl.obolibrary.org/obo/BFO_0000051 -->

    <owl:ObjectProperty rdf:about="http://purl.obolibrary.org/obo/BFO_0000051">
        <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#TransitiveProperty"/>
        <rdfs:label xml:lang="en">has part</rdfs:label>
    </owl:ObjectProperty>
    


    <!-- http://purl.obolibrary.org/obo/BFO_0000055 -->

    <owl:ObjectProperty rdf:about="http://purl.obolibrary.org/obo/BFO_0000055">
        <rdfs:label xml:lang="en">realizes</rdfs:label>
    </owl:ObjectProperty>
    


    <!-- http://purl.obolibrary.org/obo/BFO_0000062 -->

    <owl:ObjectProperty rdf:about="http://purl.obolibrary.org/obo/BFO_0000062">
        <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#TransitiveProperty"/>
        <rdfs:label xml:lang="en">preceded by</rdfs:label>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">preceded_by</rdfs:label>
    </owl:ObjectProperty>
    


    <!-- http://purl.obolibrary.org/obo/IAO_0000136 -->

    <owl:ObjectProperty rdf:about="http://purl.obolibrary.org/obo/IAO_0000136">
        <rdfs:label xml:lang="en">is about</rdfs:label>
    </owl:ObjectProperty>
    


    <!-- http://purl.obolibrary.org/obo/OBI_0000293 -->

    <owl:ObjectProperty rdf:about="http://purl.obolibrary.org/obo/OBI_0000293">
        <rdfs:label xml:lang="en">has_specified_input</rdfs:label>
    </owl:ObjectProperty>
    


    <!-- http://purl.obolibrary.org/obo/RO_0000057 -->

    <owl:ObjectProperty rdf:about="http://purl.obolibrary.org/obo/RO_0000057">
        <rdfs:label xml:lang="en">has participant</rdfs:label>
    </owl:ObjectProperty>
    


    <!-- http://purl.obolibrary.org/obo/RO_0000059 -->

    <owl:ObjectProperty rdf:about="http://purl.obolibrary.org/obo/RO_0000059">
        <rdfs:label xml:lang="en">concretizes</rdfs:label>
    </owl:ObjectProperty>
    


    <!-- http://purl.obolibrary.org/obo/RO_0000087 -->

    <owl:ObjectProperty rdf:about="http://purl.obolibrary.org/obo/RO_0000087">
        <rdfs:label xml:lang="en">has role</rdfs:label>
    </owl:ObjectProperty>
    


    <!-- http://www.w3.org/2000/01/rdf-schema#subClassOf -->

    <owl:ObjectProperty rdf:about="http://www.w3.org/2000/01/rdf-schema#subClassOf">
        <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#TransitiveProperty"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/gaz.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
    </owl:ObjectProperty>
    


    <!-- 
    ///////////////////////////////////////////////////////////////////////////////////////
    //
    // Classes
    //
    ///////////////////////////////////////////////////////////////////////////////////////
     -->

    


    <!-- http://purl.obolibrary.org/obo/BFO_0000001 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/BFO_0000001">
        <rdfs:subClassOf rdf:resource="http://www.w3.org/2002/07/owl#Thing"/>
        <obo:BFO_0000179>entity</obo:BFO_0000179>
        <obo:BFO_0000180>Entity</obo:BFO_0000180>
        <obo:IAO_0000111 xml:lang="en">entity</obo:IAO_0000111>
        <obo:IAO_0000112 xml:lang="en">Julius Caesar</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">Verdi’s Requiem</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the Second World War</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">your body mass index</obo:IAO_0000112>
        <obo:IAO_0000116 xml:lang="en">BFO 2 Reference: In all areas of empirical inquiry we encounter general terms of two sorts. First are general terms which refer to universals or types:animaltuberculosissurgical procedurediseaseSecond, are general terms used to refer to groups of entities which instantiate a given universal but do not correspond to the extension of any subuniversal of that universal because there is nothing intrinsic to the entities in question by virtue of which they – and only they – are counted as belonging to the given group. Examples are: animal purchased by the Emperortuberculosis diagnosed on a Wednesdaysurgical procedure performed on a patient from Stockholmperson identified as candidate for clinical trial #2056-555person who is signatory of Form 656-PPVpainting by Leonardo da VinciSuch terms, which represent what are called ‘specializations’ in [81</obo:IAO_0000116>
        <obo:IAO_0000116 xml:lang="en">Entity doesn&apos;t have a closure axiom because the subclasses don&apos;t necessarily exhaust all possibilites. For example Werner Ceusters &apos;portions of reality&apos; include 4 sorts, entities (as BFO construes them), universals, configurations, and relations. It is an open question as to whether entities as construed in BFO will at some point also include these other portions of reality. See, for example, &apos;How to track absolutely everything&apos; at http://www.referent-tracking.com/_RTU/papers/CeustersICbookRevised.pdf</obo:IAO_0000116>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/bfo.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/dron.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/envo.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/iao.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ico.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/mondo.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/oae.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ogms.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/omrse.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <obo:IAO_0000600 xml:lang="en">An entity is anything that exists or has existed or will exist. (axiom label in BFO2 Reference: [001-001])</obo:IAO_0000600>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/bfo.owl"/>
        <rdfs:label xml:lang="en">entity</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000001"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000116"/>
        <owl:annotatedTarget xml:lang="en">Entity doesn&apos;t have a closure axiom because the subclasses don&apos;t necessarily exhaust all possibilites. For example Werner Ceusters &apos;portions of reality&apos; include 4 sorts, entities (as BFO construes them), universals, configurations, and relations. It is an open question as to whether entities as construed in BFO will at some point also include these other portions of reality. See, for example, &apos;How to track absolutely everything&apos; at http://www.referent-tracking.com/_RTU/papers/CeustersICbookRevised.pdf</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/0000004"/>
        <rdfs:comment>per discussion with Barry Smith</rdfs:comment>
        <rdfs:seeAlso rdf:resource="http://www.referent-tracking.com/_RTU/papers/CeustersICbookRevised.pdf"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000001"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000600"/>
        <owl:annotatedTarget xml:lang="en">An entity is anything that exists or has existed or will exist. (axiom label in BFO2 Reference: [001-001])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/001-001"/>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/BFO_0000002 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/BFO_0000002">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000001"/>
        <owl:disjointWith rdf:resource="http://purl.obolibrary.org/obo/BFO_0000003"/>
        <obo:BFO_0000179>continuant</obo:BFO_0000179>
        <obo:BFO_0000180>Continuant</obo:BFO_0000180>
        <obo:IAO_0000115 xml:lang="en">An entity that exists in full at any time in which it exists at all, persists through time while maintaining its identity and has no temporal parts.</obo:IAO_0000115>
        <obo:IAO_0000116 xml:lang="en">BFO 2 Reference: Continuant entities are entities which can be sliced to yield parts only along the spatial dimension, yielding for example the parts of your table which we call its legs, its top, its nails. ‘My desk stretches from the window to the door. It has spatial parts, and can be sliced (in space) in two. With respect to time, however, a thing is a continuant.’ [60, p. 240</obo:IAO_0000116>
        <obo:IAO_0000116 xml:lang="en">Continuant doesn&apos;t have a closure axiom because the subclasses don&apos;t necessarily exhaust all possibilites. For example, in an expansion involving bringing in some of Ceuster&apos;s other portions of reality, questions are raised as to whether universals are continuants</obo:IAO_0000116>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/bfo.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/dron.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/envo.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/iao.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/oae.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ogms.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/omrse.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ro.owl"/>
        <obo:IAO_0000600 xml:lang="en">A continuant is an entity that persists, endures, or continues to exist through time while maintaining its identity. (axiom label in BFO2 Reference: [008-002])</obo:IAO_0000600>
        <obo:IAO_0000601 xml:lang="en">if b is a continuant and if, for some t, c has_continuant_part b at t, then c is a continuant. (axiom label in BFO2 Reference: [126-001])</obo:IAO_0000601>
        <obo:IAO_0000601 xml:lang="en">if b is a continuant and if, for some t, cis continuant_part of b at t, then c is a continuant. (axiom label in BFO2 Reference: [009-002])</obo:IAO_0000601>
        <obo:IAO_0000601 xml:lang="en">if b is a material entity, then there is some temporal interval (referred to below as a one-dimensional temporal region) during which b exists. (axiom label in BFO2 Reference: [011-002])</obo:IAO_0000601>
        <obo:IAO_0000602>(forall (x y) (if (and (Continuant x) (exists (t) (continuantPartOfAt y x t))) (Continuant y))) // axiom label in BFO2 CLIF: [009-002] </obo:IAO_0000602>
        <obo:IAO_0000602>(forall (x y) (if (and (Continuant x) (exists (t) (hasContinuantPartOfAt y x t))) (Continuant y))) // axiom label in BFO2 CLIF: [126-001] </obo:IAO_0000602>
        <obo:IAO_0000602>(forall (x) (if (Continuant x) (Entity x))) // axiom label in BFO2 CLIF: [008-002] </obo:IAO_0000602>
        <obo:IAO_0000602>(forall (x) (if (Material Entity x) (exists (t) (and (TemporalRegion t) (existsAt x t))))) // axiom label in BFO2 CLIF: [011-002] </obo:IAO_0000602>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/bfo.owl"/>
        <rdfs:label xml:lang="en">continuant</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000002"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(forall (x) (if (Continuant x) (Entity x))) // axiom label in BFO2 CLIF: [008-002] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/008-002"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000002"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(forall (x) (if (Material Entity x) (exists (t) (and (TemporalRegion t) (existsAt x t))))) // axiom label in BFO2 CLIF: [011-002] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/011-002"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000002"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000116"/>
        <owl:annotatedTarget xml:lang="en">Continuant doesn&apos;t have a closure axiom because the subclasses don&apos;t necessarily exhaust all possibilites. For example, in an expansion involving bringing in some of Ceuster&apos;s other portions of reality, questions are raised as to whether universals are continuants</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/0000007"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000002"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000600"/>
        <owl:annotatedTarget xml:lang="en">A continuant is an entity that persists, endures, or continues to exist through time while maintaining its identity. (axiom label in BFO2 Reference: [008-002])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/008-002"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000002"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000601"/>
        <owl:annotatedTarget xml:lang="en">if b is a continuant and if, for some t, c has_continuant_part b at t, then c is a continuant. (axiom label in BFO2 Reference: [126-001])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/126-001"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000002"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000601"/>
        <owl:annotatedTarget xml:lang="en">if b is a continuant and if, for some t, cis continuant_part of b at t, then c is a continuant. (axiom label in BFO2 Reference: [009-002])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/009-002"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000002"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000601"/>
        <owl:annotatedTarget xml:lang="en">if b is a material entity, then there is some temporal interval (referred to below as a one-dimensional temporal region) during which b exists. (axiom label in BFO2 Reference: [011-002])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/011-002"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000002"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(forall (x y) (if (and (Continuant x) (exists (t) (continuantPartOfAt y x t))) (Continuant y))) // axiom label in BFO2 CLIF: [009-002] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/009-002"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000002"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(forall (x y) (if (and (Continuant x) (exists (t) (hasContinuantPartOfAt y x t))) (Continuant y))) // axiom label in BFO2 CLIF: [126-001] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/126-001"/>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/BFO_0000003 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/BFO_0000003">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000001"/>
        <obo:BFO_0000179>occurrent</obo:BFO_0000179>
        <obo:BFO_0000180>Occurrent</obo:BFO_0000180>
        <obo:IAO_0000116 xml:lang="en">BFO 2 Reference: every occurrent that is not a temporal or spatiotemporal region is s-dependent on some independent continuant that is not a spatial region</obo:IAO_0000116>
        <obo:IAO_0000116 xml:lang="en">BFO 2 Reference: s-dependence obtains between every process and its participants in the sense that, as a matter of necessity, this process could not have existed unless these or those participants existed also. A process may have a succession of participants at different phases of its unfolding. Thus there may be different players on the field at different times during the course of a football game; but the process which is the entire game s-depends_on all of these players nonetheless. Some temporal parts of this process will s-depend_on on only some of the players.</obo:IAO_0000116>
        <obo:IAO_0000116 xml:lang="en">Occurrent doesn&apos;t have a closure axiom because the subclasses don&apos;t necessarily exhaust all possibilites. An example would be the sum of a process and the process boundary of another process.</obo:IAO_0000116>
        <obo:IAO_0000116>Simons uses different terminology for relations of occurrents to regions: Denote the spatio-temporal location of a given occurrent e by &apos;spn[e]&apos; and call this region its span. We may say an occurrent is at its span, in any larger region, and covers any smaller region. Now suppose we have fixed a frame of reference so that we can speak not merely of spatio-temporal but also of spatial regions (places) and temporal regions (times). The spread of an occurrent, (relative to a frame of reference) is the space it exactly occupies, and its spell is likewise the time it exactly occupies. We write &apos;spr[e]&apos; and `spl[e]&apos; respectively for the spread and spell of e, omitting mention of the frame.</obo:IAO_0000116>
        <obo:IAO_0000600 xml:lang="en">An occurrent is an entity that unfolds itself in time or it is the instantaneous boundary of such an entity (for example a beginning or an ending) or it is a temporal or spatiotemporal region which such an entity occupies_temporal_region or occupies_spatiotemporal_region. (axiom label in BFO2 Reference: [077-002])</obo:IAO_0000600>
        <obo:IAO_0000601 xml:lang="en">Every occurrent occupies_spatiotemporal_region some spatiotemporal region. (axiom label in BFO2 Reference: [108-001])</obo:IAO_0000601>
        <obo:IAO_0000601 xml:lang="en">b is an occurrent entity iff b is an entity that has temporal parts. (axiom label in BFO2 Reference: [079-001])</obo:IAO_0000601>
        <obo:IAO_0000602>(forall (x) (if (Occurrent x) (exists (r) (and (SpatioTemporalRegion r) (occupiesSpatioTemporalRegion x r))))) // axiom label in BFO2 CLIF: [108-001] </obo:IAO_0000602>
        <obo:IAO_0000602>(forall (x) (iff (Occurrent x) (and (Entity x) (exists (y) (temporalPartOf y x))))) // axiom label in BFO2 CLIF: [079-001] </obo:IAO_0000602>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/bfo.owl"/>
        <rdfs:label xml:lang="en">occurrent</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000003"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000116"/>
        <owl:annotatedTarget xml:lang="en">Occurrent doesn&apos;t have a closure axiom because the subclasses don&apos;t necessarily exhaust all possibilites. An example would be the sum of a process and the process boundary of another process.</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/0000006"/>
        <rdfs:comment>per discussion with Barry Smith</rdfs:comment>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000003"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000116"/>
        <owl:annotatedTarget>Simons uses different terminology for relations of occurrents to regions: Denote the spatio-temporal location of a given occurrent e by &apos;spn[e]&apos; and call this region its span. We may say an occurrent is at its span, in any larger region, and covers any smaller region. Now suppose we have fixed a frame of reference so that we can speak not merely of spatio-temporal but also of spatial regions (places) and temporal regions (times). The spread of an occurrent, (relative to a frame of reference) is the space it exactly occupies, and its spell is likewise the time it exactly occupies. We write &apos;spr[e]&apos; and `spl[e]&apos; respectively for the spread and spell of e, omitting mention of the frame.</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/0000012"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000003"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000600"/>
        <owl:annotatedTarget xml:lang="en">An occurrent is an entity that unfolds itself in time or it is the instantaneous boundary of such an entity (for example a beginning or an ending) or it is a temporal or spatiotemporal region which such an entity occupies_temporal_region or occupies_spatiotemporal_region. (axiom label in BFO2 Reference: [077-002])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/077-002"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000003"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000601"/>
        <owl:annotatedTarget xml:lang="en">Every occurrent occupies_spatiotemporal_region some spatiotemporal region. (axiom label in BFO2 Reference: [108-001])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/108-001"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000003"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000601"/>
        <owl:annotatedTarget xml:lang="en">b is an occurrent entity iff b is an entity that has temporal parts. (axiom label in BFO2 Reference: [079-001])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/079-001"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000003"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(forall (x) (if (Occurrent x) (exists (r) (and (SpatioTemporalRegion r) (occupiesSpatioTemporalRegion x r))))) // axiom label in BFO2 CLIF: [108-001] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/108-001"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000003"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(forall (x) (iff (Occurrent x) (and (Entity x) (exists (y) (temporalPartOf y x))))) // axiom label in BFO2 CLIF: [079-001] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/079-001"/>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/BFO_0000004 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/BFO_0000004">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000002"/>
        <owl:disjointWith rdf:resource="http://purl.obolibrary.org/obo/BFO_0000020"/>
        <owl:disjointWith rdf:resource="http://purl.obolibrary.org/obo/BFO_0000031"/>
        <obo:BFO_0000179>ic</obo:BFO_0000179>
        <obo:BFO_0000180>IndependentContinuant</obo:BFO_0000180>
        <obo:IAO_0000112 xml:lang="en">a chair</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">a heart</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">a leg</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">a molecule</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">a spatial region</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">an atom</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">an orchestra.</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">an organism</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the bottom right portion of a human torso</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the interior of your mouth</obo:IAO_0000112>
        <obo:IAO_0000115 xml:lang="en">b is an independent continuant = Def. b is a continuant which is such that there is no c and no t such that b s-depends_on c at t. (axiom label in BFO2 Reference: [017-002])</obo:IAO_0000115>
        <obo:IAO_0000601 xml:lang="en">For any independent continuant b and any time t there is some spatial region r such that b is located_in r at t. (axiom label in BFO2 Reference: [134-001])</obo:IAO_0000601>
        <obo:IAO_0000601 xml:lang="en">For every independent continuant b and time t during the region of time spanned by its life, there are entities which s-depends_on b during t. (axiom label in BFO2 Reference: [018-002])</obo:IAO_0000601>
        <obo:IAO_0000602>(forall (x t) (if (IndependentContinuant x) (exists (r) (and (SpatialRegion r) (locatedInAt x r t))))) // axiom label in BFO2 CLIF: [134-001] </obo:IAO_0000602>
        <obo:IAO_0000602>(forall (x t) (if (and (IndependentContinuant x) (existsAt x t)) (exists (y) (and (Entity y) (specificallyDependsOnAt y x t))))) // axiom label in BFO2 CLIF: [018-002] </obo:IAO_0000602>
        <obo:IAO_0000602>(iff (IndependentContinuant a) (and (Continuant a) (not (exists (b t) (specificallyDependsOnAt a b t))))) // axiom label in BFO2 CLIF: [017-002] </obo:IAO_0000602>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/bfo.owl"/>
        <rdfs:label xml:lang="en">independent continuant</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000004"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget xml:lang="en">b is an independent continuant = Def. b is a continuant which is such that there is no c and no t such that b s-depends_on c at t. (axiom label in BFO2 Reference: [017-002])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/017-002"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000004"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000601"/>
        <owl:annotatedTarget xml:lang="en">For any independent continuant b and any time t there is some spatial region r such that b is located_in r at t. (axiom label in BFO2 Reference: [134-001])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/134-001"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000004"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000601"/>
        <owl:annotatedTarget xml:lang="en">For every independent continuant b and time t during the region of time spanned by its life, there are entities which s-depends_on b during t. (axiom label in BFO2 Reference: [018-002])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/018-002"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000004"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(forall (x t) (if (IndependentContinuant x) (exists (r) (and (SpatialRegion r) (locatedInAt x r t))))) // axiom label in BFO2 CLIF: [134-001] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/134-001"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000004"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(forall (x t) (if (and (IndependentContinuant x) (existsAt x t)) (exists (y) (and (Entity y) (specificallyDependsOnAt y x t))))) // axiom label in BFO2 CLIF: [018-002] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/018-002"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000004"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(iff (IndependentContinuant a) (and (Continuant a) (not (exists (b t) (specificallyDependsOnAt a b t))))) // axiom label in BFO2 CLIF: [017-002] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/017-002"/>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/BFO_0000006 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/BFO_0000006">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000141"/>
        <owl:disjointWith rdf:resource="http://purl.obolibrary.org/obo/BFO_0000029"/>
        <owl:disjointWith rdf:resource="http://purl.obolibrary.org/obo/BFO_0000140"/>
        <obo:BFO_0000179>s-region</obo:BFO_0000179>
        <obo:BFO_0000180>SpatialRegion</obo:BFO_0000180>
        <obo:IAO_0000116 xml:lang="en">BFO 2 Reference: Spatial regions do not participate in processes.</obo:IAO_0000116>
        <obo:IAO_0000116 xml:lang="en">Spatial region doesn&apos;t have a closure axiom because the subclasses don&apos;t exhaust all possibilites. An example would be the union of a spatial point and a spatial line that doesn&apos;t overlap the point, or two spatial lines that intersect at a single point. In both cases the resultant spatial region is neither 0-dimensional, 1-dimensional, 2-dimensional, or 3-dimensional.</obo:IAO_0000116>
        <obo:IAO_0000600 xml:lang="en">A spatial region is a continuant entity that is a continuant_part_of spaceR as defined relative to some frame R. (axiom label in BFO2 Reference: [035-001])</obo:IAO_0000600>
        <obo:IAO_0000601 xml:lang="en">All continuant parts of spatial regions are spatial regions. (axiom label in BFO2 Reference: [036-001])</obo:IAO_0000601>
        <obo:IAO_0000602>(forall (x y t) (if (and (SpatialRegion x) (continuantPartOfAt y x t)) (SpatialRegion y))) // axiom label in BFO2 CLIF: [036-001] </obo:IAO_0000602>
        <obo:IAO_0000602>(forall (x) (if (SpatialRegion x) (Continuant x))) // axiom label in BFO2 CLIF: [035-001] </obo:IAO_0000602>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/bfo.owl"/>
        <rdfs:label xml:lang="en">spatial region</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000006"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000116"/>
        <owl:annotatedTarget xml:lang="en">Spatial region doesn&apos;t have a closure axiom because the subclasses don&apos;t exhaust all possibilites. An example would be the union of a spatial point and a spatial line that doesn&apos;t overlap the point, or two spatial lines that intersect at a single point. In both cases the resultant spatial region is neither 0-dimensional, 1-dimensional, 2-dimensional, or 3-dimensional.</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/0000002"/>
        <rdfs:comment>per discussion with Barry Smith</rdfs:comment>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000006"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000600"/>
        <owl:annotatedTarget xml:lang="en">A spatial region is a continuant entity that is a continuant_part_of spaceR as defined relative to some frame R. (axiom label in BFO2 Reference: [035-001])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/035-001"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000006"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000601"/>
        <owl:annotatedTarget xml:lang="en">All continuant parts of spatial regions are spatial regions. (axiom label in BFO2 Reference: [036-001])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/036-001"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000006"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(forall (x y t) (if (and (SpatialRegion x) (continuantPartOfAt y x t)) (SpatialRegion y))) // axiom label in BFO2 CLIF: [036-001] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/036-001"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000006"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(forall (x) (if (SpatialRegion x) (Continuant x))) // axiom label in BFO2 CLIF: [035-001] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/035-001"/>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/BFO_0000008 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/BFO_0000008">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000003"/>
        <owl:disjointWith rdf:resource="http://purl.obolibrary.org/obo/BFO_0000011"/>
        <owl:disjointWith rdf:resource="http://purl.obolibrary.org/obo/BFO_0000015"/>
        <owl:disjointWith rdf:resource="http://purl.obolibrary.org/obo/BFO_0000035"/>
        <obo:BFO_0000179>t-region</obo:BFO_0000179>
        <obo:BFO_0000180>TemporalRegion</obo:BFO_0000180>
        <obo:IAO_0000116 xml:lang="en">Temporal region doesn&apos;t have a closure axiom because the subclasses don&apos;t exhaust all possibilites. An example would be the mereological sum of a temporal instant and a temporal interval that doesn&apos;t overlap the instant. In this case the resultant temporal region is neither 0-dimensional nor 1-dimensional</obo:IAO_0000116>
        <obo:IAO_0000600 xml:lang="en">A temporal region is an occurrent entity that is part of time as defined relative to some reference frame. (axiom label in BFO2 Reference: [100-001])</obo:IAO_0000600>
        <obo:IAO_0000601 xml:lang="en">All parts of temporal regions are temporal regions. (axiom label in BFO2 Reference: [101-001])</obo:IAO_0000601>
        <obo:IAO_0000601 xml:lang="en">Every temporal region t is such that t occupies_temporal_region t. (axiom label in BFO2 Reference: [119-002])</obo:IAO_0000601>
        <obo:IAO_0000602>(forall (r) (if (TemporalRegion r) (occupiesTemporalRegion r r))) // axiom label in BFO2 CLIF: [119-002] </obo:IAO_0000602>
        <obo:IAO_0000602>(forall (x y) (if (and (TemporalRegion x) (occurrentPartOf y x)) (TemporalRegion y))) // axiom label in BFO2 CLIF: [101-001] </obo:IAO_0000602>
        <obo:IAO_0000602>(forall (x) (if (TemporalRegion x) (Occurrent x))) // axiom label in BFO2 CLIF: [100-001] </obo:IAO_0000602>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/bfo.owl"/>
        <rdfs:label xml:lang="en">temporal region</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000008"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000116"/>
        <owl:annotatedTarget xml:lang="en">Temporal region doesn&apos;t have a closure axiom because the subclasses don&apos;t exhaust all possibilites. An example would be the mereological sum of a temporal instant and a temporal interval that doesn&apos;t overlap the instant. In this case the resultant temporal region is neither 0-dimensional nor 1-dimensional</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/0000003"/>
        <rdfs:comment>per discussion with Barry Smith</rdfs:comment>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000008"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000600"/>
        <owl:annotatedTarget xml:lang="en">A temporal region is an occurrent entity that is part of time as defined relative to some reference frame. (axiom label in BFO2 Reference: [100-001])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/100-001"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000008"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000601"/>
        <owl:annotatedTarget xml:lang="en">All parts of temporal regions are temporal regions. (axiom label in BFO2 Reference: [101-001])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/101-001"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000008"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000601"/>
        <owl:annotatedTarget xml:lang="en">Every temporal region t is such that t occupies_temporal_region t. (axiom label in BFO2 Reference: [119-002])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/119-002"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000008"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(forall (r) (if (TemporalRegion r) (occupiesTemporalRegion r r))) // axiom label in BFO2 CLIF: [119-002] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/119-002"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000008"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(forall (x y) (if (and (TemporalRegion x) (occurrentPartOf y x)) (TemporalRegion y))) // axiom label in BFO2 CLIF: [101-001] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/101-001"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000008"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(forall (x) (if (TemporalRegion x) (Occurrent x))) // axiom label in BFO2 CLIF: [100-001] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/100-001"/>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/BFO_0000009 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/BFO_0000009">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000006"/>
        <owl:disjointWith rdf:resource="http://purl.obolibrary.org/obo/BFO_0000028"/>
        <obo:BFO_0000179>2d-s-region</obo:BFO_0000179>
        <obo:BFO_0000180>TwoDimensionalSpatialRegion</obo:BFO_0000180>
        <obo:IAO_0000112 xml:lang="en">an infinitely thin plane in space.</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the surface of a sphere-shaped part of space</obo:IAO_0000112>
        <obo:IAO_0000600 xml:lang="en">A two-dimensional spatial region is a spatial region that is of two dimensions. (axiom label in BFO2 Reference: [039-001])</obo:IAO_0000600>
        <obo:IAO_0000602>(forall (x) (if (TwoDimensionalSpatialRegion x) (SpatialRegion x))) // axiom label in BFO2 CLIF: [039-001] </obo:IAO_0000602>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/bfo.owl"/>
        <rdfs:label xml:lang="en">two-dimensional spatial region</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000009"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000600"/>
        <owl:annotatedTarget xml:lang="en">A two-dimensional spatial region is a spatial region that is of two dimensions. (axiom label in BFO2 Reference: [039-001])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/039-001"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000009"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(forall (x) (if (TwoDimensionalSpatialRegion x) (SpatialRegion x))) // axiom label in BFO2 CLIF: [039-001] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/039-001"/>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/BFO_0000011 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/BFO_0000011">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000003"/>
        <obo:BFO_0000179>st-region</obo:BFO_0000179>
        <obo:BFO_0000180>SpatiotemporalRegion</obo:BFO_0000180>
        <obo:IAO_0000112 xml:lang="en">the spatiotemporal region occupied by a human life</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the spatiotemporal region occupied by a process of cellular meiosis.</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the spatiotemporal region occupied by the development of a cancer tumor</obo:IAO_0000112>
        <obo:IAO_0000600 xml:lang="en">A spatiotemporal region is an occurrent entity that is part of spacetime. (axiom label in BFO2 Reference: [095-001])</obo:IAO_0000600>
        <obo:IAO_0000601 xml:lang="en">All parts of spatiotemporal regions are spatiotemporal regions. (axiom label in BFO2 Reference: [096-001])</obo:IAO_0000601>
        <obo:IAO_0000601 xml:lang="en">Each spatiotemporal region at any time t projects_onto some spatial region at t. (axiom label in BFO2 Reference: [099-001])</obo:IAO_0000601>
        <obo:IAO_0000601 xml:lang="en">Each spatiotemporal region projects_onto some temporal region. (axiom label in BFO2 Reference: [098-001])</obo:IAO_0000601>
        <obo:IAO_0000601 xml:lang="en">Every spatiotemporal region occupies_spatiotemporal_region itself.</obo:IAO_0000601>
        <obo:IAO_0000601 xml:lang="en">Every spatiotemporal region s is such that s occupies_spatiotemporal_region s. (axiom label in BFO2 Reference: [107-002])</obo:IAO_0000601>
        <obo:IAO_0000602>(forall (r) (if (SpatioTemporalRegion r) (occupiesSpatioTemporalRegion r r))) // axiom label in BFO2 CLIF: [107-002] </obo:IAO_0000602>
        <obo:IAO_0000602>(forall (x t) (if (SpatioTemporalRegion x) (exists (y) (and (SpatialRegion y) (spatiallyProjectsOntoAt x y t))))) // axiom label in BFO2 CLIF: [099-001] </obo:IAO_0000602>
        <obo:IAO_0000602>(forall (x y) (if (and (SpatioTemporalRegion x) (occurrentPartOf y x)) (SpatioTemporalRegion y))) // axiom label in BFO2 CLIF: [096-001] </obo:IAO_0000602>
        <obo:IAO_0000602>(forall (x) (if (SpatioTemporalRegion x) (Occurrent x))) // axiom label in BFO2 CLIF: [095-001] </obo:IAO_0000602>
        <obo:IAO_0000602>(forall (x) (if (SpatioTemporalRegion x) (exists (y) (and (TemporalRegion y) (temporallyProjectsOnto x y))))) // axiom label in BFO2 CLIF: [098-001] </obo:IAO_0000602>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/bfo.owl"/>
        <rdfs:label xml:lang="en">spatiotemporal region</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000011"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000600"/>
        <owl:annotatedTarget xml:lang="en">A spatiotemporal region is an occurrent entity that is part of spacetime. (axiom label in BFO2 Reference: [095-001])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/095-001"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000011"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000601"/>
        <owl:annotatedTarget xml:lang="en">All parts of spatiotemporal regions are spatiotemporal regions. (axiom label in BFO2 Reference: [096-001])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/096-001"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000011"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000601"/>
        <owl:annotatedTarget xml:lang="en">Each spatiotemporal region at any time t projects_onto some spatial region at t. (axiom label in BFO2 Reference: [099-001])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/099-001"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000011"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000601"/>
        <owl:annotatedTarget xml:lang="en">Each spatiotemporal region projects_onto some temporal region. (axiom label in BFO2 Reference: [098-001])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/098-001"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000011"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000601"/>
        <owl:annotatedTarget xml:lang="en">Every spatiotemporal region s is such that s occupies_spatiotemporal_region s. (axiom label in BFO2 Reference: [107-002])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/107-002"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000011"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(forall (r) (if (SpatioTemporalRegion r) (occupiesSpatioTemporalRegion r r))) // axiom label in BFO2 CLIF: [107-002] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/107-002"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000011"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(forall (x t) (if (SpatioTemporalRegion x) (exists (y) (and (SpatialRegion y) (spatiallyProjectsOntoAt x y t))))) // axiom label in BFO2 CLIF: [099-001] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/099-001"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000011"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(forall (x y) (if (and (SpatioTemporalRegion x) (occurrentPartOf y x)) (SpatioTemporalRegion y))) // axiom label in BFO2 CLIF: [096-001] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/096-001"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000011"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(forall (x) (if (SpatioTemporalRegion x) (Occurrent x))) // axiom label in BFO2 CLIF: [095-001] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/095-001"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000011"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(forall (x) (if (SpatioTemporalRegion x) (exists (y) (and (TemporalRegion y) (temporallyProjectsOnto x y))))) // axiom label in BFO2 CLIF: [098-001] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/098-001"/>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/BFO_0000015 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/BFO_0000015">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000003"/>
        <obo:BFO_0000179>process</obo:BFO_0000179>
        <obo:BFO_0000180>Process</obo:BFO_0000180>
        <obo:IAO_0000112 xml:lang="en">a process of cell-division, \ a beating of the heart</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">a process of meiosis</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">a process of sleeping</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the course of a disease</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the flight of a bird</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the life of an organism</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">your process of aging.</obo:IAO_0000112>
        <obo:IAO_0000115 xml:lang="en">An occurrent that has temporal proper parts and for some time t, p s-depends_on some material entity at t.</obo:IAO_0000115>
        <obo:IAO_0000115 xml:lang="en">p is a process = Def. p is an occurrent that has temporal proper parts and for some time t, p s-depends_on some material entity at t. (axiom label in BFO2 Reference: [083-003])</obo:IAO_0000115>
        <obo:IAO_0000116 xml:lang="en">BFO 2 Reference: The realm of occurrents is less pervasively marked by the presence of natural units than is the case in the realm of independent continuants. Thus there is here no counterpart of ‘object’. In BFO 1.0 ‘process’ served as such a counterpart. In BFO 2.0 ‘process’ is, rather, the occurrent counterpart of ‘material entity’. Those natural – as contrasted with engineered, which here means: deliberately executed – units which do exist in the realm of occurrents are typically either parasitic on the existence of natural units on the continuant side, or they are fiat in nature. Thus we can count lives; we can count football games; we can count chemical reactions performed in experiments or in chemical manufacturing. We cannot count the processes taking place, for instance, in an episode of insect mating behavior.Even where natural units are identifiable, for example cycles in a cyclical process such as the beating of a heart or an organism’s sleep/wake cycle, the processes in question form a sequence with no discontinuities (temporal gaps) of the sort that we find for instance where billiard balls or zebrafish or planets are separated by clear spatial gaps. Lives of organisms are process units, but they too unfold in a continuous series from other, prior processes such as fertilization, and they unfold in turn in continuous series of post-life processes such as post-mortem decay. Clear examples of boundaries of processes are almost always of the fiat sort (midnight, a time of death as declared in an operating theater or on a death certificate, the initiation of a state of war)</obo:IAO_0000116>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/bfo.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ero.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/oae.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ro.owl"/>
        <obo:IAO_0000602>(iff (Process a) (and (Occurrent a) (exists (b) (properTemporalPartOf b a)) (exists (c t) (and (MaterialEntity c) (specificallyDependsOnAt a c t))))) // axiom label in BFO2 CLIF: [083-003] </obo:IAO_0000602>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/bfo.owl"/>
        <rdfs:label xml:lang="en">process</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000015"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget xml:lang="en">p is a process = Def. p is an occurrent that has temporal proper parts and for some time t, p s-depends_on some material entity at t. (axiom label in BFO2 Reference: [083-003])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/083-003"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000015"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(iff (Process a) (and (Occurrent a) (exists (b) (properTemporalPartOf b a)) (exists (c t) (and (MaterialEntity c) (specificallyDependsOnAt a c t))))) // axiom label in BFO2 CLIF: [083-003] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/083-003"/>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/BFO_0000016 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/BFO_0000016">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000017"/>
        <owl:disjointWith rdf:resource="http://purl.obolibrary.org/obo/BFO_0000023"/>
        <obo:BFO_0000179>disposition</obo:BFO_0000179>
        <obo:BFO_0000180>Disposition</obo:BFO_0000180>
        <obo:IAO_0000112 xml:lang="en">an atom of element X has the disposition to decay to an atom of element Y</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">certain people have a predisposition to colon cancer</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">children are innately disposed to categorize objects in certain ways.</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the cell wall is disposed to filter chemicals in endocytosis and exocytosis</obo:IAO_0000112>
        <obo:IAO_0000116 xml:lang="en">BFO 2 Reference: Dispositions exist along a strength continuum. Weaker forms of disposition are realized in only a fraction of triggering cases. These forms occur in a significant number of cases of a similar type.</obo:IAO_0000116>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ogms.owl"/>
        <obo:IAO_0000600 xml:lang="en">b is a disposition means: b is a realizable entity &amp; b’s bearer is some material entity &amp; b is such that if it ceases to exist, then its bearer is physically changed, &amp; b’s realization occurs when and because this bearer is in some special physical circumstances, &amp; this realization occurs in virtue of the bearer’s physical make-up. (axiom label in BFO2 Reference: [062-002])</obo:IAO_0000600>
        <obo:IAO_0000601 xml:lang="en">If b is a realizable entity then for all t at which b exists, b s-depends_on some material entity at t. (axiom label in BFO2 Reference: [063-002])</obo:IAO_0000601>
        <obo:IAO_0000602>(forall (x t) (if (and (RealizableEntity x) (existsAt x t)) (exists (y) (and (MaterialEntity y) (specificallyDepends x y t))))) // axiom label in BFO2 CLIF: [063-002] </obo:IAO_0000602>
        <obo:IAO_0000602>(forall (x) (if (Disposition x) (and (RealizableEntity x) (exists (y) (and (MaterialEntity y) (bearerOfAt x y t)))))) // axiom label in BFO2 CLIF: [062-002] </obo:IAO_0000602>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/bfo.owl"/>
        <rdfs:label xml:lang="en">disposition</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000016"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000600"/>
        <owl:annotatedTarget xml:lang="en">b is a disposition means: b is a realizable entity &amp; b’s bearer is some material entity &amp; b is such that if it ceases to exist, then its bearer is physically changed, &amp; b’s realization occurs when and because this bearer is in some special physical circumstances, &amp; this realization occurs in virtue of the bearer’s physical make-up. (axiom label in BFO2 Reference: [062-002])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/062-002"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000016"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000601"/>
        <owl:annotatedTarget xml:lang="en">If b is a realizable entity then for all t at which b exists, b s-depends_on some material entity at t. (axiom label in BFO2 Reference: [063-002])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/063-002"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000016"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(forall (x t) (if (and (RealizableEntity x) (existsAt x t)) (exists (y) (and (MaterialEntity y) (specificallyDepends x y t))))) // axiom label in BFO2 CLIF: [063-002] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/063-002"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000016"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(forall (x) (if (Disposition x) (and (RealizableEntity x) (exists (y) (and (MaterialEntity y) (bearerOfAt x y t)))))) // axiom label in BFO2 CLIF: [062-002] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/062-002"/>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/BFO_0000017 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/BFO_0000017">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000020"/>
        <owl:disjointWith rdf:resource="http://purl.obolibrary.org/obo/BFO_0000019"/>
        <obo:BFO_0000179>realizable</obo:BFO_0000179>
        <obo:BFO_0000180>RealizableEntity</obo:BFO_0000180>
        <obo:IAO_0000112 xml:lang="en">the disposition of this piece of metal to conduct electricity.</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the disposition of your blood to coagulate</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the function of your reproductive organs</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the role of being a doctor</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the role of this boundary to delineate where Utah and Colorado meet</obo:IAO_0000112>
        <obo:IAO_0000115 xml:lang="en">A specifically dependent continuant  that inheres in continuant  entities and are not exhibited in full at every time in which it inheres in an entity or group of entities. The exhibition or actualization of a realizable entity is a particular manifestation, functioning or process that occurs under certain circumstances.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/dron.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/envo.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ogms.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/omrse.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <obo:IAO_0000600 xml:lang="en">To say that b is a realizable entity is to say that b is a specifically dependent continuant that inheres in some independent continuant which is not a spatial region and is of a type instances of which are realized in processes of a correlated type. (axiom label in BFO2 Reference: [058-002])</obo:IAO_0000600>
        <obo:IAO_0000601 xml:lang="en">All realizable dependent continuants have independent continuants that are not spatial regions as their bearers. (axiom label in BFO2 Reference: [060-002])</obo:IAO_0000601>
        <obo:IAO_0000602>(forall (x t) (if (RealizableEntity x) (exists (y) (and (IndependentContinuant y) (not (SpatialRegion y)) (bearerOfAt y x t))))) // axiom label in BFO2 CLIF: [060-002] </obo:IAO_0000602>
        <obo:IAO_0000602>(forall (x) (if (RealizableEntity x) (and (SpecificallyDependentContinuant x) (exists (y) (and (IndependentContinuant y) (not (SpatialRegion y)) (inheresIn x y)))))) // axiom label in BFO2 CLIF: [058-002] </obo:IAO_0000602>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/bfo.owl"/>
        <rdfs:label xml:lang="en">realizable entity</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000017"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000600"/>
        <owl:annotatedTarget xml:lang="en">To say that b is a realizable entity is to say that b is a specifically dependent continuant that inheres in some independent continuant which is not a spatial region and is of a type instances of which are realized in processes of a correlated type. (axiom label in BFO2 Reference: [058-002])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/058-002"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000017"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000601"/>
        <owl:annotatedTarget xml:lang="en">All realizable dependent continuants have independent continuants that are not spatial regions as their bearers. (axiom label in BFO2 Reference: [060-002])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/060-002"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000017"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(forall (x t) (if (RealizableEntity x) (exists (y) (and (IndependentContinuant y) (not (SpatialRegion y)) (bearerOfAt y x t))))) // axiom label in BFO2 CLIF: [060-002] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/060-002"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000017"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(forall (x) (if (RealizableEntity x) (and (SpecificallyDependentContinuant x) (exists (y) (and (IndependentContinuant y) (not (SpatialRegion y)) (inheresIn x y)))))) // axiom label in BFO2 CLIF: [058-002] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/058-002"/>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/BFO_0000018 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/BFO_0000018">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000006"/>
        <owl:disjointWith rdf:resource="http://purl.obolibrary.org/obo/BFO_0000028"/>
        <obo:BFO_0000179>0d-s-region</obo:BFO_0000179>
        <obo:BFO_0000180>ZeroDimensionalSpatialRegion</obo:BFO_0000180>
        <obo:IAO_0000600 xml:lang="en">A zero-dimensional spatial region is a point in space. (axiom label in BFO2 Reference: [037-001])</obo:IAO_0000600>
        <obo:IAO_0000602>(forall (x) (if (ZeroDimensionalSpatialRegion x) (SpatialRegion x))) // axiom label in BFO2 CLIF: [037-001] </obo:IAO_0000602>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/bfo.owl"/>
        <rdfs:label xml:lang="en">zero-dimensional spatial region</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000018"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000600"/>
        <owl:annotatedTarget xml:lang="en">A zero-dimensional spatial region is a point in space. (axiom label in BFO2 Reference: [037-001])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/037-001"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000018"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(forall (x) (if (ZeroDimensionalSpatialRegion x) (SpatialRegion x))) // axiom label in BFO2 CLIF: [037-001] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/037-001"/>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/BFO_0000019 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/BFO_0000019">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000020"/>
        <obo:BFO_0000179>quality</obo:BFO_0000179>
        <obo:BFO_0000180>Quality</obo:BFO_0000180>
        <obo:IAO_0000112 xml:lang="en">the ambient temperature of this portion of air</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the color of a tomato</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the length of the circumference of your waist</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the mass of this piece of gold.</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the shape of your nose</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the shape of your nostril</obo:IAO_0000112>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/bfo.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/envo.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/oae.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ro.owl"/>
        <obo:IAO_0000600 xml:lang="en">a quality is a specifically dependent continuant that, in contrast to roles and dispositions, does not require any further process in order to be realized. (axiom label in BFO2 Reference: [055-001])</obo:IAO_0000600>
        <obo:IAO_0000601 xml:lang="en">If an entity is a quality at any time that it exists, then it is a quality at every time that it exists. (axiom label in BFO2 Reference: [105-001])</obo:IAO_0000601>
        <obo:IAO_0000602>(forall (x) (if (Quality x) (SpecificallyDependentContinuant x))) // axiom label in BFO2 CLIF: [055-001] </obo:IAO_0000602>
        <obo:IAO_0000602>(forall (x) (if (exists (t) (and (existsAt x t) (Quality x))) (forall (t_1) (if (existsAt x t_1) (Quality x))))) // axiom label in BFO2 CLIF: [105-001] </obo:IAO_0000602>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/bfo.owl"/>
        <rdfs:label xml:lang="en">quality</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000019"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000600"/>
        <owl:annotatedTarget xml:lang="en">a quality is a specifically dependent continuant that, in contrast to roles and dispositions, does not require any further process in order to be realized. (axiom label in BFO2 Reference: [055-001])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/055-001"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000019"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000601"/>
        <owl:annotatedTarget xml:lang="en">If an entity is a quality at any time that it exists, then it is a quality at every time that it exists. (axiom label in BFO2 Reference: [105-001])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/105-001"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000019"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(forall (x) (if (Quality x) (SpecificallyDependentContinuant x))) // axiom label in BFO2 CLIF: [055-001] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/055-001"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000019"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(forall (x) (if (exists (t) (and (existsAt x t) (Quality x))) (forall (t_1) (if (existsAt x t_1) (Quality x))))) // axiom label in BFO2 CLIF: [105-001] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/105-001"/>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/BFO_0000020 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/BFO_0000020">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000002"/>
        <owl:disjointWith rdf:resource="http://purl.obolibrary.org/obo/BFO_0000031"/>
        <obo:BFO_0000179>sdc</obo:BFO_0000179>
        <obo:BFO_0000180>SpecificallyDependentContinuant</obo:BFO_0000180>
        <obo:IAO_0000112 xml:lang="en">Reciprocal specifically dependent continuants: the function of this key to open this lock and the mutually dependent disposition of this lock: to be opened by this key</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">of one-sided specifically dependent continuants: the mass of this tomato</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">of relational dependent continuants (multiple bearers): John’s love for Mary, the ownership relation between John and this statue, the relation of authority between John and his subordinates.</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the disposition of this fish to decay</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the function of this heart: to pump blood</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the mutual dependence of proton donors and acceptors in chemical reactions [79</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the mutual dependence of the role predator and the role prey as played by two organisms in a given interaction</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the pink color of a medium rare piece of grilled filet mignon at its center</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the role of being a doctor</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the shape of this hole.</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the smell of this portion of mozzarella</obo:IAO_0000112>
        <obo:IAO_0000115 xml:lang="en">b is a specifically dependent continuant = Def. b is a continuant &amp; there is some independent continuant c which is not a spatial region and which is such that b s-depends_on c at every time t during the course of b’s existence. (axiom label in BFO2 Reference: [050-003])</obo:IAO_0000115>
        <obo:IAO_0000116 xml:lang="en">Specifically dependent continuant doesn&apos;t have a closure axiom because the subclasses don&apos;t necessarily exhaust all possibilites. We&apos;re not sure what else will develop here, but for example there are questions such as what are promises, obligation, etc.</obo:IAO_0000116>
        <obo:IAO_0000602>(iff (SpecificallyDependentContinuant a) (and (Continuant a) (forall (t) (if (existsAt a t) (exists (b) (and (IndependentContinuant b) (not (SpatialRegion b)) (specificallyDependsOnAt a b t))))))) // axiom label in BFO2 CLIF: [050-003] </obo:IAO_0000602>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/bfo.owl"/>
        <rdfs:label xml:lang="en">specifically dependent continuant</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000020"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget xml:lang="en">b is a specifically dependent continuant = Def. b is a continuant &amp; there is some independent continuant c which is not a spatial region and which is such that b s-depends_on c at every time t during the course of b’s existence. (axiom label in BFO2 Reference: [050-003])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/050-003"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000020"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000116"/>
        <owl:annotatedTarget xml:lang="en">Specifically dependent continuant doesn&apos;t have a closure axiom because the subclasses don&apos;t necessarily exhaust all possibilites. We&apos;re not sure what else will develop here, but for example there are questions such as what are promises, obligation, etc.</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/0000005"/>
        <rdfs:comment>per discussion with Barry Smith</rdfs:comment>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000020"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(iff (SpecificallyDependentContinuant a) (and (Continuant a) (forall (t) (if (existsAt a t) (exists (b) (and (IndependentContinuant b) (not (SpatialRegion b)) (specificallyDependsOnAt a b t))))))) // axiom label in BFO2 CLIF: [050-003] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/050-003"/>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/BFO_0000023 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/BFO_0000023">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000017"/>
        <obo:BFO_0000179>role</obo:BFO_0000179>
        <obo:BFO_0000180>Role</obo:BFO_0000180>
        <obo:IAO_0000112 xml:lang="en">John’s role of husband to Mary is dependent on Mary’s role of wife to John, and both are dependent on the object aggregate comprising John and Mary as member parts joined together through the relational quality of being married.</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the priest role</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the role of a boundary to demarcate two neighboring administrative territories</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the role of a building in serving as a military target</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the role of a stone in marking a property boundary</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the role of subject in a clinical trial</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the student role</obo:IAO_0000112>
        <obo:IAO_0000115 xml:lang="en">A realizable entity  the manifestation of which brings about some result or end that is not essential to a continuant  in virtue of the kind of thing that it is but that can be served or participated in by that kind of continuant  in some kinds of natural, social or institutional contexts.</obo:IAO_0000115>
        <obo:IAO_0000116 xml:lang="en">BFO 2 Reference: One major family of examples of non-rigid universals involves roles, and ontologies developed for corresponding administrative purposes may consist entirely of representatives of entities of this sort. Thus ‘professor’, defined as follows,b instance_of professor at t =Def. there is some c, c instance_of professor role &amp; c inheres_in b at t.denotes a non-rigid universal and so also do ‘nurse’, ‘student’, ‘colonel’, ‘taxpayer’, and so forth. (These terms are all, in the jargon of philosophy, phase sortals.) By using role terms in definitions, we can create a BFO conformant treatment of such entities drawing on the fact that, while an instance of professor may be simultaneously an instance of trade union member, no instance of the type professor role is also (at any time) an instance of the type trade union member role (any more than any instance of the type color is at any time an instance of the type length).If an ontology of employment positions should be defined in terms of roles following the above pattern, this enables the ontology to do justice to the fact that individuals instantiate the corresponding universals –  professor, sergeant, nurse – only during certain phases in their lives.</obo:IAO_0000116>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/omrse.owl"/>
        <obo:IAO_0000600 xml:lang="en">b is a role means: b is a realizable entity &amp; b exists because there is some single bearer that is in some special physical, social, or institutional set of circumstances in which this bearer does not have to be&amp; b is not such that, if it ceases to exist, then the physical make-up of the bearer is thereby changed. (axiom label in BFO2 Reference: [061-001])</obo:IAO_0000600>
        <obo:IAO_0000602>(forall (x) (if (Role x) (RealizableEntity x))) // axiom label in BFO2 CLIF: [061-001] </obo:IAO_0000602>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/bfo.owl"/>
        <rdfs:label xml:lang="en">role</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000023"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000600"/>
        <owl:annotatedTarget xml:lang="en">b is a role means: b is a realizable entity &amp; b exists because there is some single bearer that is in some special physical, social, or institutional set of circumstances in which this bearer does not have to be&amp; b is not such that, if it ceases to exist, then the physical make-up of the bearer is thereby changed. (axiom label in BFO2 Reference: [061-001])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/061-001"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000023"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(forall (x) (if (Role x) (RealizableEntity x))) // axiom label in BFO2 CLIF: [061-001] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/061-001"/>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/BFO_0000024 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/BFO_0000024">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000040"/>
        <obo:BFO_0000179>fiat-object-part</obo:BFO_0000179>
        <obo:BFO_0000180>FiatObjectPart</obo:BFO_0000180>
        <obo:IAO_0000112 xml:lang="en">or with divisions drawn by cognitive subjects for practical reasons, such as the division of a cake (before slicing) into (what will become) slices (and thus member parts of an object aggregate). However, this does not mean that fiat object parts are dependent for their existence on divisions or delineations effected by cognitive subjects. If, for example, it is correct to conceive geological layers of the Earth as fiat object parts of the Earth, then even though these layers were first delineated in recent times, still existed long before such delineation and what holds of these layers (for example that the oldest layers are also the lowest layers) did not begin to hold because of our acts of delineation.Treatment of material entity in BFOExamples viewed by some as problematic cases for the trichotomy of fiat object part, object, and object aggregate include: a mussel on (and attached to) a rock, a slime mold, a pizza, a cloud, a galaxy, a railway train with engine and multiple carriages, a clonal stand of quaking aspen, a bacterial community (biofilm), a broken femur. Note that, as Aristotle already clearly recognized, such problematic cases – which lie at or near the penumbra of instances defined by the categories in question – need not invalidate these categories. The existence of grey objects does not prove that there are not objects which are black and objects which are white; the existence of mules does not prove that there are not objects which are donkeys and objects which are horses. It does, however, show that the examples in question need to be addressed carefully in order to show how they can be fitted into the proposed scheme, for example by recognizing additional subdivisions [29</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the FMA:regional parts of an intact human body.</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the Western hemisphere of the Earth</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the division of the brain into regions</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the division of the planet into hemispheres</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the dorsal and ventral surfaces of the body</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the upper and lower lobes of the left lung</obo:IAO_0000112>
        <obo:IAO_0000116 xml:lang="en">BFO 2 Reference: Most examples of fiat object parts are associated with theoretically drawn divisions</obo:IAO_0000116>
        <obo:IAO_0000600 xml:lang="en">b is a fiat object part = Def. b is a material entity which is such that for all times t, if b exists at t then there is some object c such that b proper continuant_part of  c at t and c is demarcated from the remainder of c by a two-dimensional continuant fiat boundary. (axiom label in BFO2 Reference: [027-004])</obo:IAO_0000600>
        <obo:IAO_0000602>(forall (x) (if (FiatObjectPart x) (and (MaterialEntity x) (forall (t) (if (existsAt x t) (exists (y) (and (Object y) (properContinuantPartOfAt x y t)))))))) // axiom label in BFO2 CLIF: [027-004] </obo:IAO_0000602>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/bfo.owl"/>
        <rdfs:label xml:lang="en">fiat object part</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000024"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000600"/>
        <owl:annotatedTarget xml:lang="en">b is a fiat object part = Def. b is a material entity which is such that for all times t, if b exists at t then there is some object c such that b proper continuant_part of  c at t and c is demarcated from the remainder of c by a two-dimensional continuant fiat boundary. (axiom label in BFO2 Reference: [027-004])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/027-004"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000024"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(forall (x) (if (FiatObjectPart x) (and (MaterialEntity x) (forall (t) (if (existsAt x t) (exists (y) (and (Object y) (properContinuantPartOfAt x y t)))))))) // axiom label in BFO2 CLIF: [027-004] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/027-004"/>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/BFO_0000026 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/BFO_0000026">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000006"/>
        <owl:disjointWith rdf:resource="http://purl.obolibrary.org/obo/BFO_0000028"/>
        <obo:BFO_0000179>1d-s-region</obo:BFO_0000179>
        <obo:BFO_0000180>OneDimensionalSpatialRegion</obo:BFO_0000180>
        <obo:IAO_0000112 xml:lang="en">an edge of a cube-shaped portion of space.</obo:IAO_0000112>
        <obo:IAO_0000600 xml:lang="en">A one-dimensional spatial region is a line or aggregate of lines stretching from one point in space to another. (axiom label in BFO2 Reference: [038-001])</obo:IAO_0000600>
        <obo:IAO_0000602>(forall (x) (if (OneDimensionalSpatialRegion x) (SpatialRegion x))) // axiom label in BFO2 CLIF: [038-001] </obo:IAO_0000602>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/bfo.owl"/>
        <rdfs:label xml:lang="en">one-dimensional spatial region</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000026"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000600"/>
        <owl:annotatedTarget xml:lang="en">A one-dimensional spatial region is a line or aggregate of lines stretching from one point in space to another. (axiom label in BFO2 Reference: [038-001])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/038-001"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000026"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(forall (x) (if (OneDimensionalSpatialRegion x) (SpatialRegion x))) // axiom label in BFO2 CLIF: [038-001] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/038-001"/>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/BFO_0000027 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/BFO_0000027">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000040"/>
        <obo:BFO_0000179>object-aggregate</obo:BFO_0000179>
        <obo:BFO_0000180>ObjectAggregate</obo:BFO_0000180>
        <obo:IAO_0000112 xml:lang="en">a collection of cells in a blood biobank.</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">a swarm of bees is an aggregate of members who are linked together through natural bonds</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">a symphony orchestra</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">an organization is an aggregate whose member parts have roles of specific types (for example in a jazz band, a chess club, a football team)</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">defined by fiat: the aggregate of members of an organization</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">defined through physical attachment: the aggregate of atoms in a lump of granite</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">defined through physical containment: the aggregate of molecules of carbon dioxide in a sealed container</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">defined via attributive delimitations such as: the patients in this hospital</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the aggregate of bearings in a constant velocity axle joint</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the aggregate of blood cells in your body</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the nitrogen atoms in the atmosphere</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the restaurants in Palo Alto</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">your collection of Meissen ceramic plates.</obo:IAO_0000112>
        <obo:IAO_0000116>An entity a is an object aggregate if and only if there is a mutually exhaustive and pairwise disjoint partition of a into objects </obo:IAO_0000116>
        <obo:IAO_0000116 xml:lang="en">BFO 2 Reference: object aggregates may gain and lose parts while remaining numerically identical (one and the same individual) over time. This holds both for aggregates whose membership is determined naturally (the aggregate of cells in your body) and aggregates determined by fiat (a baseball team, a congressional committee).</obo:IAO_0000116>
        <obo:IAO_0000119>ISBN:978-3-938793-98-5pp124-158#Thomas Bittner and Barry Smith, &apos;A Theory of Granular Partitions&apos;, in K. Munn and B. Smith (eds.), Applied Ontology: An Introduction, Frankfurt/Lancaster: ontos, 2008, 125-158.</obo:IAO_0000119>
        <obo:IAO_0000600 xml:lang="en">b is an object aggregate means: b is a material entity consisting exactly of a plurality of objects as member_parts at all times at which b exists. (axiom label in BFO2 Reference: [025-004])</obo:IAO_0000600>
        <obo:IAO_0000602>(forall (x) (if (ObjectAggregate x) (and (MaterialEntity x) (forall (t) (if (existsAt x t) (exists (y z) (and (Object y) (Object z) (memberPartOfAt y x t) (memberPartOfAt z x t) (not (= y z)))))) (not (exists (w t_1) (and (memberPartOfAt w x t_1) (not (Object w)))))))) // axiom label in BFO2 CLIF: [025-004] </obo:IAO_0000602>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/bfo.owl"/>
        <rdfs:label xml:lang="en">object aggregate</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000027"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000116"/>
        <owl:annotatedTarget>An entity a is an object aggregate if and only if there is a mutually exhaustive and pairwise disjoint partition of a into objects </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/0000011"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000027"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000116"/>
        <owl:annotatedTarget>An entity a is an object aggregate if and only if there is a mutually exhaustive and pairwise disjoint partition of a into objects </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/0000301"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000027"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000119"/>
        <owl:annotatedTarget>ISBN:978-3-938793-98-5pp124-158#Thomas Bittner and Barry Smith, &apos;A Theory of Granular Partitions&apos;, in K. Munn and B. Smith (eds.), Applied Ontology: An Introduction, Frankfurt/Lancaster: ontos, 2008, 125-158.</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/0000300"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000027"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000600"/>
        <owl:annotatedTarget xml:lang="en">b is an object aggregate means: b is a material entity consisting exactly of a plurality of objects as member_parts at all times at which b exists. (axiom label in BFO2 Reference: [025-004])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/025-004"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000027"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(forall (x) (if (ObjectAggregate x) (and (MaterialEntity x) (forall (t) (if (existsAt x t) (exists (y z) (and (Object y) (Object z) (memberPartOfAt y x t) (memberPartOfAt z x t) (not (= y z)))))) (not (exists (w t_1) (and (memberPartOfAt w x t_1) (not (Object w)))))))) // axiom label in BFO2 CLIF: [025-004] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/025-004"/>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/BFO_0000028 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/BFO_0000028">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000006"/>
        <obo:BFO_0000179>3d-s-region</obo:BFO_0000179>
        <obo:BFO_0000180>ThreeDimensionalSpatialRegion</obo:BFO_0000180>
        <obo:IAO_0000112 xml:lang="en">a cube-shaped region of space</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">a sphere-shaped region of space,</obo:IAO_0000112>
        <obo:IAO_0000600 xml:lang="en">A three-dimensional spatial region is a spatial region that is of three dimensions. (axiom label in BFO2 Reference: [040-001])</obo:IAO_0000600>
        <obo:IAO_0000602>(forall (x) (if (ThreeDimensionalSpatialRegion x) (SpatialRegion x))) // axiom label in BFO2 CLIF: [040-001] </obo:IAO_0000602>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/bfo.owl"/>
        <rdfs:label xml:lang="en">three-dimensional spatial region</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000028"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000600"/>
        <owl:annotatedTarget xml:lang="en">A three-dimensional spatial region is a spatial region that is of three dimensions. (axiom label in BFO2 Reference: [040-001])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/040-001"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000028"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(forall (x) (if (ThreeDimensionalSpatialRegion x) (SpatialRegion x))) // axiom label in BFO2 CLIF: [040-001] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/040-001"/>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/BFO_0000029 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/BFO_0000029">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000141"/>
        <obo:BFO_0000179>site</obo:BFO_0000179>
        <obo:BFO_0000180>Site</obo:BFO_0000180>
        <obo:IAO_0000112 xml:lang="en">Manhattan Canyon)</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">a hole in the interior of a portion of cheese</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">a rabbit hole</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">an air traffic control region defined in the airspace above an airport</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the Grand Canyon</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the Piazza San Marco</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the cockpit of an aircraft</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the hold of a ship</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the interior of a kangaroo pouch</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the interior of the trunk of your car</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the interior of your bedroom</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the interior of your office</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the interior of your refrigerator</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the lumen of your gut</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">your left nostril (a fiat part – the opening – of your left nasal cavity)</obo:IAO_0000112>
        <obo:IAO_0000600 xml:lang="en">b is a site means: b is a three-dimensional immaterial entity that is (partially or wholly) bounded by a material entity or it is a three-dimensional immaterial part thereof. (axiom label in BFO2 Reference: [034-002])</obo:IAO_0000600>
        <obo:IAO_0000602>(forall (x) (if (Site x) (ImmaterialEntity x))) // axiom label in BFO2 CLIF: [034-002] </obo:IAO_0000602>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/bfo.owl"/>
        <rdfs:label xml:lang="en">site</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000029"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000600"/>
        <owl:annotatedTarget xml:lang="en">b is a site means: b is a three-dimensional immaterial entity that is (partially or wholly) bounded by a material entity or it is a three-dimensional immaterial part thereof. (axiom label in BFO2 Reference: [034-002])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/034-002"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000029"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(forall (x) (if (Site x) (ImmaterialEntity x))) // axiom label in BFO2 CLIF: [034-002] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/034-002"/>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/BFO_0000030 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/BFO_0000030">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000040"/>
        <obo:BFO_0000179>object</obo:BFO_0000179>
        <obo:BFO_0000180>Object</obo:BFO_0000180>
        <obo:IAO_0000112 xml:lang="en">atom</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">cell</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">cells and organisms</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">engineered artifacts</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">grain of sand</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">molecule</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">organelle</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">organism</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">planet</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">solid portions of matter</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">star</obo:IAO_0000112>
        <obo:IAO_0000116 xml:lang="en">BFO 2 Reference: BFO rests on the presupposition that at multiple micro-, meso- and macroscopic scales reality exhibits certain stable, spatially separated or separable material units, combined or combinable into aggregates of various sorts (for example organisms into what are called ‘populations’). Such units play a central role in almost all domains of natural science from particle physics to cosmology. Many scientific laws govern the units in question, employing general terms (such as ‘molecule’ or ‘planet’) referring to the types and subtypes of units, and also to the types and subtypes of the processes through which such units develop and interact. The division of reality into such natural units is at the heart of biological science, as also is the fact that these units may form higher-level units (as cells form multicellular organisms) and that they may also form aggregates of units, for example as cells form portions of tissue and organs form families, herds, breeds, species, and so on. At the same time, the division of certain portions of reality into engineered units (manufactured artifacts) is the basis of modern industrial technology, which rests on the distributed mass production of engineered parts through division of labor and on their assembly into larger, compound units such as cars and laptops. The division of portions of reality into units is one starting point for the phenomenon of counting.</obo:IAO_0000116>
        <obo:IAO_0000116 xml:lang="en">BFO 2 Reference: Each object is such that there are entities of which we can assert unproblematically that they lie in its interior, and other entities of which we can assert unproblematically that they lie in its exterior. This may not be so for entities lying at or near the boundary between the interior and exterior. This means that two objects – for example the two cells depicted in Figure 3 – may be such that there are material entities crossing their boundaries which belong determinately to neither cell. Something similar obtains in certain cases of conjoined twins (see below).</obo:IAO_0000116>
        <obo:IAO_0000116 xml:lang="en">BFO 2 Reference: To say that b is causally unified means: b is a material entity which is such that its material parts are tied together in such a way that, in environments typical for entities of the type in question,if c, a continuant part of b that is in the interior of b at t, is larger than a certain threshold size (which will be determined differently from case to case, depending on factors such as porosity of external cover) and is moved in space to be at t at a location on the exterior of the spatial region that had been occupied by b at t, then either b’s other parts will be moved in coordinated fashion or b will be damaged (be affected, for example, by breakage or tearing) in the interval between t and t.causal changes in one part of b can have consequences for other parts of b without the mediation of any entity that lies on the exterior of b. Material entities with no proper material parts would satisfy these conditions trivially. Candidate examples of types of causal unity for material entities of more complex sorts are as follows (this is not intended to be an exhaustive list):CU1: Causal unity via physical coveringHere the parts in the interior of the unified entity are combined together causally through a common membrane or other physical covering\. The latter points outwards toward and may serve a protective function in relation to what lies on the exterior of the entity [13, 47</obo:IAO_0000116>
        <obo:IAO_0000116 xml:lang="en">BFO 2 Reference: an object is a maximal causally unified material entity</obo:IAO_0000116>
        <obo:IAO_0000116 xml:lang="en">BFO 2 Reference: ‘objects’ are sometimes referred to as ‘grains’ [74</obo:IAO_0000116>
        <obo:IAO_0000600 xml:lang="en">b is an object means: b is a material entity which manifests causal unity of one or other of the types CUn listed above &amp; is of a type (a material universal) instances of which are maximal relative to this criterion of causal unity. (axiom label in BFO2 Reference: [024-001])</obo:IAO_0000600>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/bfo.owl"/>
        <rdfs:label xml:lang="en">object</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000030"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000600"/>
        <owl:annotatedTarget xml:lang="en">b is an object means: b is a material entity which manifests causal unity of one or other of the types CUn listed above &amp; is of a type (a material universal) instances of which are maximal relative to this criterion of causal unity. (axiom label in BFO2 Reference: [024-001])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/024-001"/>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/BFO_0000031 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/BFO_0000031">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000002"/>
        <obo:BFO_0000179>gdc</obo:BFO_0000179>
        <obo:BFO_0000180>GenericallyDependentContinuant</obo:BFO_0000180>
        <obo:IAO_0000112 xml:lang="en">The entries in your database are patterns instantiated as quality instances in your hard drive. The database itself is an aggregate of such patterns. When you create the database you create a particular instance of the generically dependent continuant type database. Each entry in the database is an instance of the generically dependent continuant type IAO: information content entity.</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the pdf file on your laptop, the pdf file that is a copy thereof on my laptop</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the sequence of this protein molecule; the sequence that is a copy thereof in that protein molecule.</obo:IAO_0000112>
        <obo:IAO_0000115 xml:lang="en">A continuant that is dependent on one or other independent continuant bearers. For every instance of A requires some instance of (an independent continuant type) B but which instance of B serves can change from time to time.</obo:IAO_0000115>
        <obo:IAO_0000115 xml:lang="en">b is a generically dependent continuant = Def. b is a continuant that g-depends_on one or more other entities. (axiom label in BFO2 Reference: [074-001])</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/dron.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/envo.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/iao.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ogms.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/omrse.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <obo:IAO_0000602>(iff (GenericallyDependentContinuant a) (and (Continuant a) (exists (b t) (genericallyDependsOnAt a b t)))) // axiom label in BFO2 CLIF: [074-001] </obo:IAO_0000602>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/bfo.owl"/>
        <rdfs:label xml:lang="en">generically dependent continuant</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000031"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget xml:lang="en">b is a generically dependent continuant = Def. b is a continuant that g-depends_on one or more other entities. (axiom label in BFO2 Reference: [074-001])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/074-001"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000031"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(iff (GenericallyDependentContinuant a) (and (Continuant a) (exists (b t) (genericallyDependsOnAt a b t)))) // axiom label in BFO2 CLIF: [074-001] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/074-001"/>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/BFO_0000034 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/BFO_0000034">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000016"/>
        <obo:BFO_0000179>function</obo:BFO_0000179>
        <obo:BFO_0000180>Function</obo:BFO_0000180>
        <obo:IAO_0000112 xml:lang="en">the function of a hammer to drive in nails</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the function of a heart pacemaker to regulate the beating of a heart through electricity</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the function of amylase in saliva to break down starch into sugar</obo:IAO_0000112>
        <obo:IAO_0000116 xml:lang="en">BFO 2 Reference: In the past, we have distinguished two varieties of function, artifactual function and biological function. These are not asserted subtypes of BFO:function however, since the same function – for example: to pump, to transport – can exist both in artifacts and in biological entities. The asserted subtypes of function that would be needed in order to yield a separate monoheirarchy are not artifactual function, biological function, etc., but rather transporting function, pumping function, etc.</obo:IAO_0000116>
        <obo:IAO_0000600 xml:lang="en">A function is a disposition that exists in virtue of the bearer’s physical make-up and this physical make-up is something the bearer possesses because it came into being, either through evolution (in the case of natural biological entities) or through intentional design (in the case of artifacts), in order to realize processes of a certain sort. (axiom label in BFO2 Reference: [064-001])</obo:IAO_0000600>
        <obo:IAO_0000602>(forall (x) (if (Function x) (Disposition x))) // axiom label in BFO2 CLIF: [064-001] </obo:IAO_0000602>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/bfo.owl"/>
        <rdfs:label xml:lang="en">function</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000034"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000600"/>
        <owl:annotatedTarget xml:lang="en">A function is a disposition that exists in virtue of the bearer’s physical make-up and this physical make-up is something the bearer possesses because it came into being, either through evolution (in the case of natural biological entities) or through intentional design (in the case of artifacts), in order to realize processes of a certain sort. (axiom label in BFO2 Reference: [064-001])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/064-001"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000034"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(forall (x) (if (Function x) (Disposition x))) // axiom label in BFO2 CLIF: [064-001] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/064-001"/>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/BFO_0000035 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/BFO_0000035">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000003"/>
        <obo:BFO_0000179>p-boundary</obo:BFO_0000179>
        <obo:BFO_0000180>ProcessBoundary</obo:BFO_0000180>
        <obo:IAO_0000112 xml:lang="en">the boundary between the 2nd and 3rd year of your life.</obo:IAO_0000112>
        <obo:IAO_0000115 xml:lang="en">p is a process boundary =Def. p is a temporal part of a process &amp; p has no proper temporal parts. (axiom label in BFO2 Reference: [084-001])</obo:IAO_0000115>
        <obo:IAO_0000601 xml:lang="en">Every process boundary occupies_temporal_region a zero-dimensional temporal region. (axiom label in BFO2 Reference: [085-002])</obo:IAO_0000601>
        <obo:IAO_0000602>(forall (x) (if (ProcessBoundary x) (exists (y) (and (ZeroDimensionalTemporalRegion y) (occupiesTemporalRegion x y))))) // axiom label in BFO2 CLIF: [085-002] </obo:IAO_0000602>
        <obo:IAO_0000602>(iff (ProcessBoundary a) (exists (p) (and (Process p) (temporalPartOf a p) (not (exists (b) (properTemporalPartOf b a)))))) // axiom label in BFO2 CLIF: [084-001] </obo:IAO_0000602>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/bfo.owl"/>
        <rdfs:label xml:lang="en">process boundary</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000035"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget xml:lang="en">p is a process boundary =Def. p is a temporal part of a process &amp; p has no proper temporal parts. (axiom label in BFO2 Reference: [084-001])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/084-001"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000035"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000601"/>
        <owl:annotatedTarget xml:lang="en">Every process boundary occupies_temporal_region a zero-dimensional temporal region. (axiom label in BFO2 Reference: [085-002])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/085-002"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000035"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(forall (x) (if (ProcessBoundary x) (exists (y) (and (ZeroDimensionalTemporalRegion y) (occupiesTemporalRegion x y))))) // axiom label in BFO2 CLIF: [085-002] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/085-002"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000035"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(iff (ProcessBoundary a) (exists (p) (and (Process p) (temporalPartOf a p) (not (exists (b) (properTemporalPartOf b a)))))) // axiom label in BFO2 CLIF: [084-001] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/084-001"/>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/BFO_0000038 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/BFO_0000038">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000008"/>
        <owl:disjointWith rdf:resource="http://purl.obolibrary.org/obo/BFO_0000148"/>
        <obo:BFO_0000179>1d-t-region</obo:BFO_0000179>
        <obo:BFO_0000180>OneDimensionalTemporalRegion</obo:BFO_0000180>
        <obo:IAO_0000112 xml:lang="en">the temporal region during which a process occurs.</obo:IAO_0000112>
        <obo:IAO_0000116 xml:lang="en">BFO 2 Reference: A temporal interval is a special kind of one-dimensional temporal region, namely one that is self-connected (is without gaps or breaks).</obo:IAO_0000116>
        <obo:IAO_0000600 xml:lang="en">A one-dimensional temporal region is a temporal region that is extended. (axiom label in BFO2 Reference: [103-001])</obo:IAO_0000600>
        <obo:IAO_0000602>(forall (x) (if (OneDimensionalTemporalRegion x) (TemporalRegion x))) // axiom label in BFO2 CLIF: [103-001] </obo:IAO_0000602>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/bfo.owl"/>
        <rdfs:label xml:lang="en">one-dimensional temporal region</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000038"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000600"/>
        <owl:annotatedTarget xml:lang="en">A one-dimensional temporal region is a temporal region that is extended. (axiom label in BFO2 Reference: [103-001])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/103-001"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000038"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(forall (x) (if (OneDimensionalTemporalRegion x) (TemporalRegion x))) // axiom label in BFO2 CLIF: [103-001] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/103-001"/>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/BFO_0000040 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/BFO_0000040">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000004"/>
        <owl:disjointWith rdf:resource="http://purl.obolibrary.org/obo/BFO_0000141"/>
        <obo:BFO_0000179>material</obo:BFO_0000179>
        <obo:BFO_0000180>MaterialEntity</obo:BFO_0000180>
        <obo:IAO_0000112 xml:lang="en">a flame</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">a forest fire</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">a human being</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">a hurricane</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">a photon</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">a puff of smoke</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">a sea wave</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">a tornado</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">an aggregate of human beings.</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">an energy wave</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">an epidemic</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the undetached arm of a human being</obo:IAO_0000112>
        <obo:IAO_0000115 xml:lang="en">An independent continuant that is spatially extended whose identity is independent of that of other entities and can be maintained through time.</obo:IAO_0000115>
        <obo:IAO_0000116 xml:lang="en">BFO 2 Reference: Material entities (continuants) can preserve their identity even while gaining and losing material parts. Continuants are contrasted with occurrents, which unfold themselves in successive temporal parts or phases [60</obo:IAO_0000116>
        <obo:IAO_0000116 xml:lang="en">BFO 2 Reference: Object, Fiat Object Part and Object Aggregate are not intended to be exhaustive of Material Entity. Users are invited to propose new subcategories of Material Entity.</obo:IAO_0000116>
        <obo:IAO_0000116 xml:lang="en">BFO 2 Reference: ‘Matter’ is intended to encompass both mass and energy (we will address the ontological treatment of portions of energy in a later version of BFO). A portion of matter is anything that includes elementary particles among its proper or improper parts: quarks and leptons, including electrons, as the smallest particles thus far discovered; baryons (including protons and neutrons) at a higher level of granularity; atoms and molecules at still higher levels, forming the cells, organs, organisms and other material entities studied by biologists, the portions of rock studied by geologists, the fossils studied by paleontologists, and so on.Material entities are three-dimensional entities (entities extended in three spatial dimensions), as contrasted with the processes in which they participate, which are four-dimensional entities (entities extended also along the dimension of time).According to the FMA, material entities may have immaterial entities as parts – including the entities identified below as sites; for example the interior (or ‘lumen’) of your small intestine is a part of your body. BFO 2.0 embodies a decision to follow the FMA here.</obo:IAO_0000116>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/dron.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ero.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <obo:IAO_0000600 xml:lang="en">A material entity is an independent continuant that has some portion of matter as proper or improper continuant part. (axiom label in BFO2 Reference: [019-002])</obo:IAO_0000600>
        <obo:IAO_0000601 xml:lang="en">Every entity which has a material entity as continuant part is a material entity. (axiom label in BFO2 Reference: [020-002])</obo:IAO_0000601>
        <obo:IAO_0000601 xml:lang="en">every entity of which a material entity is continuant part is also a material entity. (axiom label in BFO2 Reference: [021-002])</obo:IAO_0000601>
        <obo:IAO_0000602>(forall (x) (if (MaterialEntity x) (IndependentContinuant x))) // axiom label in BFO2 CLIF: [019-002] </obo:IAO_0000602>
        <obo:IAO_0000602>(forall (x) (if (and (Entity x) (exists (y t) (and (MaterialEntity y) (continuantPartOfAt x y t)))) (MaterialEntity x))) // axiom label in BFO2 CLIF: [021-002] </obo:IAO_0000602>
        <obo:IAO_0000602>(forall (x) (if (and (Entity x) (exists (y t) (and (MaterialEntity y) (continuantPartOfAt y x t)))) (MaterialEntity x))) // axiom label in BFO2 CLIF: [020-002] </obo:IAO_0000602>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/bfo.owl"/>
        <rdfs:label xml:lang="en">material entity</rdfs:label>
        <rdfs:label xml:lang="en">material_entity</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000040"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000600"/>
        <owl:annotatedTarget xml:lang="en">A material entity is an independent continuant that has some portion of matter as proper or improper continuant part. (axiom label in BFO2 Reference: [019-002])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/019-002"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000040"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000601"/>
        <owl:annotatedTarget xml:lang="en">Every entity which has a material entity as continuant part is a material entity. (axiom label in BFO2 Reference: [020-002])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/020-002"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000040"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000601"/>
        <owl:annotatedTarget xml:lang="en">every entity of which a material entity is continuant part is also a material entity. (axiom label in BFO2 Reference: [021-002])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/021-002"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000040"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(forall (x) (if (MaterialEntity x) (IndependentContinuant x))) // axiom label in BFO2 CLIF: [019-002] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/019-002"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000040"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(forall (x) (if (and (Entity x) (exists (y t) (and (MaterialEntity y) (continuantPartOfAt x y t)))) (MaterialEntity x))) // axiom label in BFO2 CLIF: [021-002] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/021-002"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000040"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(forall (x) (if (and (Entity x) (exists (y t) (and (MaterialEntity y) (continuantPartOfAt y x t)))) (MaterialEntity x))) // axiom label in BFO2 CLIF: [020-002] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/020-002"/>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/BFO_0000140 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/BFO_0000140">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000141"/>
        <obo:BFO_0000179>cf-boundary</obo:BFO_0000179>
        <obo:BFO_0000180>ContinuantFiatBoundary</obo:BFO_0000180>
        <obo:IAO_0000115 xml:lang="en">b is a continuant fiat boundary = Def. b is an immaterial entity that is of zero, one or two dimensions and does not include a spatial region as part. (axiom label in BFO2 Reference: [029-001])</obo:IAO_0000115>
        <obo:IAO_0000116 xml:lang="en">BFO 2 Reference: In BFO 1.1 the assumption was made that the external surface of a material entity such as a cell could be treated as if it were a boundary in the mathematical sense. The new document propounds the view that when we talk about external surfaces of material objects in this way then we are talking about something fiat. To be dealt with in a future version: fiat boundaries at different levels of granularity.More generally, the focus in discussion of boundaries in BFO 2.0 is now on fiat boundaries, which means: boundaries for which there is no assumption that they coincide with physical discontinuities. The ontology of boundaries becomes more closely allied with the ontology of regions.</obo:IAO_0000116>
        <obo:IAO_0000116 xml:lang="en">BFO 2 Reference: a continuant fiat boundary is a boundary of some material entity (for example: the plane separating the Northern and Southern hemispheres; the North Pole), or it is a boundary of some immaterial entity (for example of some portion of airspace). Three basic kinds of continuant fiat boundary can be distinguished (together with various combination kinds [29</obo:IAO_0000116>
        <obo:IAO_0000116 xml:lang="en">Continuant fiat boundary doesn&apos;t have a closure axiom because the subclasses don&apos;t necessarily exhaust all possibilites. An example would be the mereological sum of two-dimensional continuant fiat boundary and a one dimensional continuant fiat boundary that doesn&apos;t overlap it. The situation is analogous to temporal and spatial regions.</obo:IAO_0000116>
        <obo:IAO_0000601 xml:lang="en">Every continuant fiat boundary is located at some spatial region at every time at which it exists</obo:IAO_0000601>
        <obo:IAO_0000602>(iff (ContinuantFiatBoundary a) (and (ImmaterialEntity a) (exists (b) (and (or (ZeroDimensionalSpatialRegion b) (OneDimensionalSpatialRegion b) (TwoDimensionalSpatialRegion b)) (forall (t) (locatedInAt a b t)))) (not (exists (c t) (and (SpatialRegion c) (continuantPartOfAt c a t)))))) // axiom label in BFO2 CLIF: [029-001] </obo:IAO_0000602>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/bfo.owl"/>
        <rdfs:label xml:lang="en">continuant fiat boundary</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000140"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget xml:lang="en">b is a continuant fiat boundary = Def. b is an immaterial entity that is of zero, one or two dimensions and does not include a spatial region as part. (axiom label in BFO2 Reference: [029-001])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/029-001"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000140"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000116"/>
        <owl:annotatedTarget xml:lang="en">Continuant fiat boundary doesn&apos;t have a closure axiom because the subclasses don&apos;t necessarily exhaust all possibilites. An example would be the mereological sum of two-dimensional continuant fiat boundary and a one dimensional continuant fiat boundary that doesn&apos;t overlap it. The situation is analogous to temporal and spatial regions.</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/0000008"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000140"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(iff (ContinuantFiatBoundary a) (and (ImmaterialEntity a) (exists (b) (and (or (ZeroDimensionalSpatialRegion b) (OneDimensionalSpatialRegion b) (TwoDimensionalSpatialRegion b)) (forall (t) (locatedInAt a b t)))) (not (exists (c t) (and (SpatialRegion c) (continuantPartOfAt c a t)))))) // axiom label in BFO2 CLIF: [029-001] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/029-001"/>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/BFO_0000141 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/BFO_0000141">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000004"/>
        <obo:BFO_0000179>immaterial</obo:BFO_0000179>
        <obo:BFO_0000180>ImmaterialEntity</obo:BFO_0000180>
        <obo:IAO_0000116 xml:lang="en">BFO 2 Reference: Immaterial entities are divided into two subgroups:boundaries and sites, which bound, or are demarcated in relation, to material entities, and which can thus change location, shape and size and as their material hosts move or change shape or size (for example: your nasal passage; the hold of a ship; the boundary of Wales (which moves with the rotation of the Earth) [38, 7, 10</obo:IAO_0000116>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/bfo.owl"/>
        <rdfs:label xml:lang="en">immaterial entity</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/BFO_0000142 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/BFO_0000142">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000140"/>
        <owl:disjointWith rdf:resource="http://purl.obolibrary.org/obo/BFO_0000146"/>
        <owl:disjointWith rdf:resource="http://purl.obolibrary.org/obo/BFO_0000147"/>
        <obo:BFO_0000179>1d-cf-boundary</obo:BFO_0000179>
        <obo:BFO_0000180>OneDimensionalContinuantFiatBoundary</obo:BFO_0000180>
        <obo:IAO_0000112 xml:lang="en">The Equator</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">all geopolitical boundaries</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">all lines of latitude and longitude</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the line separating the outer surface of the mucosa of the lower lip from the outer surface of the skin of the chin.</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the median sulcus of your tongue</obo:IAO_0000112>
        <obo:IAO_0000600 xml:lang="en">a one-dimensional continuant fiat boundary is a continuous fiat line whose location is defined in relation to some material entity. (axiom label in BFO2 Reference: [032-001])</obo:IAO_0000600>
        <obo:IAO_0000602>(iff (OneDimensionalContinuantFiatBoundary a) (and (ContinuantFiatBoundary a) (exists (b) (and (OneDimensionalSpatialRegion b) (forall (t) (locatedInAt a b t)))))) // axiom label in BFO2 CLIF: [032-001] </obo:IAO_0000602>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/bfo.owl"/>
        <rdfs:label xml:lang="en">one-dimensional continuant fiat boundary</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000142"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000600"/>
        <owl:annotatedTarget xml:lang="en">a one-dimensional continuant fiat boundary is a continuous fiat line whose location is defined in relation to some material entity. (axiom label in BFO2 Reference: [032-001])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/032-001"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000142"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(iff (OneDimensionalContinuantFiatBoundary a) (and (ContinuantFiatBoundary a) (exists (b) (and (OneDimensionalSpatialRegion b) (forall (t) (locatedInAt a b t)))))) // axiom label in BFO2 CLIF: [032-001] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/032-001"/>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/BFO_0000144 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/BFO_0000144">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000015"/>
        <owl:disjointWith rdf:resource="http://purl.obolibrary.org/obo/BFO_0000182"/>
        <obo:BFO_0000179>process-profile</obo:BFO_0000179>
        <obo:BFO_0000180>ProcessProfile</obo:BFO_0000180>
        <obo:IAO_0000112 xml:lang="en">On a somewhat higher level of complexity are what we shall call rate process profiles, which are the targets of selective abstraction focused not on determinate quality magnitudes plotted over time, but rather on certain ratios between these magnitudes and elapsed times. A speed process profile, for example, is represented by a graph plotting against time the ratio of distance covered per unit of time. Since rates may change, and since such changes, too, may have rates of change, we have to deal here with a hierarchy of process profile universals at successive levels</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">One important sub-family of rate process profiles is illustrated by the beat or frequency profiles of cyclical processes, illustrated by the 60 beats per minute beating process of John’s heart, or the 120 beats per minute drumming process involved in one of John’s performances in a rock band, and so on. Each such process includes what we shall call a beat process profile instance as part, a subtype of rate process profile in which the salient ratio is not distance covered but rather number of beat cycles per unit of time. Each beat process profile instance instantiates the determinable universal beat process profile. But it also instantiates multiple more specialized universals at lower levels of generality, selected from   rate process profilebeat process profileregular beat process profile3 bpm beat process profile4 bpm beat process profileirregular beat process profileincreasing beat process profileand so on.In the case of a regular beat process profile, a rate can be assigned in the simplest possible fashion by dividing the number of cycles by the length of the temporal region occupied by the beating process profile as a whole. Irregular process profiles of this sort, for example as identified in the clinic, or in the readings on an aircraft instrument panel, are often of diagnostic significance.</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">The simplest type of process profiles are what we shall call ‘quality process profiles’, which are the process profiles which serve as the foci of the sort of selective abstraction that is involved when measurements are made of changes in single qualities, as illustrated, for example, by process profiles of mass, temperature, aortic pressure, and so on.</obo:IAO_0000112>
        <obo:IAO_0000115 xml:lang="en">b is a process_profile =Def. there is some process c such that b process_profile_of c (axiom label in BFO2 Reference: [093-002])</obo:IAO_0000115>
        <obo:IAO_0000600 xml:lang="en">b process_profile_of c holds when b proper_occurrent_part_of c&amp; there is some proper_occurrent_part d of c which has no parts in common with b &amp; is mutually dependent on b&amp; is such that b, c and d occupy the same temporal region (axiom label in BFO2 Reference: [094-005])</obo:IAO_0000600>
        <obo:IAO_0000602>(forall (x y) (if (processProfileOf x y) (and (properContinuantPartOf x y) (exists (z t) (and (properOccurrentPartOf z y) (TemporalRegion t) (occupiesSpatioTemporalRegion x t) (occupiesSpatioTemporalRegion y t) (occupiesSpatioTemporalRegion z t) (not (exists (w) (and (occurrentPartOf w x) (occurrentPartOf w z))))))))) // axiom label in BFO2 CLIF: [094-005] </obo:IAO_0000602>
        <obo:IAO_0000602>(iff (ProcessProfile a) (exists (b) (and (Process b) (processProfileOf a b)))) // axiom label in BFO2 CLIF: [093-002] </obo:IAO_0000602>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/bfo.owl"/>
        <rdfs:label xml:lang="en">process profile</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000144"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget xml:lang="en">b is a process_profile =Def. there is some process c such that b process_profile_of c (axiom label in BFO2 Reference: [093-002])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/093-002"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000144"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000600"/>
        <owl:annotatedTarget xml:lang="en">b process_profile_of c holds when b proper_occurrent_part_of c&amp; there is some proper_occurrent_part d of c which has no parts in common with b &amp; is mutually dependent on b&amp; is such that b, c and d occupy the same temporal region (axiom label in BFO2 Reference: [094-005])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/094-005"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000144"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(forall (x y) (if (processProfileOf x y) (and (properContinuantPartOf x y) (exists (z t) (and (properOccurrentPartOf z y) (TemporalRegion t) (occupiesSpatioTemporalRegion x t) (occupiesSpatioTemporalRegion y t) (occupiesSpatioTemporalRegion z t) (not (exists (w) (and (occurrentPartOf w x) (occurrentPartOf w z))))))))) // axiom label in BFO2 CLIF: [094-005] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/094-005"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000144"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(iff (ProcessProfile a) (exists (b) (and (Process b) (processProfileOf a b)))) // axiom label in BFO2 CLIF: [093-002] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/093-002"/>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/BFO_0000145 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/BFO_0000145">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000019"/>
        <obo:BFO_0000179>r-quality</obo:BFO_0000179>
        <obo:BFO_0000180>RelationalQuality</obo:BFO_0000180>
        <obo:IAO_0000112 xml:lang="en">John’s role of husband to Mary is dependent on Mary’s role of wife to John, and both are dependent on the object aggregate comprising John and Mary as member parts joined together through the relational quality of being married.</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">a marriage bond, an instance of requited love, an obligation between one person and another.</obo:IAO_0000112>
        <obo:IAO_0000115 xml:lang="en">b is a relational quality = Def. for some independent continuants c, d and for some time t: b quality_of c at t &amp; b quality_of d at t. (axiom label in BFO2 Reference: [057-001])</obo:IAO_0000115>
        <obo:IAO_0000602>(iff (RelationalQuality a) (exists (b c t) (and (IndependentContinuant b) (IndependentContinuant c) (qualityOfAt a b t) (qualityOfAt a c t)))) // axiom label in BFO2 CLIF: [057-001] </obo:IAO_0000602>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/bfo.owl"/>
        <rdfs:label xml:lang="en">relational quality</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000145"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget xml:lang="en">b is a relational quality = Def. for some independent continuants c, d and for some time t: b quality_of c at t &amp; b quality_of d at t. (axiom label in BFO2 Reference: [057-001])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/057-001"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000145"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(iff (RelationalQuality a) (exists (b c t) (and (IndependentContinuant b) (IndependentContinuant c) (qualityOfAt a b t) (qualityOfAt a c t)))) // axiom label in BFO2 CLIF: [057-001] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/057-001"/>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/BFO_0000146 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/BFO_0000146">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000140"/>
        <obo:BFO_0000179>2d-cf-boundary</obo:BFO_0000179>
        <obo:BFO_0000180>TwoDimensionalContinuantFiatBoundary</obo:BFO_0000180>
        <obo:IAO_0000600 xml:lang="en">a two-dimensional continuant fiat boundary (surface) is a self-connected fiat surface whose location is defined in relation to some material entity. (axiom label in BFO2 Reference: [033-001])</obo:IAO_0000600>
        <obo:IAO_0000602>(iff (TwoDimensionalContinuantFiatBoundary a) (and (ContinuantFiatBoundary a) (exists (b) (and (TwoDimensionalSpatialRegion b) (forall (t) (locatedInAt a b t)))))) // axiom label in BFO2 CLIF: [033-001] </obo:IAO_0000602>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/bfo.owl"/>
        <rdfs:label xml:lang="en">two-dimensional continuant fiat boundary</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000146"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000600"/>
        <owl:annotatedTarget xml:lang="en">a two-dimensional continuant fiat boundary (surface) is a self-connected fiat surface whose location is defined in relation to some material entity. (axiom label in BFO2 Reference: [033-001])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/033-001"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000146"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(iff (TwoDimensionalContinuantFiatBoundary a) (and (ContinuantFiatBoundary a) (exists (b) (and (TwoDimensionalSpatialRegion b) (forall (t) (locatedInAt a b t)))))) // axiom label in BFO2 CLIF: [033-001] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/033-001"/>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/BFO_0000147 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/BFO_0000147">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000140"/>
        <obo:BFO_0000179>0d-cf-boundary</obo:BFO_0000179>
        <obo:BFO_0000180>ZeroDimensionalContinuantFiatBoundary</obo:BFO_0000180>
        <obo:IAO_0000112 xml:lang="en">the geographic North Pole</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the point of origin of some spatial coordinate system.</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the quadripoint where the boundaries of Colorado, Utah, New Mexico, and Arizona meet</obo:IAO_0000112>
        <obo:IAO_0000116 xml:lang="en">zero dimension continuant fiat boundaries are not spatial points. Considering the example &apos;the quadripoint where the boundaries of Colorado, Utah, New Mexico, and Arizona meet&apos; : There are many frames in which that point is zooming through many points in space. Whereas, no matter what the frame, the quadripoint is always in the same relation to the boundaries of Colorado, Utah, New Mexico, and Arizona.</obo:IAO_0000116>
        <obo:IAO_0000600 xml:lang="en">a zero-dimensional continuant fiat boundary is a fiat point whose location is defined in relation to some material entity. (axiom label in BFO2 Reference: [031-001])</obo:IAO_0000600>
        <obo:IAO_0000602>(iff (ZeroDimensionalContinuantFiatBoundary a) (and (ContinuantFiatBoundary a) (exists (b) (and (ZeroDimensionalSpatialRegion b) (forall (t) (locatedInAt a b t)))))) // axiom label in BFO2 CLIF: [031-001] </obo:IAO_0000602>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/bfo.owl"/>
        <rdfs:label xml:lang="en">zero-dimensional continuant fiat boundary</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000147"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000116"/>
        <owl:annotatedTarget xml:lang="en">zero dimension continuant fiat boundaries are not spatial points. Considering the example &apos;the quadripoint where the boundaries of Colorado, Utah, New Mexico, and Arizona meet&apos; : There are many frames in which that point is zooming through many points in space. Whereas, no matter what the frame, the quadripoint is always in the same relation to the boundaries of Colorado, Utah, New Mexico, and Arizona.</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/0000001"/>
        <rdfs:comment>requested by Melanie Courtot</rdfs:comment>
        <rdfs:seeAlso rdf:resource="https://groups.google.com/d/msg/bfo-owl-devel/s9Uug5QmAws/ZDRnpiIi_TUJ"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000147"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000600"/>
        <owl:annotatedTarget xml:lang="en">a zero-dimensional continuant fiat boundary is a fiat point whose location is defined in relation to some material entity. (axiom label in BFO2 Reference: [031-001])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/031-001"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000147"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(iff (ZeroDimensionalContinuantFiatBoundary a) (and (ContinuantFiatBoundary a) (exists (b) (and (ZeroDimensionalSpatialRegion b) (forall (t) (locatedInAt a b t)))))) // axiom label in BFO2 CLIF: [031-001] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/031-001"/>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/BFO_0000148 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/BFO_0000148">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000008"/>
        <obo:BFO_0000179>0d-t-region</obo:BFO_0000179>
        <obo:BFO_0000180>ZeroDimensionalTemporalRegion</obo:BFO_0000180>
        <obo:IAO_0000112 xml:lang="en">a temporal region that is occupied by a process boundary</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">right now</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the moment at which a child is born</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the moment at which a finger is detached in an industrial accident</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">the moment of death.</obo:IAO_0000112>
        <obo:IAO_0000118 xml:lang="en">temporal instant.</obo:IAO_0000118>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <obo:IAO_0000600 xml:lang="en">A zero-dimensional temporal region is a temporal region that is without extent. (axiom label in BFO2 Reference: [102-001])</obo:IAO_0000600>
        <obo:IAO_0000602>(forall (x) (if (ZeroDimensionalTemporalRegion x) (TemporalRegion x))) // axiom label in BFO2 CLIF: [102-001] </obo:IAO_0000602>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/bfo.owl"/>
        <rdfs:label xml:lang="en">zero-dimensional temporal region</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000148"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000600"/>
        <owl:annotatedTarget xml:lang="en">A zero-dimensional temporal region is a temporal region that is without extent. (axiom label in BFO2 Reference: [102-001])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/102-001"/>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000148"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000602"/>
        <owl:annotatedTarget>(forall (x) (if (ZeroDimensionalTemporalRegion x) (TemporalRegion x))) // axiom label in BFO2 CLIF: [102-001] </owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/102-001"/>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/BFO_0000182 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/BFO_0000182">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000015"/>
        <obo:BFO_0000179>history</obo:BFO_0000179>
        <obo:BFO_0000180>History</obo:BFO_0000180>
        <obo:IAO_0000600 xml:lang="en">A history is a process that is the sum of the totality of processes taking place in the spatiotemporal region occupied by a material entity or site, including processes on the surface of the entity or within the cavities to which it serves as host. (axiom label in BFO2 Reference: [138-001])</obo:IAO_0000600>
        <rdfs:isDefinedBy rdf:resource="http://purl.obolibrary.org/obo/bfo.owl"/>
        <rdfs:label xml:lang="en">history</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/BFO_0000182"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000600"/>
        <owl:annotatedTarget xml:lang="en">A history is a process that is the sum of the totality of processes taking place in the spatiotemporal region occupied by a material entity or site, including processes on the surface of the entity or within the cavities to which it serves as host. (axiom label in BFO2 Reference: [138-001])</owl:annotatedTarget>
        <obo:IAO_0010000 rdf:resource="http://purl.obolibrary.org/obo/bfo/axiom/138-001"/>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/DRON_00000005 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/DRON_00000005">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000040"/>
        <obo:IAO_0000115 xml:lang="en">a material entity (1) containing at least one scattered molecular aggregate as part that is the bearer of an active ingredient role and (2) that is itself the bearer of a clinical drug role</obo:IAO_0000115>
        <obo:IAO_0000117 xml:lang="en">William Hogan</obo:IAO_0000117>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/dron.owl"/>
        <dc:creator xml:lang="en">William Hogan</dc:creator>
        <rdfs:label xml:lang="en">drug product</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/ERO_0000014 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/ERO_0000014">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000011"/>
        <obo:IAO_0000112 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A project to study the role of a specific protein in cell signaling.</obo:IAO_0000112>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000120"/>
        <obo:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A funded collection of investigations as described in a research proposal.</obo:IAO_0000115>
        <obo:IAO_0000117 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PERSON: Melissa Haendel</obo:IAO_0000117>
        <obo:IAO_0000119 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PERSON: Melissa Haendel</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ero.owl"/>
        <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Maybe SameAs &quot;Investigation&quot; but is the subject of funding</rdfs:comment>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">research project</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/ERO_0000015 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/ERO_0000015">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/ERO_0000014"/>
        <obo:IAO_0000111 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">human study</obo:IAO_0000111>
        <obo:IAO_0000112 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A clinical trial.</obo:IAO_0000112>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000120"/>
        <obo:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Research project that uses or collects measurements or assessments about humans.</obo:IAO_0000115>
        <obo:IAO_0000117 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PERSON: Melissa Haendel</obo:IAO_0000117>
        <obo:IAO_0000119 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">OCRe</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ero.owl"/>
        <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">This should be imported from OCRE- but they currently have no generic human study type. Def is modified.</rdfs:comment>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">human study</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/ERO_0000016 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/ERO_0000016">
        <rdfs:subClassOf rdf:resource="http://purl.org/net/OCRe/research.owl#Interventional_study"/>
        <obo:IAO_0000112 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A clinical trial to evaluate the efficacy of a new drug.</obo:IAO_0000112>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000120"/>
        <obo:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An interventional study that contains a set of procedures in medical research and drug development that are conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g., drugs, diagnostics, devices, therapy protocols) that is performed over phases.</obo:IAO_0000115>
        <obo:IAO_0000117 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PERSON: Nicole Vasilevsky</obo:IAO_0000117>
        <obo:IAO_0000119 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://en.wikipedia.org/wiki/Clinical_trial</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ero.owl"/>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">clinical trial</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/ERO_0000017 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/ERO_0000017">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/ERO_0000015"/>
        <obo:IAO_0000111 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">epidemiological study</obo:IAO_0000111>
        <obo:IAO_0000112 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A study of the populations and demographic of the avian flu.</obo:IAO_0000112>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000120"/>
        <obo:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A human study of diseases in populations of humans or other animals, specifically how, when and where they occur. Epidemiological studies can never prove causation, epidemiological evidence can only show that this risk factor is correlated with a higher incidence of disease in the population exposed to that risk factor. The higher the correlation the more certain the association, but it cannot prove the causation.</obo:IAO_0000115>
        <obo:IAO_0000117 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PERSON: Karen Corday</obo:IAO_0000117>
        <obo:IAO_0000119 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://pmep.cce.cornell.edu/profiles/extoxnet/TIB/epidemiology.html</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ero.owl"/>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">epidemiological study</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/ERO_0000348 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/ERO_0000348">
        <rdfs:subClassOf rdf:resource="http://purl.org/net/OCRe/research.owl#Observational_study"/>
        <obo:IAO_0000111 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">case-only study</obo:IAO_0000111>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000123"/>
        <obo:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Observational study whereby there is a single group of individuals with specific characteristics. This is a method that analyzes data from a case series and is used in case-crossover studies, in case-specular designs, and in molecular and genetic epidemiology to assess relationships between environmental exposures and genotypes.</obo:IAO_0000115>
        <obo:IAO_0000115>single group of individuals with specific characteristics.</obo:IAO_0000115>
        <obo:IAO_0000117 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PERSON: Melissa Haendel</obo:IAO_0000117>
        <obo:IAO_0000119 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A Dictionary of Epidemiology, Fifth Edition, Edited by Miquel Porta. p. 33. ISBN:978-0-19-531449-6 http://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ero.owl"/>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">case-only study</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/ERO_0000348"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>single group of individuals with specific characteristics.</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/ERO_0000356 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/ERO_0000356">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCIT_C70840"/>
        <obo:IAO_0000111 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">open blinded study</obo:IAO_0000111>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000123"/>
        <obo:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An interventional study in which the person collecting the data and the subject know whether the subjects are in the control or experimental groups.</obo:IAO_0000115>
        <obo:IAO_0000117 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PERSON: Nicole Vasilevsky</obo:IAO_0000117>
        <obo:IAO_0000118 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Open trial</obo:IAO_0000118>
        <obo:IAO_0000118 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Open-label trial</obo:IAO_0000118>
        <obo:IAO_0000119 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://medical-dictionary.thefreedictionary.com/single-blind+study</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ero.owl"/>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">open blinded study</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/ERO_0000357 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/ERO_0000357">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCIT_C70840"/>
        <obo:IAO_0000111 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">single blinded study</obo:IAO_0000111>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000123"/>
        <obo:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An interventional study in which the person collecting the data knows whether the subjects are in the control or experimental groups but the subjects do not.</obo:IAO_0000115>
        <obo:IAO_0000117 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PERSON: Nicole Vasilevsky</obo:IAO_0000117>
        <obo:IAO_0000119 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://medical-dictionary.thefreedictionary.com/single-blind+study</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ero.owl"/>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">single blinded study</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/ERO_0000358 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/ERO_0000358">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCIT_C70840"/>
        <obo:IAO_0000111 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">double blinded study</obo:IAO_0000111>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000123"/>
        <obo:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An interventional study in which neither the subjects of the experiment nor the persons administering the experiment know the critical aspects of the experiment; a double-blind procedure is used to guard against both experimenter bias and placebo effects.</obo:IAO_0000115>
        <obo:IAO_0000117 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PERSON: Nicole Vasilevsky</obo:IAO_0000117>
        <obo:IAO_0000119 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://www.thefreedictionary.com/double-blind+study</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ero.owl"/>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">double blinded study</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/ERO_0001092 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/ERO_0001092">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000040"/>
        <obo:IAO_0000112 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A blood pressure monitor is a medical device.</obo:IAO_0000112>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000120"/>
        <obo:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An instrument used in the diagnosis of disease or other conditions or for use in the care, treatment, or prevention of disease that does not achieve any of its primary intended purposes by chemical action or by being metabolized.</obo:IAO_0000115>
        <obo:IAO_0000117 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PERSON: Nicole Vasilevsky</obo:IAO_0000117>
        <obo:IAO_0000119 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://medical-dictionary.thefreedictionary.com/medical+device </obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ero.owl"/>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">medical device </rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/ERO_0001402 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/ERO_0001402">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/ERO_0000015"/>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000123"/>
        <obo:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A preliminary study to determine the practicability of a proposed health program or procedure or of a larger study and to appraise the factors that may influence its practicability. A feasibility study aims to discover those things which may affect successful study conduct on a larger scale.</obo:IAO_0000115>
        <obo:IAO_0000117 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PERSON: Melanie Wilson</obo:IAO_0000117>
        <obo:IAO_0000119 rdf:datatype="http://www.w3.org/2001/XMLSchema#string"> Dictionary of Epidemiology, 5th edition.</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ero.owl"/>
        <rdfs:label xml:lang="en">feasibility study</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/ERO_0001843 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/ERO_0001843">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000245"/>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000123"/>
        <obo:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An organization dedicated to the collection, storage and dissemination of a set of scientific or clinical data.</obo:IAO_0000115>
        <obo:IAO_0000117 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PERSON: Nicole Vasilevsky</obo:IAO_0000117>
        <obo:IAO_0000119 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PERSON: Scott Hoffmann</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ero.owl"/>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">registry</rdfs:label>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/trds/en/</rdfs:seeAlso>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/IAO_0000005 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/IAO_0000005">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000033"/>
        <obo:IAO_0000111 xml:lang="en">objective specification</obo:IAO_0000111>
        <obo:IAO_0000112 xml:lang="en">In the protocol of a ChIP assay the objective specification says to identify protein and DNA interaction.</obo:IAO_0000112>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000122"/>
        <obo:IAO_0000115 xml:lang="en">a directive information entity that describes an intended process endpoint. When part of a plan specification the concretization is realized in a planned process in which the bearer tries to effect the world so that the process endpoint is achieved.</obo:IAO_0000115>
        <obo:IAO_0000116 xml:lang="en">2009-03-16: original definition when imported from OBI read: &quot;objective is an non realizable information entity which can serve as that  proper part of a plan towards which the realization of the plan is directed.&quot;</obo:IAO_0000116>
        <obo:IAO_0000116 xml:lang="en">2014-03-31: In the example of usage (&quot;In the protocol of a ChIP assay the objective specification says to identify protein and DNA interaction&quot;) there is a protocol which is the ChIP assay protocol. In addition to being concretized on paper, the protocol can be concretized as a realizable entity, such as a plan that inheres in a person. The objective specification is the part that says that some protein and DNA interactions are identified. This is a specification of a process endpoint: the boundary in the process before which they are not identified and after which they are. During the realization of the plan, the goal is to get to the point of having the interactions, and participants in the realization of the plan try to do that.</obo:IAO_0000116>
        <obo:IAO_0000116 xml:lang="en">Answers the question, why did you do this experiment?</obo:IAO_0000116>
        <obo:IAO_0000117 xml:lang="en">PERSON: Alan Ruttenberg</obo:IAO_0000117>
        <obo:IAO_0000117 xml:lang="en">PERSON: Barry Smith</obo:IAO_0000117>
        <obo:IAO_0000117 xml:lang="en">PERSON: Bjoern Peters</obo:IAO_0000117>
        <obo:IAO_0000117 xml:lang="en">PERSON: Jennifer Fostel</obo:IAO_0000117>
        <obo:IAO_0000118 xml:lang="en">goal specification</obo:IAO_0000118>
        <obo:IAO_0000119 xml:lang="en">OBI Plan and Planned Process/Roles Branch</obo:IAO_0000119>
        <obo:IAO_0000119 xml:lang="en">OBI_0000217</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <rdfs:label xml:lang="en">objective specification</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/IAO_0000007 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/IAO_0000007">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000033"/>
        <obo:IAO_0000112 xml:lang="en">Pour the contents of flask 1 into flask 2</obo:IAO_0000112>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000122"/>
        <obo:IAO_0000115 xml:lang="en">a directive information entity that describes an action the bearer will take</obo:IAO_0000115>
        <obo:IAO_0000117 xml:lang="en">Alan Ruttenberg</obo:IAO_0000117>
        <obo:IAO_0000119 xml:lang="en">OBI Plan and Planned Process branch</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/iao.owl"/>
        <rdfs:label xml:lang="en">action specification</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/IAO_0000027 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/IAO_0000027">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000030"/>
        <obo:IAO_0000111 xml:lang="en">data item</obo:IAO_0000111>
        <obo:IAO_0000112 xml:lang="en">Data items include counts of things, analyte concentrations, and statistical summaries.</obo:IAO_0000112>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000125"/>
        <obo:IAO_0000115 xml:lang="en">a data item is an information content entity that is intended to be a truthful statement about something (modulo, e.g., measurement precision or other systematic errors) and is constructed/acquired by a method which reliably tends to produce (approximately) truthful statements.</obo:IAO_0000115>
        <obo:IAO_0000116 xml:lang="en">2/2/2009 Alan and Bjoern discussing FACS run output data. This is a data item because it is about the cell population. Each element records an event and is typically further composed a set of measurment data items that record the fluorescent intensity stimulated by one of the lasers.</obo:IAO_0000116>
        <obo:IAO_0000116 xml:lang="en">2009-03-16: data item deliberatly ambiguous: we merged data set and datum to be one entity, not knowing how to define singular versus plural. So data item is more general than datum.</obo:IAO_0000116>
        <obo:IAO_0000116 xml:lang="en">2009-03-16: removed datum as alternative term as datum specifically refers to singular form, and is thus not an exact synonym.</obo:IAO_0000116>
        <obo:IAO_0000116>2014-03-31: See discussion at http://odontomachus.wordpress.com/2014/03/30/aboutness-objects-propositions/</obo:IAO_0000116>
        <obo:IAO_0000116 xml:lang="en">JAR: datum     -- well, this will be very tricky to define, but maybe some 
information-like stuff that might be put into a computer and that is 
meant, by someone, to denote and/or to be interpreted by some 
process... I would include lists, tables, sentences... I think I might 
defer to Barry, or to Brian Cantwell Smith

JAR: A data item is an approximately justified approximately true approximate belief</obo:IAO_0000116>
        <obo:IAO_0000117 xml:lang="en">PERSON: Alan Ruttenberg</obo:IAO_0000117>
        <obo:IAO_0000117 xml:lang="en">PERSON: Chris Stoeckert</obo:IAO_0000117>
        <obo:IAO_0000117 xml:lang="en">PERSON: Jonathan Rees</obo:IAO_0000117>
        <obo:IAO_0000118 xml:lang="en">data</obo:IAO_0000118>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/iao.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ogms.owl"/>
        <rdfs:label xml:lang="en">data item</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/IAO_0000030 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/IAO_0000030">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000031"/>
        <rdfs:subClassOf>
            <owl:Restriction>
                <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000136"/>
                <owl:someValuesFrom rdf:resource="http://purl.obolibrary.org/obo/BFO_0000001"/>
            </owl:Restriction>
        </rdfs:subClassOf>
        <obo:IAO_0000111 xml:lang="en">information content entity</obo:IAO_0000111>
        <obo:IAO_0000112 xml:lang="en">Examples of information content entites include journal articles, data, graphical layouts, and graphs.</obo:IAO_0000112>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000122"/>
        <obo:IAO_0000115 xml:lang="en">A generically dependent continuant that is about some thing.</obo:IAO_0000115>
        <obo:IAO_0000115 xml:lang="en">An information content entity is an entity that is generically dependent on some artifact and stands in relation of aboutness to some entity</obo:IAO_0000115>
        <obo:IAO_0000116 xml:lang="en">2014-03-10: The use of &quot;thing&quot; is intended to be general enough to include universals and configurations (see https://groups.google.com/d/msg/information-ontology/GBxvYZCk1oc/-L6B5fSBBTQJ).</obo:IAO_0000116>
        <obo:IAO_0000116 xml:lang="en">information_content_entity &apos;is_encoded_in&apos; some digital_entity in obi before split (040907). information_content_entity &apos;is_encoded_in&apos; some physical_document in obi before split (040907).

Previous. An information content entity is a non-realizable information entity that &apos;is encoded in&apos; some digital or physical entity.</obo:IAO_0000116>
        <obo:IAO_0000117 xml:lang="en">PERSON: Chris Stoeckert</obo:IAO_0000117>
        <obo:IAO_0000119 xml:lang="en">OBI_0000142</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/dron.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/envo.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/iao.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ico.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ogms.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/omrse.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ontoneo.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/pdro.owl"/>
        <rdfs:label>information content entity</rdfs:label>
        <rdfs:label xml:lang="en">information content entity</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/IAO_0000033 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/IAO_0000033">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000030"/>
        <rdfs:subClassOf>
            <owl:Restriction>
                <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000136"/>
                <owl:someValuesFrom rdf:resource="http://purl.obolibrary.org/obo/BFO_0000017"/>
            </owl:Restriction>
        </rdfs:subClassOf>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000122"/>
        <obo:IAO_0000115 xml:lang="en">An information content entity whose concretizations indicate to their bearer how to realize them in a process.</obo:IAO_0000115>
        <obo:IAO_0000116 xml:lang="en">2009-03-16: provenance: a term realizable information entity was proposed for OBI (OBI_0000337) , edited by the PlanAndPlannedProcess branch. Original definition was  &quot;is the specification of a process that can be concretized and realized by an actor&quot; with alternative term  &quot;instruction&quot;.It has been subsequently moved to IAO where the objective for which the original term was defined was satisfied with the definitionof this, different, term.</obo:IAO_0000116>
        <obo:IAO_0000116 xml:lang="en">2013-05-30 Alan Ruttenberg: What differentiates a directive information entity from an information concretization is that it can have concretizations that are either qualities or realizable entities. The concretizations that are realizable entities are created when an individual chooses to take up the direction, i.e. has the intention to (try to) realize it.</obo:IAO_0000116>
        <obo:IAO_0000116 xml:lang="en">8/6/2009 Alan Ruttenberg: Changed label from &quot;information entity about a realizable&quot; after discussions at ICBO</obo:IAO_0000116>
        <obo:IAO_0000116 xml:lang="en">Werner pushed back on calling it realizable information entity as it isn&apos;t realizable. However this name isn&apos;t right either. An example would be a recipe. The realizable entity would be a plan, but the information entity isn&apos;t about the plan, it, once concretized, *is* the plan. -Alan</obo:IAO_0000116>
        <obo:IAO_0000117 xml:lang="en">PERSON: Alan Ruttenberg</obo:IAO_0000117>
        <obo:IAO_0000117 xml:lang="en">PERSON: Bjoern Peters</obo:IAO_0000117>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/iao.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <rdfs:label xml:lang="en">directive information entity</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/IAO_0000078 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/IAO_0000078">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000102"/>
        <obo:IAO_0000111 xml:lang="en">curation status specification</obo:IAO_0000111>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000125"/>
        <obo:IAO_0000115 xml:lang="en">The curation status of the term. The allowed values come from an enumerated list of predefined terms. See the specification of these instances for more detailed definitions of each enumerated value.</obo:IAO_0000115>
        <obo:IAO_0000116 xml:lang="en">Better to represent curation as a process with parts and then relate labels to that process (in IAO meeting)</obo:IAO_0000116>
        <obo:IAO_0000117 xml:lang="en">PERSON:Bill Bug</obo:IAO_0000117>
        <obo:IAO_0000119 xml:lang="en">GROUP:OBI:&lt;http://purl.obolibrary.org/obo/obi&gt;</obo:IAO_0000119>
        <obo:IAO_0000119 xml:lang="en">OBI_0000266</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/iao.owl"/>
        <rdfs:label xml:lang="en">curation status specification</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/IAO_0000088 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/IAO_0000088">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000310"/>
        <obo:IAO_0000111 xml:lang="en">report</obo:IAO_0000111>
        <obo:IAO_0000112 xml:lang="en">Examples of reports are gene lists and investigation reports. These are not published (journal) articles but may be included in a journal article.</obo:IAO_0000112>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000125"/>
        <obo:IAO_0000115 xml:lang="en">a document assembled by an author for the purpose of providing information for the audience. A report is the output of a documenting process and has the objective to be consumed by a specific audience. Topic of the report is on something that has completed. A report is not a single figure. Examples of reports are journal article, patent application, grant progress report, case report (not patient record)</obo:IAO_0000115>
        <obo:IAO_0000116 xml:lang="en">2009-03-16: comment from Darren Natale: I am slightly uneasy with the sentence &quot;Topic of the report is on
something that has completed.&quot;  Should it be restricted to those things
that are completed?  For example, a progress report is (usually) about
something that definitely has *not* been completed, or may include
(only) projections.  I think the definition would not suffer if the
whole sentence is deleted.</obo:IAO_0000116>
        <obo:IAO_0000116 xml:lang="en">2009-03-16: this was report of results with definition: A report is a narrative object that is a formal statement of the results of an investigation, or of any matter on which definite information is required, made by some person or body instructed or required to do so.</obo:IAO_0000116>
        <obo:IAO_0000116 xml:lang="en">2009-03-16: work has been done on this term during during the OBI workshop winter 2009 and the current definition was considered acceptable for use in OBI. If there is a need to modify this definition please notify OBI.</obo:IAO_0000116>
        <obo:IAO_0000116 xml:lang="en">2009-08-10 Alan Ruttenberg: Larry Hunter suggests that this be obsoleted and replaced by &apos;document&apos;. Alan restored as there are OBI dependencies and this merits further discussion</obo:IAO_0000116>
        <obo:IAO_0000116 xml:lang="en">disagreement about where reports go. alan: only some gene lists are reports. Is a report all the content of some document? The example of usage suggests that a report may be part of  some article. Term needs clarification</obo:IAO_0000116>
        <obo:IAO_0000117 xml:lang="en">PERSON: Alan Ruttenberg</obo:IAO_0000117>
        <obo:IAO_0000117 xml:lang="en">PERSON: Melanie Courtot</obo:IAO_0000117>
        <obo:IAO_0000117 xml:lang="en">PERSON:Chris Stoeckert</obo:IAO_0000117>
        <obo:IAO_0000119 xml:lang="en">GROUP: OBI</obo:IAO_0000119>
        <obo:IAO_0000119 xml:lang="en">OBI_0000099</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/iao.owl"/>
        <rdfs:label xml:lang="en">report</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/IAO_0000102 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/IAO_0000102">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000027"/>
        <obo:IAO_0000115 xml:lang="en">data about an ontology part is a data item about a part of an ontology, for example a term</obo:IAO_0000115>
        <obo:IAO_0000117 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Person:Alan Ruttenberg</obo:IAO_0000117>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/iao.owl"/>
        <rdfs:label xml:lang="en">data about an ontology part</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/IAO_0000104 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/IAO_0000104">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000033"/>
        <obo:IAO_0000111 xml:lang="en">plan specification</obo:IAO_0000111>
        <obo:IAO_0000112 xml:lang="en">PMID: 18323827.Nat Med. 2008 Mar;14(3):226.New plan proposed to help resolve conflicting medical advice.</obo:IAO_0000112>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000122"/>
        <obo:IAO_0000115 xml:lang="en">A directive information entity with action specifications and objective specifications as parts that, when concretized, is realized in a process in which the bearer tries to achieve the objectives by taking the actions specified.</obo:IAO_0000115>
        <obo:IAO_0000116 xml:lang="en">2009-03-16: provenance: a term a plan was proposed for OBI (OBI_0000344) , edited by the PlanAndPlannedProcess branch. Original definition was &quot; a plan is a specification of a process that is realized by an actor to achieve the objective specified as part of the plan&quot;. It has been subsequently moved to IAO where the objective for which the original term was defined was satisfied with the definitionof this, different, term.</obo:IAO_0000116>
        <obo:IAO_0000116 xml:lang="en">2014-03-31: A plan specification can have other parts, such as conditional specifications.</obo:IAO_0000116>
        <obo:IAO_0000116 xml:lang="en">Alternative previous definition: a plan is a set of instructions that specify how an objective should be achieved</obo:IAO_0000116>
        <obo:IAO_0000117 xml:lang="en">Alan Ruttenberg</obo:IAO_0000117>
        <obo:IAO_0000119 xml:lang="en">OBI Plan and Planned Process branch</obo:IAO_0000119>
        <obo:IAO_0000119 xml:lang="en">OBI_0000344</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <rdfs:comment xml:lang="en">2/3/2009 Comment from OBI review.

Action specification not well enough specified.
Conditional specification not well enough specified.
Question whether all plan specifications have objective specifications.

Request that IAO either clarify these or change definitions not to use them</rdfs:comment>
        <rdfs:label xml:lang="en">plan specification</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/IAO_0000300 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/IAO_0000300">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000030"/>
        <obo:IAO_0000111 xml:lang="en">textual entity</obo:IAO_0000111>
        <obo:IAO_0000112 xml:lang="en">Words, sentences, paragraphs, and the written (non-figure) parts of publications are all textual entities</obo:IAO_0000112>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000123"/>
        <obo:IAO_0000115 xml:lang="en">A textual entity is a part of a manifestation (FRBR sense), a generically dependent continuant whose concretizations are patterns of glyphs intended to be interpreted as words, formulas, etc.</obo:IAO_0000115>
        <obo:IAO_0000116 xml:lang="en">AR, (IAO call 2009-09-01): a document as a whole is not typically a textual entity, because it has pictures in it - rather there are parts of it that are textual entities. Examples: The title, paragraph 2 sentence 7, etc.</obo:IAO_0000116>
        <obo:IAO_0000116 xml:lang="en">MC, 2009-09-14 (following IAO call 2009-09-01): textual entities live at the FRBR (http://en.wikipedia.org/wiki/Functional_Requirements_for_Bibliographic_Records) manifestation level. Everything is significant: line break, pdf and html versions of same document are different textual entities.</obo:IAO_0000116>
        <obo:IAO_0000117 xml:lang="en">PERSON: Lawrence Hunter</obo:IAO_0000117>
        <obo:IAO_0000118 xml:lang="en">text</obo:IAO_0000118>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/iao.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <rdfs:label xml:lang="en">textual entity</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/IAO_0000310 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/IAO_0000310">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000030"/>
        <obo:IAO_0000111 xml:lang="en">document</obo:IAO_0000111>
        <obo:IAO_0000112 xml:lang="en">A journal article, patent application, laboratory notebook, or a book</obo:IAO_0000112>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000120"/>
        <obo:IAO_0000115 xml:lang="en">A collection of information content entities intended to be understood together as a whole</obo:IAO_0000115>
        <obo:IAO_0000117 xml:lang="en">PERSON: Lawrence Hunter</obo:IAO_0000117>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/iao.owl"/>
        <rdfs:label xml:lang="en">document</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/IAO_0000422 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/IAO_0000422">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000300"/>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000123"/>
        <obo:IAO_0000115>A textual entity that is used as directive to deliver something to a person, or organization</obo:IAO_0000115>
        <obo:IAO_0000116>2010-05-24 Alan Ruttenberg. Use label for the string representation. See issue https://github.com/information-artifact-ontology/IAO/issues/59</obo:IAO_0000116>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <rdfs:label xml:lang="en">postal address</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/IAO_0000429 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/IAO_0000429">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000030"/>
        <obo:IAO_0000111 xml:lang="en">email address</obo:IAO_0000111>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000123"/>
        <obo:IAO_0000116 xml:lang="en">Alan Ruttenberg 1/3/2012 - Provisional id, see issue at https://github.com/information-artifact-ontology/IAO/issues/130&amp;thanks=130&amp;ts=1325636583</obo:IAO_0000116>
        <obo:IAO_0000117 xml:lang="en">Person:Alan Ruttenberg</obo:IAO_0000117>
        <obo:IAO_0000117 xml:lang="en">Person:Chris Stoeckart</obo:IAO_0000117>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <rdfs:label xml:lang="en">email address</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/IAO_0000578 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/IAO_0000578">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000030"/>
        <obo:IAO_0000112 xml:lang="en">Entries in a Column of which the header is &quot;Pubmed ID&quot; </obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">PMID:12345</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">The following URL: &quot;http://www.ncbi.nlm.nih.gov/pubmed/19918065&quot;</obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">The following sentence contains a CRID: &quot;The article with Pubmed ID: 19918065&quot;. </obo:IAO_0000112>
        <obo:IAO_0000112 xml:lang="en">The sentence &quot;The article has Pubmed ID 12345.&quot; contains a CRID that has two parts: one part is the CRID symbol, which is &apos;12345&apos;; the other part denotes the CRID registry, which is Pubmed.</obo:IAO_0000112>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000120"/>
        <obo:IAO_0000115 xml:lang="en">An information content entity that consists of a CRID symbol and additional information about the CRID registry to which it belongs.</obo:IAO_0000115>
        <obo:IAO_0000115 xml:lang="en">An information content entity that consists of a CRID symbol and additional information about which CRID registry it belongs. </obo:IAO_0000115>
        <obo:IAO_0000116 xml:lang="en">2014-05-05: In defining this term we take no position on what the CRID denotes. In particular do not assume it denotes a *record* in the CRID registry (since the registry might not have &apos;records&apos;).</obo:IAO_0000116>
        <obo:IAO_0000116 xml:lang="en">Alan, IAO call 20101124: potentially the CRID denotes the instance it was associated with during creation. 
</obo:IAO_0000116>
        <obo:IAO_0000116 xml:lang="en">Note, IAO call 20101124: URIs are not always CRID, as not centrally registered. We acknowledge that CRID is a subset of a larger identifier class, but this subset fulfills our current needs. OBI PURLs are CRID as they are registered with OCLC. UPCs (Universal Product Codes from AC Nielsen)are not CRID as they are not centrally registered.</obo:IAO_0000116>
        <obo:IAO_0000117 xml:lang="en">PERSON: Alan Ruttenberg</obo:IAO_0000117>
        <obo:IAO_0000117 xml:lang="en">PERSON: Bill Hogan</obo:IAO_0000117>
        <obo:IAO_0000117 xml:lang="en">PERSON: Bjoern Peters</obo:IAO_0000117>
        <obo:IAO_0000117 xml:lang="en">PERSON: Melanie Courtot</obo:IAO_0000117>
        <obo:IAO_0000118>CRID</obo:IAO_0000118>
        <obo:IAO_0000118>Centrally Registered IDentifier</obo:IAO_0000118>
        <obo:IAO_0000119 xml:lang="en">Original proposal from Bjoern, discussions at IAO calls</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/iao.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/omrse.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <obo:IAO_0000412 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://purl.obolibrary.org/obo/iao.owl</obo:IAO_0000412>
        <oboInOwl:hasNarrowSynonym>Primary Registry and Trial Identifying Number</oboInOwl:hasNarrowSynonym>
        <rdfs:label xml:lang="en">CRID</rdfs:label>
        <rdfs:label xml:lang="en">centrally registered identifier</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/IAO_0000578"/>
        <owl:annotatedProperty rdf:resource="http://www.geneontology.org/formats/oboInOwl#hasNarrowSynonym"/>
        <owl:annotatedTarget>Primary Registry and Trial Identifying Number</owl:annotatedTarget>
        <rdfs:seeAlso>http://www.icmje.org/recommendations/ 
http://www.who.int/ictrp/network/trds/en/index.html</rdfs:seeAlso>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/MS_1000590 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/MS_1000590">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000300"/>
        <obo:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Home institution of the contact person.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ms.owl"/>
        <oboInOwl:hasDbXref rdf:datatype="http://www.w3.org/2001/XMLSchema#string">value-type:xsd:string</oboInOwl:hasDbXref>
        <oboInOwl:hasOBONamespace rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MS</oboInOwl:hasOBONamespace>
        <oboInOwl:id rdf:datatype="http://www.w3.org/2001/XMLSchema#string">MS:1000590</oboInOwl:id>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">contact affiliation</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCBITaxon_1 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCBITaxon_1">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000040"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncbitaxon.owl"/>
        <oboInOwl:hasDbXref rdf:datatype="http://www.w3.org/2001/XMLSchema#string">GC_ID:1</oboInOwl:hasDbXref>
        <oboInOwl:hasOBONamespace rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ncbi_taxonomy</oboInOwl:hasOBONamespace>
        <oboInOwl:hasRelatedSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">all</oboInOwl:hasRelatedSynonym>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">root</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCBITaxon_131567 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCBITaxon_131567">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCBITaxon_1"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncbitaxon.owl"/>
        <oboInOwl:hasDbXref rdf:datatype="http://www.w3.org/2001/XMLSchema#string">GC_ID:1</oboInOwl:hasDbXref>
        <oboInOwl:hasOBONamespace rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ncbi_taxonomy</oboInOwl:hasOBONamespace>
        <oboInOwl:hasRelatedSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">biota</oboInOwl:hasRelatedSynonym>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">cellular organisms</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCBITaxon_2759 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCBITaxon_2759">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCBITaxon_131567"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncbitaxon.owl"/>
        <ncbitaxon:has_rank rdf:resource="http://purl.obolibrary.org/obo/NCBITaxon_superkingdom"/>
        <oboInOwl:hasDbXref rdf:datatype="http://www.w3.org/2001/XMLSchema#string">GC_ID:1</oboInOwl:hasDbXref>
        <oboInOwl:hasDbXref rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PMID:23020233</oboInOwl:hasDbXref>
        <oboInOwl:hasDbXref rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PMID:30257078</oboInOwl:hasDbXref>
        <oboInOwl:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">eucaryotes</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">eukaryotes</oboInOwl:hasExactSynonym>
        <oboInOwl:hasOBONamespace rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ncbi_taxonomy</oboInOwl:hasOBONamespace>
        <oboInOwl:hasRelatedSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Eucarya</oboInOwl:hasRelatedSynonym>
        <oboInOwl:hasRelatedSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Eucaryotae</oboInOwl:hasRelatedSynonym>
        <oboInOwl:hasRelatedSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Eukarya</oboInOwl:hasRelatedSynonym>
        <oboInOwl:hasRelatedSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Eukaryotae</oboInOwl:hasRelatedSynonym>
        <oboInOwl:hasRelatedSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">eukaryotes</oboInOwl:hasRelatedSynonym>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Eukaryota</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCBITaxon_40674 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCBITaxon_40674">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCBITaxon_7742"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncbitaxon.owl"/>
        <ncbitaxon:has_rank rdf:resource="http://purl.obolibrary.org/obo/NCBITaxon_class"/>
        <oboInOwl:hasDbXref rdf:datatype="http://www.w3.org/2001/XMLSchema#string">GC_ID:1</oboInOwl:hasDbXref>
        <oboInOwl:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">mammals</oboInOwl:hasExactSynonym>
        <oboInOwl:hasOBONamespace rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ncbi_taxonomy</oboInOwl:hasOBONamespace>
        <oboInOwl:hasRelatedSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">mammals</oboInOwl:hasRelatedSynonym>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Mammalia</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCBITaxon_7742 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCBITaxon_7742">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCBITaxon_2759"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncbitaxon.owl"/>
        <oboInOwl:hasDbXref rdf:datatype="http://www.w3.org/2001/XMLSchema#string">GC_ID:1</oboInOwl:hasDbXref>
        <oboInOwl:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Vertebrata</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">vertebrates</oboInOwl:hasExactSynonym>
        <oboInOwl:hasOBONamespace rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ncbi_taxonomy</oboInOwl:hasOBONamespace>
        <oboInOwl:hasRelatedSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">vertebrates</oboInOwl:hasRelatedSynonym>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Vertebrata &lt;vertebrates&gt;</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCBITaxon_9606 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCBITaxon_9606">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCBITaxon_40674"/>
        <obo:IAO_0000111 xml:lang="en">Homo sapiens</obo:IAO_0000111>
        <obo:IAO_0000111 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Homo sapiens</obo:IAO_0000111>
        <obo:IAO_0000118>human</obo:IAO_0000118>
        <obo:IAO_0000118 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">human being</obo:IAO_0000118>
        <obo:IAO_0000118 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">man</obo:IAO_0000118>
        <obo:IAO_0000118>person</obo:IAO_0000118>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/envo.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncbitaxon.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/omrse.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <ncbitaxon:has_rank rdf:resource="http://purl.obolibrary.org/obo/NCBITaxon_species"/>
        <oboInOwl:hasDbXref rdf:datatype="http://www.w3.org/2001/XMLSchema#string">GC_ID:1</oboInOwl:hasDbXref>
        <oboInOwl:hasExactSynonym>human</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">man</oboInOwl:hasExactSynonym>
        <oboInOwl:hasOBONamespace rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ncbi_taxonomy</oboInOwl:hasOBONamespace>
        <oboInOwl:hasRelatedSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Home sapiens</oboInOwl:hasRelatedSynonym>
        <oboInOwl:hasRelatedSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Homo sampiens</oboInOwl:hasRelatedSynonym>
        <oboInOwl:hasRelatedSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Homo sapeins</oboInOwl:hasRelatedSynonym>
        <oboInOwl:hasRelatedSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Homo sapian</oboInOwl:hasRelatedSynonym>
        <oboInOwl:hasRelatedSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Homo sapians</oboInOwl:hasRelatedSynonym>
        <oboInOwl:hasRelatedSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Homo sapien</oboInOwl:hasRelatedSynonym>
        <oboInOwl:hasRelatedSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Homo sapience</oboInOwl:hasRelatedSynonym>
        <oboInOwl:hasRelatedSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Homo sapiense</oboInOwl:hasRelatedSynonym>
        <oboInOwl:hasRelatedSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Homo sapients</oboInOwl:hasRelatedSynonym>
        <oboInOwl:hasRelatedSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Homo sapines</oboInOwl:hasRelatedSynonym>
        <oboInOwl:hasRelatedSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Homo spaiens</oboInOwl:hasRelatedSynonym>
        <oboInOwl:hasRelatedSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Homo spiens</oboInOwl:hasRelatedSynonym>
        <oboInOwl:hasRelatedSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Humo sapiens</oboInOwl:hasRelatedSynonym>
        <oboInOwl:hasRelatedSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">humans</oboInOwl:hasRelatedSynonym>
        <rdfs:label xml:lang="en">Homo sapiens</rdfs:label>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Homo sapiens</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C115575 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C115575">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000088"/>
        <obo:IAO_0000115>Records containing any interim or final results, as well as clinical and statistical descriptions, presentations, analyses and interpretations of any therapeutic, prophylactic, or diagnostic agent used in human subjects in a clinical trial.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C115575</obo:NCIT_NHC0>
        <obo:NCIT_P106>Intellectual Product</obo:NCIT_P106>
        <obo:NCIT_P108>Clinical Trial Final Report</obo:NCIT_P108>
        <obo:NCIT_P207>C3889645</obo:NCIT_P207>
        <obo:NCIT_P322>CDISC-GLOSS</obo:NCIT_P322>
        <obo:NCIT_P322>CareLex</obo:NCIT_P322>
        <obo:NCIT_P325>A written description of a trial/study of any therapeutic, prophylactic, or diagnostic agent conducted in human subjects, in which the clinical and statistical description, presentations, and analyses are fully integrated into a single report. [ICH E3]</obo:NCIT_P325>
        <obo:NCIT_P325>Subcategory name for the eTMF domain used to classify clinical study report documents.</obo:NCIT_P325>
        <oboInOwl:hasExactSynonym>CTrial Fin Rept Subcat</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Central Trial Final Reports Subcategory</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Clinical Trial Final Report</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Reports</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>final report</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C114548"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67497"/>
        <rdfs:label>Clinical Trial Final Report</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C129000 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C129000">
        <rdfs:subClassOf rdf:resource="http://purl.org/net/OCRe/research.owl#Observational_study"/>
        <obo:IAO_0000115>An observational study that is also considered to be a Patient Registry. This type of study should only be registered once in the Protocol Registration and Results System (PRS), by the sponsor responsible for the primary data collection and analysis.</obo:IAO_0000115>
        <obo:IAO_0000115>Observational studies which include an organized system that uses observational methods to collect uniform data (clinical and other) prospectively for a population defined by a particular disorder/disease, condition (including susceptibility to a disorder), or exposure (including products, health care services, and/or procedures) and that serves a predetermined scientific, clinical, or policy purpose. Patient registries may be single purpose or on-going data collection programs that address one or more questions. (AHRQ)</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C129000</obo:NCIT_NHC0>
        <obo:NCIT_P106>Research Activity</obo:NCIT_P106>
        <obo:NCIT_P108>Patient Registry Study</obo:NCIT_P108>
        <obo:NCIT_P207>C0920631</obo:NCIT_P207>
        <obo:NCIT_P322>CDISC</obo:NCIT_P322>
        <obo:NCIT_P325>Observational studies which include an organized system that uses observational methods to collect uniform data (clinical and other) prospectively for a population defined by a particular disorder/disease, condition (including susceptibility to a disorder), or exposure (including products, health care services, and/or procedures) and that serves a predetermined scientific, clinical, or policy purpose. Patient registries may be single purpose or on-going data collection programs that address one or more questions. (AHRQ)</obo:NCIT_P325>
        <oboInOwl:hasExactSynonym>PATIENT REGISTRY</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Patient Registry Study</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C99077"/>
        <rdfs:label>Patient Registry Study</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/NCIT_C129000"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>An observational study that is also considered to be a Patient Registry. This type of study should only be registered once in the Protocol Registration and Results System (PRS), by the sponsor responsible for the primary data collection and analysis.</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C142175 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C142175">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/ERO_0000015"/>
        <obo:IAO_0000115>The nature of the investigation or the investigational use for which clinical study is being done.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C142175</obo:NCIT_NHC0>
        <obo:NCIT_P106>Research Activity</obo:NCIT_P106>
        <obo:NCIT_P108>Study Type</obo:NCIT_P108>
        <obo:NCIT_P208>CL540168</obo:NCIT_P208>
        <obo:NCIT_P322>CDISC</obo:NCIT_P322>
        <obo:NCIT_P325>Describes the role the study plays in determining the interventions a subject receives.</obo:NCIT_P325>
        <oboInOwl:hasExactSynonym>STYPE</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Study Type</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C142191"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66738"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67152"/>
        <rdfs:label>Study Type</rdfs:label>
        <rdfs:seeAlso>https://prsinfo.clinicaltrials.gov/definitions.html</rdfs:seeAlso>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/trds/en/</rdfs:seeAlso>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C142660 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C142660">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCIT_C52580"/>
        <obo:IAO_0000115>Participants are assigned to intervention groups by chance</obo:IAO_0000115>
        <obo:IAO_0000115>The process of resource distribution that is done by chance.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C142660</obo:NCIT_NHC0>
        <obo:NCIT_P106>Activity</obo:NCIT_P106>
        <obo:NCIT_P108>Random Allocation</obo:NCIT_P108>
        <obo:NCIT_P208>CL540611</obo:NCIT_P208>
        <obo:NCIT_P322>CDISC-GLOSS</obo:NCIT_P322>
        <obo:NCIT_P325>Assignment of subjects to treatment (or control) groups in an unpredictable way. NOTE: in a blinded study, assignment sequences are concealed, but available for disclosure in the event a subject has an adverse experience.</obo:NCIT_P325>
        <oboInOwl:hasExactSynonym>Random Allocation</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>random allocation</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>randomized</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67497"/>
        <rdfs:label>Random Allocation</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/NCIT_C142660"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>Participants are assigned to intervention groups by chance</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C147141 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C147141">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000104"/>
        <obo:IAO_0000115>The main objective of the intervention(s) being evaluated by the clinical trial.</obo:IAO_0000115>
        <obo:IAO_0000115>The principal reason or intention for the execution of an interventional or non-interventional clinical study.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C147141</obo:NCIT_NHC0>
        <obo:NCIT_P106>Idea or Concept</obo:NCIT_P106>
        <obo:NCIT_P108>Study Primary Purpose</obo:NCIT_P108>
        <obo:NCIT_P208>CL545057</obo:NCIT_P208>
        <obo:NCIT_P322>CDISC</obo:NCIT_P322>
        <obo:NCIT_P325>The principal reason or intention for the execution of an interventional or non-interventional clinical study. (NCI)</obo:NCIT_P325>
        <oboInOwl:hasExactSynonym>Study Primary Purpose</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C147066"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410"/>
        <rdfs:label>Study Primary Purpose</rdfs:label>
        <rdfs:seeAlso>http://www.icmje.org/recommendations/ 
http://www.who.int/ictrp/network/trds/en/index.html</rdfs:seeAlso>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/NCIT_C147141"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>The main objective of the intervention(s) being evaluated by the clinical trial.</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C15238 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C15238">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OAE_0000002"/>
        <obo:IAO_0000115>Application of genetic material (usually DNA) into cells in order to permanently correct an inherited disease or acquired disease.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C15238</obo:NCIT_NHC0>
        <obo:NCIT_P106>Therapeutic or Preventive Procedure</obo:NCIT_P106>
        <obo:NCIT_P107>Gene Therapy</obo:NCIT_P107>
        <obo:NCIT_P108>Gene Therapy</obo:NCIT_P108>
        <obo:NCIT_P207>C0017296</obo:NCIT_P207>
        <obo:NCIT_P322>CDISC</obo:NCIT_P322>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P325>Application of genetic material into cells in order to correct an inherited or acquired disease.</obo:NCIT_P325>
        <obo:NCIT_P325>Treatment of human disease by gene transfer.</obo:NCIT_P325>
        <obo:NCIT_P325>Treatment that alters a gene. In studies of gene therapy for cancer, researchers are trying to improve the body&apos;s natural ability to fight the disease or to make the cancer cells more sensitive to other kinds of therapy.</obo:NCIT_P325>
        <obo:NCIT_P366>Gene_Therapy</obo:NCIT_P366>
        <obo:NCIT_P98>Gene therapy techniques attempt to replace a faulty or missing gene associated with a particular disease, mediate localized delivery of a protein producing specified therapeutic effects, or introduce new cellular functions.</obo:NCIT_P98>
        <oboInOwl:hasExactSynonym>DNA Therapy</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>GENETIC</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Gene Therapy</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Gene Transfer Procedure</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Gene transfer</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Genetic</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Intervention, Genetic</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Molecular Biology, Gene Therapy</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>gene therapy</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C118169"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C99078"/>
        <rdfs:label>Gene Therapy</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/NCIT_C15238"/>
        <owl:annotatedProperty rdf:resource="http://www.geneontology.org/formats/oboInOwl#hasExactSynonym"/>
        <owl:annotatedTarget>Genetic</owl:annotatedTarget>
        <rdfs:seeAlso>https://prsinfo.clinicaltrials.gov/definitions.html</rdfs:seeAlso>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C15245 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C15245">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCIT_C147141"/>
        <obo:IAO_0000115>A multidisciplinary field of inquiry that examines the costs, quality, accessibility, delivery, organization, financing, and outcomes of health care services.</obo:IAO_0000115>
        <obo:IAO_0000115>One or more interventions for evaluating the delivery, processes, management, organization, or financing of healthcare.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C15245</obo:NCIT_NHC0>
        <obo:NCIT_P106>Research Activity</obo:NCIT_P106>
        <obo:NCIT_P108>Health Services Research</obo:NCIT_P108>
        <obo:NCIT_P207>C0018757</obo:NCIT_P207>
        <obo:NCIT_P322>CDISC</obo:NCIT_P322>
        <obo:NCIT_P325>A type of study designed to evaluate the delivery, processes, management, organization or financing of health care. (ClinicalTrials.gov)</obo:NCIT_P325>
        <obo:NCIT_P366>Health_Services_Research</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>HEALTH SERVICES RESEARCH</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Health Services Research</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C147067"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66736"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830"/>
        <rdfs:label>Health Services Research</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/NCIT_C15245"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>One or more interventions for evaluating the delivery, processes, management, organization, or financing of healthcare.</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C15329 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C15329">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OAE_0002807"/>
        <obo:IAO_0000115>A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A11 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C25218"/>
        <obo:NCIT_NHC0>C15329</obo:NCIT_NHC0>
        <obo:NCIT_P106>Health Care Activity</obo:NCIT_P106>
        <obo:NCIT_P107>Surgical Procedure</obo:NCIT_P107>
        <obo:NCIT_P108>Surgical Procedure</obo:NCIT_P108>
        <obo:NCIT_P207>C0543467</obo:NCIT_P207>
        <obo:NCIT_P322>CPTAC</obo:NCIT_P322>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>NICHD</obo:NCIT_P322>
        <obo:NCIT_P325>A procedure to remove or repair a part of the body or to find out whether disease is present. An operation.</obo:NCIT_P325>
        <obo:NCIT_P366>Surgical_Procedure</obo:NCIT_P366>
        <obo:NCIT_P371>Surgical Procedure</obo:NCIT_P371>
        <obo:NCIT_P375>Surgery</obo:NCIT_P375>
        <obo:NCIT_P375>Surgically Treated</obo:NCIT_P375>
        <oboInOwl:hasExactSynonym>Operation</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Surgery</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Surgical</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Surgical Interventions</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Surgical Procedure</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Surgical Procedures</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Surgically</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Type of Surgery</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>surgery</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C118169"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C156952"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C156953"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C156954"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157524"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157526"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157527"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157528"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157529"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157530"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157532"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157533"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157534"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C159412"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C90259"/>
        <rdfs:label>Surgical Procedure</rdfs:label>
        <rdfs:seeAlso>https://prsinfo.clinicaltrials.gov/definitions.html</rdfs:seeAlso>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C15600 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C15600">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/ERO_0000016"/>
        <obo:IAO_0000115>A clinical research protocol designed to test a new biomedical intervention in a small group of people for the first time. A Phase I trial can be to establish the toxicity of a new treatment with escalating intensity of the treatment administered and/or to determine the side effects of a new treatment for a particular indication in subjects.</obo:IAO_0000115>
        <obo:IAO_0000115>Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C15600</obo:NCIT_NHC0>
        <obo:NCIT_P106>Research Activity</obo:NCIT_P106>
        <obo:NCIT_P108>Phase I Trial</obo:NCIT_P108>
        <obo:NCIT_P207>C0920321</obo:NCIT_P207>
        <obo:NCIT_P322>CDISC</obo:NCIT_P322>
        <obo:NCIT_P322>CDISC-GLOSS</obo:NCIT_P322>
        <obo:NCIT_P325>The first step in testing a new treatment in humans. These studies test the best way to give a new treatment (for example, by mouth, intravenous infusion, or injection) and the best dose. The dose is usually increased a little at a time in order to find the highest dose that does not cause harmful side effects. Because little is known about the possible risks and benefits of the treatments being tested, phase I trials usually include only a small number of patients who have not been helped by other treatments.</obo:NCIT_P325>
        <obo:NCIT_P325>The initial introduction of an investigational new drug into humans. Phase 1 studies are typically closely monitored and may be conducted in patients or normal volunteer subjects. NOTE: These studies are designed to determine the metabolism and pharmacologic actions of the drug in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. During Phase 1, sufficient information about the drug&apos;s pharmacokinetics and pharmacological effects should be obtained to permit the design of well-controlled, scientifically valid Phase 2 studies. The total number of subjects and patients included in Phase 1 studies varies with the drug, but is generally in the range of 20 to 80. Phase 1 studies also include studies of drug metabolism, structure-activity relationships, and mechanism of action in humans, as well as studies in which investigational drugs are used as research tools to explore biological phenomena or disease processes. [after FDA CDER handbook, ICH E8]</obo:NCIT_P325>
        <obo:NCIT_P325>The initial introduction of an investigational new drug into humans. Phase 1 studies are typically closely monitored and may be conducted in patients or normal volunteer subjects. NOTE: These studies are designed to determine the metabolism and pharmacologic actions of the drug in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. During Phase 1, sufficient information about the drug&apos;s pharmacokinetics and pharmacological effects should be obtained to permit the design of well-controlled, scientifically valid, Phase 2 studies. The total number of subjects and patients included in Phase I studies varies with the drug, but is generally in the range of 20 to 80. Phase 1 studies also include studies of drug metabolism, structure-activity relationships, and mechanism of action in humans, as well as studies in which investigational drugs are used as research tools to explore biological phenomena or disease processes. [After FDA CDER Handbook, ICH E8] (CDISC glossary)</obo:NCIT_P325>
        <obo:NCIT_P366>Phase_I_Trial</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>1</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Clinical Trials, Phase I</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Early-Stage Clinical Trials</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>PHASE I TRIAL</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Phase 1 Study</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Phase I Clinical Trials</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Phase I Protocol</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Phase I Study</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Phase I Trial</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Trial Phase 1</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>phase 1</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>phase I trial</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66737"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67497"/>
        <rdfs:label>Phase I Trial</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/NCIT_C15600"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C15601 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C15601">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/ERO_0000016"/>
        <obo:IAO_0000115>A clinical research protocol designed to study a biomedical or behavioral intervention in a larger group of people (several hundred), to evaluate the drug&apos;s effectiveness for a particular indication in patients with the disease or condition under study, and to determine the common short-term side effects and risks associated with the intervention.</obo:IAO_0000115>
        <obo:IAO_0000115>Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C15601</obo:NCIT_NHC0>
        <obo:NCIT_P106>Research Activity</obo:NCIT_P106>
        <obo:NCIT_P108>Phase II Trial</obo:NCIT_P108>
        <obo:NCIT_P207>C0282460</obo:NCIT_P207>
        <obo:NCIT_P322>CDISC</obo:NCIT_P322>
        <obo:NCIT_P322>CDISC-GLOSS</obo:NCIT_P322>
        <obo:NCIT_P325>A study to test whether a new treatment has an anticancer effect (for example, whether it shrinks a tumor or improves blood test results) and whether it works against a certain type of cancer.</obo:NCIT_P325>
        <obo:NCIT_P325>Controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks associated with the drug. NOTE: Phase 2 studies are typically well controlled, closely monitored, and conducted in a relatively small number of patients, usually involving no more than several hundred subjects. [after FDA CDER handbook, ICH E8]</obo:NCIT_P325>
        <obo:NCIT_P325>Phase 2. Controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks associated with the drug. NOTE: Phase 2 studies are typically well controlled, closely monitored, and conducted in a relatively small number of patients, usually involving no more than several hundred subjects. [After FDA CDER Handbook, ICH E8] (CDISC glossary)</obo:NCIT_P325>
        <obo:NCIT_P366>Phase_II_Trial</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>2</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Clinical Trials, Phase II</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>PHASE II TRIAL</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Phase 2 Study</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Phase II Clinical Trial</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Phase II Protocol</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Phase II Study</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Phase II Trial</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Trial Phase 2</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>phase 2</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>phase II trial</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66737"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67497"/>
        <rdfs:label>Phase II Trial</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/NCIT_C15601"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C15602 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C15602">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/ERO_0000016"/>
        <obo:IAO_0000115>A clinical research protocol designed to investigate the efficacy of the biomedical or behavioral intervention in large groups of human subjects (from several hundred to several thousand), to confirm efficacy, to monitor adverse reactions to the new medication or treatment regimen with respect to long-term use and by comparing the intervention to other standard or experimental interventions as well as to a placebo.</obo:IAO_0000115>
        <obo:IAO_0000115>Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C15602</obo:NCIT_NHC0>
        <obo:NCIT_P106>Research Activity</obo:NCIT_P106>
        <obo:NCIT_P108>Phase III Trial</obo:NCIT_P108>
        <obo:NCIT_P207>C0282461</obo:NCIT_P207>
        <obo:NCIT_P322>CDISC</obo:NCIT_P322>
        <obo:NCIT_P322>CDISC-GLOSS</obo:NCIT_P322>
        <obo:NCIT_P325>A study to compare the results of people taking a new treatment with the results of people taking the standard treatment (for example, which group has better survival rates or fewer side effects). In most cases, studies move into phase III only after a treatment seems to work in phases I and II. Phase III trials may include hundreds of people.</obo:NCIT_P325>
        <obo:NCIT_P325>Phase 3. Studies are expanded controlled and uncontrolled trials. They are performed after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather the additional information about effectiveness and safety that is needed to confirm efficacy and evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling. NOTE: Phase 3 studies usually include from several hundred to several thousand subjects. [After FDA CDER Handbook, ICH E8] (CDISC glossary)</obo:NCIT_P325>
        <obo:NCIT_P325>Studies are expanded controlled and uncontrolled trials. They are performed after preliminary evidence suggesting effectiveness of the drug has been obtained and are intended to gather the additional information about effectiveness and safety that is needed to confirm efficacy and evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling. NOTE: Phase 3 studies usually include from several hundred to several thousand subjects. [after FDA CDER handbook, ICH E8]</obo:NCIT_P325>
        <obo:NCIT_P366>Phase_III_Trial</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>3</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Clinical Trials, Phase III</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>PHASE III TRIAL</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Phase 3 Study</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Phase III Clinical Trial</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Phase III Protocol</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Phase III Study</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Phase III Trial</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Phase III Trials</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Trial Phase 3</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>phase 3</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>phase III trial</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66737"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67497"/>
        <rdfs:label>Phase III Trial</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/NCIT_C15602"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.</owl:annotatedTarget>
        <rdfs:comment>https://prsinfo.clinicaltrials.gov/definitions.html</rdfs:comment>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C15603 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C15603">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/ERO_0000016"/>
        <obo:IAO_0000115>A randomized, controlled trial that is designed to evaluate the long-term safety and efficacy of a drug for a given indication. Often they are designed to study side effects that may have become apparent after the phase III study was completed.</obo:IAO_0000115>
        <obo:IAO_0000115>Studies of FDA-approved drugs to delineate additional information including the drug&apos;s risks, benefits, and optimal use.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C15603</obo:NCIT_NHC0>
        <obo:NCIT_P106>Research Activity</obo:NCIT_P106>
        <obo:NCIT_P108>Phase IV Trial</obo:NCIT_P108>
        <obo:NCIT_P207>C0282462</obo:NCIT_P207>
        <obo:NCIT_P322>CDISC</obo:NCIT_P322>
        <obo:NCIT_P322>CDISC-GLOSS</obo:NCIT_P322>
        <obo:NCIT_P325>After a treatment has been approved and is being marketed, it is studied in a phase IV trial to evaluate side effects that were not apparent in the phase III trial. Thousands of people are involved in a phase IV trial.</obo:NCIT_P325>
        <obo:NCIT_P325>Phase 4. Postmarketing (Phase 4) studies to delineate additional information about the drug&apos;s risks, benefits, and optimal use that may be requested by regulatory authorities in conjunction with marketing approval. NOTE: These studies could include, but would not be limited to, studying different doses or schedules of administration than were used in Phase 2 studies, use of the drug in other patient populations or other stages of the disease, or use of the drug over a longer period of time. [After FDA CDER Handbook, ICH E8] (CDISC glossary)</obo:NCIT_P325>
        <obo:NCIT_P325>Post approval studies to delineate additional information about the drug&apos;s risks, benefits, and optimal use that may be requested by regulatory authorities in conjunction with marketing approval. NOTE: These studies could include, but would not be limited to, studying different doses or schedules of administration than were used in Phase 2 studies, use of the drug in other patient populations or other stages of the disease, or use of the drug over a longer period of time. [after FDA CDER handbook, ICH E8]</obo:NCIT_P325>
        <obo:NCIT_P366>Phase_IV_Trial</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>4</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Clinical Trials, Phase IV</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>PHASE IV TRIAL</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Phase 4 Study</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Phase IV Clinical Trials</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Phase IV Study</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Phase IV Trial</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Trial Phase 4</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>phase 4</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>phase IV trial</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66737"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67497"/>
        <rdfs:label>Phase IV Trial</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/NCIT_C15603"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>Studies of FDA-approved drugs to delineate additional information including the drug&apos;s risks, benefits, and optimal use.</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C15693 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C15693">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/ERO_0000016"/>
        <obo:IAO_0000115>A clinical research protocol designed to study the safety, dosage levels and response to new treatment. Phase I/II trials combine a Phase I and a Phase II trial of the same treatment into a single protocol.</obo:IAO_0000115>
        <obo:IAO_0000115>Trials that are a combination of phases 1 and 2.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C15693</obo:NCIT_NHC0>
        <obo:NCIT_P106>Research Activity</obo:NCIT_P106>
        <obo:NCIT_P108>Phase I/II Trial</obo:NCIT_P108>
        <obo:NCIT_P207>C1519043</obo:NCIT_P207>
        <obo:NCIT_P322>CDISC</obo:NCIT_P322>
        <obo:NCIT_P325>A class of clinical study that combines elements characteristic of traditional Phase I and Phase II trials. See also Phase I, Phase II.</obo:NCIT_P325>
        <obo:NCIT_P325>A trial to study the safety, dosage levels, and response to a new treatment.</obo:NCIT_P325>
        <obo:NCIT_P366>Phase_I_II_Trial</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>1-2</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>PHASE I/II TRIAL</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Phase I/II Trial</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Phase I/II trial</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Trial Phase 1-2</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Trial Phase 1/2</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66737"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830"/>
        <rdfs:label>Phase I/II Trial</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/NCIT_C15693"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>Trials that are a combination of phases 1 and 2.</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C15694 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C15694">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/ERO_0000016"/>
        <obo:IAO_0000115>A type of clinical study that combines elements characteristic of traditional Phase II and Phase III trials.</obo:IAO_0000115>
        <obo:IAO_0000115>Trials that are a combination of phases 2 and 3.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C15694</obo:NCIT_NHC0>
        <obo:NCIT_P106>Research Activity</obo:NCIT_P106>
        <obo:NCIT_P108>Phase II/III Trial</obo:NCIT_P108>
        <obo:NCIT_P207>C1519042</obo:NCIT_P207>
        <obo:NCIT_P322>CDISC</obo:NCIT_P322>
        <obo:NCIT_P325>A class of clinical study that combines elements characteristic of traditional Phase II and Phase III trials.</obo:NCIT_P325>
        <obo:NCIT_P325>A trial to study response to a new treatment and the effectiveness of the treatment compared with the standard treatment regimen.</obo:NCIT_P325>
        <obo:NCIT_P366>Phase_II_III_Trial</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>2-3</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>PHASE II/III TRIAL</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Phase II/III Trial</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Trial Phase 2-3</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Trial Phase 2/3</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>phase II/III trial</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66737"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830"/>
        <rdfs:label>Phase II/III Trial</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/NCIT_C15694"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>Trials that are a combination of phases 2 and 3.</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C15714 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C15714">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCIT_C147141"/>
        <obo:IAO_0000115>Fundamental research designed to obtain or increase general scientific knowledge.</obo:IAO_0000115>
        <obo:IAO_0000115>One or more interventions for examining the basic mechanism of action (for example, physiology or biomechanics of an intervention).</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C15714</obo:NCIT_NHC0>
        <obo:NCIT_P106>Research Activity</obo:NCIT_P106>
        <obo:NCIT_P108>Basic Research</obo:NCIT_P108>
        <obo:NCIT_P207>C0681833</obo:NCIT_P207>
        <obo:NCIT_P322>CDISC</obo:NCIT_P322>
        <obo:NCIT_P325>A type of study designed to examine the basic mechanism of action (e.g., physiology, biomechanics) of an intervention. (ClinicalTrials.gov)</obo:NCIT_P325>
        <obo:NCIT_P366>Basic_Science</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>BASIC SCIENCE</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Basic Research</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Basic Science</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Basic Science Research</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C147067"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66736"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830"/>
        <rdfs:label>Basic Research</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/NCIT_C15714"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>One or more interventions for examining the basic mechanism of action (for example, physiology or biomechanics of an intervention).</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C161319 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C161319">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCIT_C93360"/>
        <obo:IAO_0000115>Primary disease(s) or condition(s) being studied in the trial, or the focus of the study. (clinicaltrials.gov)</obo:IAO_0000115>
        <obo:IAO_0000115>The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.</obo:IAO_0000115>
        <obo:IAO_0000115>The name(s) of the disease(s) or condition(s) studied in the clinical study, or the focus of the clinical study. Use, if available, appropriate descriptors from NLM&apos;s Medical Subject Headings (MeSH)-controlled vocabulary thesaurus or terms from another vocabulary, such as the Systematized Nomenclature of Medicine—Clinical Terms (SNOMED CT), that has been mapped to MeSH within the Unified Medical Language System (UMLS) Metathesaurus.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C161319</obo:NCIT_NHC0>
        <obo:NCIT_P106>Qualitative Concept</obo:NCIT_P106>
        <obo:NCIT_P108>Condition or Disease under Study</obo:NCIT_P108>
        <obo:NCIT_P322>CDISC</obo:NCIT_P322>
        <obo:NCIT_P325>Primary disease(s) or condition(s) being studied in the trial, or the focus of the study. (clinicaltrials.gov)</obo:NCIT_P325>
        <oboInOwl:hasExactSynonym>Condition or Disease under Study</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>health condition(s) or problem(s) studied</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>target disease</oboInOwl:hasExactSynonym>
        <oboInOwl:hasNarrowSynonym>condition</oboInOwl:hasNarrowSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C160921"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410"/>
        <rdfs:label>Condition or Disease under Study</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/NCIT_C161319"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.</owl:annotatedTarget>
        <obo:IAO_0000119>https://clinicaltrials.gov/ct2/about-studies/glossary</obo:IAO_0000119>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/NCIT_C161319"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>The name(s) of the disease(s) or condition(s) studied in the clinical study, or the focus of the clinical study. Use, if available, appropriate descriptors from NLM&apos;s Medical Subject Headings (MeSH)-controlled vocabulary thesaurus or terms from another vocabulary, such as the Systematized Nomenclature of Medicine—Clinical Terms (SNOMED CT), that has been mapped to MeSH within the Unified Medical Language System (UMLS) Metathesaurus.</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/NCIT_C161319"/>
        <owl:annotatedProperty rdf:resource="http://www.geneontology.org/formats/oboInOwl#hasExactSynonym"/>
        <owl:annotatedTarget>health condition(s) or problem(s) studied</owl:annotatedTarget>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/trds/en/</rdfs:seeAlso>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C19332 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C19332">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000030"/>
        <obo:IAO_0000115>The distinguishing qualities or prominent aspects of an individual person.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <obo:NCIT_NHC0>C19332</obo:NCIT_NHC0>
        <obo:NCIT_P106>Organism Attribute</obo:NCIT_P106>
        <obo:NCIT_P108>Personal Attribute</obo:NCIT_P108>
        <obo:NCIT_P207>C0681884</obo:NCIT_P207>
        <obo:NCIT_P366>Personal_Attribute</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>Personal</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Personal Attribute</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Subject Characteristics</oboInOwl:hasExactSynonym>
        <rdfs:label>Personal Attribute</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C25150 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C25150">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCIT_C19332"/>
        <obo:IAO_0000115>A type of eligibility criteria that indicates the age a person must be to participate in a clinical study.</obo:IAO_0000115>
        <obo:IAO_0000115>How long something has existed; elapsed time since birth.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <obo:NCIT_A11 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C89335"/>
        <obo:NCIT_NHC0>C25150</obo:NCIT_NHC0>
        <obo:NCIT_P106>Organism Attribute</obo:NCIT_P106>
        <obo:NCIT_P108>Age</obo:NCIT_P108>
        <obo:NCIT_P207>C0001779</obo:NCIT_P207>
        <obo:NCIT_P322>CDISC</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P322>NICHD</obo:NCIT_P322>
        <obo:NCIT_P325>How long something has existed; elapsed time since birth. (NCI)</obo:NCIT_P325>
        <obo:NCIT_P325>The time elapsed since birth.</obo:NCIT_P325>
        <obo:NCIT_P366>Age</obo:NCIT_P366>
        <obo:NCIT_P371>Chronological Age</obo:NCIT_P371>
        <oboInOwl:hasExactSynonym>AGE</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Age</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Aged</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Chronological Age</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Postnatal Age</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>age</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwlInOwllibrary.org/oboInOwlInOwl/NCIT_C118466"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwlInOwllibrary.org/oboInOwlInOwl/NCIT_C19752"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwlInOwllibrary.org/oboInOwlInOwl/NCIT_C54447"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwlInOwllibrary.org/oboInOwlInOwl/NCIT_C61410"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwlInOwllibrary.org/oboInOwlInOwl/NCIT_C77526"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwlInOwllibrary.org/oboInOwlInOwl/NCIT_C83187"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwlInOwllibrary.org/oboInOwlInOwl/NCIT_C83188"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwlInOwllibrary.org/oboInOwlInOwl/NCIT_C90007"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwlInOwllibrary.org/oboInOwlInOwl/NCIT_C90009"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwlInOwllibrary.org/oboInOwlInOwl/NCIT_C90259"/>
        <rdfs:label>Age</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/NCIT_C25150"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>A type of eligibility criteria that indicates the age a person must be to participate in a clinical study.</owl:annotatedTarget>
        <obo:IAO_0000119>https://clinicaltrials.gov/ct2/about-studies/glossary</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C25320 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C25320">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCIT_C70817"/>
        <rdfs:subClassOf>
            <owl:Restriction>
                <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/BFO_0000051"/>
                <owl:someValuesFrom rdf:resource="https://bio.scai.fraunhofer.de/ontology/CTO_0000008"/>
            </owl:Restriction>
        </rdfs:subClassOf>
        <rdfs:subClassOf>
            <owl:Restriction>
                <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/BFO_0000051"/>
                <owl:someValuesFrom rdf:resource="https://bio.scai.fraunhofer.de/ontology/CTO_0000035"/>
            </owl:Restriction>
        </rdfs:subClassOf>
        <obo:IAO_0000115>A formal document that describes a complete plan of research activity in the framework of a clinical study; specifically, the study objective(s), design, methodology, eligibility requests for prospective subjects and controls; intervention regimen(s), proposed methods of analysis of data; statistical considerations, and organization of the study. The protocol usually also provides the background and rationale for the trial, but these could be represented in other protocol referenced documents.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C25320</obo:NCIT_NHC0>
        <obo:NCIT_P106>Intellectual Product</obo:NCIT_P106>
        <obo:NCIT_P108>Clinical Study Protocol</obo:NCIT_P108>
        <obo:NCIT_P207>C1507394</obo:NCIT_P207>
        <obo:NCIT_P322>BRIDG</obo:NCIT_P322>
        <obo:NCIT_P322>CDISC-GLOSS</obo:NCIT_P322>
        <obo:NCIT_P322>CareLex</obo:NCIT_P322>
        <obo:NCIT_P325>A detailed plan of a scientific or medical experiment, treatment, or procedure. In clinical trials, it states what the study will do, how it will be done, and why it is being done. It explains how many people will be in the study, who is eligible to take part in it, what study drugs or other interventions will be given, what tests will be done and how often, and what information will be collected.</obo:NCIT_P325>
        <obo:NCIT_P325>A discrete, structured plan (that persists over time) of a formal investigation to assess the utility, impact, pharmacological, physiological, and/or psychological effects of a particular treatment, procedure, drug, device, biologic, food product, cosmetic, care plan, or subject characteristic. NOTE(S): The term &quot;protocol&quot; is somewhat overloaded and must be qualified to provide semantic context. Therefore the term &quot;study protocol&quot; was chosen to disambiguate it from other protocols. In previous versions of BRIDG, there was one class for StudyProtocol. However this too represented multiple distinct aspects of the semantics of study protocol, each of which have now been split into separate classes:- The StudyProtocol class represents the content of the study protocol and can exist even before the information is put into document form. - The details of the structured plan for the study protocol are represented by the StudyProtocolVersion, so named because any aspect of the definition can change from version to version. These details include, but are not limited to, the characteristics, specifications, objective(s), background, the pre-study/study/post-study portions of the plan (including the design, methodology, statistical considerations, organization).- The protocol and its versions can each be represented in document form, respectively StudyProtocolDocument and StudyProtocolDocumentVersion. A StudyProtocolDocument groups the various document versions (StudyProtocolDocumentVersions).- The conduct of a study based on a study protocol definition is represented by the StudyExecution class.</obo:NCIT_P325>
        <obo:NCIT_P325>A formal document that describes a complete plan of research activity in the framework of a clinical study; specifically, the study objective(s), design, methodology, eligibility requests for prospective subjects and controls; intervention regimen(s), proposed methods of analysis of data; statistical considerations, and organization of the study. The protocol usually also provides the background and rationale for the trial, but these could be represented in other protocol referenced documents. [NCI]</obo:NCIT_P325>
        <obo:NCIT_P325>See protocol.</obo:NCIT_P325>
        <obo:NCIT_P366>Protocol</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>Clinical Study Protocol</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Clinical Trial Protocol</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Full Protocol</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Prot</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Protocol</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Protocol Amendment</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Study Protocol</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>StudyProtocol</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Trial Protocol</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>clinical protocol</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>protocol</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C114548"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C159501"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C159503"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67497"/>
        <rdfs:label>Clinical Study Protocol</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C48355 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C48355">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCBITaxon_9606"/>
        <obo:IAO_0000115>A person or organization that supports or champions something.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C48355</obo:NCIT_NHC0>
        <obo:NCIT_P106>Human</obo:NCIT_P106>
        <obo:NCIT_P108>Sponsor</obo:NCIT_P108>
        <obo:NCIT_P207>C1711305</obo:NCIT_P207>
        <obo:NCIT_P366>Sponsor</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>Applicant</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Sponsor</oboInOwl:hasExactSynonym>
        <rdfs:label>Sponsor</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C49653 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C49653">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCIT_C147141"/>
        <obo:IAO_0000115>A type of study designed to evaluate method(s) aimed at identifying a disease or condition.</obo:IAO_0000115>
        <obo:IAO_0000115>One or more interventions are being evaluated for identifying a disease or health condition.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C49653</obo:NCIT_NHC0>
        <obo:NCIT_P106>Research Activity</obo:NCIT_P106>
        <obo:NCIT_P108>Diagnosis Study</obo:NCIT_P108>
        <obo:NCIT_P207>C1704656</obo:NCIT_P207>
        <obo:NCIT_P322>CDISC</obo:NCIT_P322>
        <obo:NCIT_P325>A type of study designed to evaluate intervention(s) aimed at identifying a disease or condition.</obo:NCIT_P325>
        <obo:NCIT_P366>Diagnosis_Study</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>DIAGNOSIS</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Diagnosis Study</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Diagnostic Study</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66736"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66739"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830"/>
        <rdfs:label>Diagnosis Study</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/NCIT_C49653"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>One or more interventions are being evaluated for identifying a disease or health condition.</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C49656 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C49656">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCIT_C147141"/>
        <obo:IAO_0000115>A type of study protocol designed to evaluate intervention(s) for disease treatment.</obo:IAO_0000115>
        <obo:IAO_0000115>One or more interventions are being evaluated for treating a disease, syndrome, or condition.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C49656</obo:NCIT_NHC0>
        <obo:NCIT_P106>Research Activity</obo:NCIT_P106>
        <obo:NCIT_P108>Treatment Study</obo:NCIT_P108>
        <obo:NCIT_P207>C3161471</obo:NCIT_P207>
        <obo:NCIT_P322>CDISC</obo:NCIT_P322>
        <obo:NCIT_P325>A type of study designed to evaluate intervention(s) for treatment of disease, syndrome or condition.</obo:NCIT_P325>
        <obo:NCIT_P366>Treatment_Study</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>TREATMENT</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Therapy Trial</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Treatment Study</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66736"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66739"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830"/>
        <rdfs:label>Treatment Study</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/NCIT_C49656"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>One or more interventions are being evaluated for treating a disease, syndrome, or condition.</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C49657 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C49657">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCIT_C147141"/>
        <obo:IAO_0000115>A type of study protocol designed to evaluate intervention(s) for disease prevention.</obo:IAO_0000115>
        <obo:IAO_0000115>One or more interventions are being assessed for preventing the development of a specific disease or health condition.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C49657</obo:NCIT_NHC0>
        <obo:NCIT_P106>Research Activity</obo:NCIT_P106>
        <obo:NCIT_P108>Prevention Study</obo:NCIT_P108>
        <obo:NCIT_P207>C1706420</obo:NCIT_P207>
        <obo:NCIT_P322>CDISC</obo:NCIT_P322>
        <obo:NCIT_P325>A type of study designed to identify actions necessary to permanently eliminate or reduce the long-term risk to human life as a result of a particular medication or treatment regimen.</obo:NCIT_P325>
        <obo:NCIT_P366>Prevention_Study</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>PREVENTION</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Prevention Study</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Preventive Clinical Trial</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Prophylaxis Study</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66736"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66739"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830"/>
        <rdfs:label>Prevention Study</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/NCIT_C49657"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>One or more interventions are being assessed for preventing the development of a specific disease or health condition.</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C49692 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C49692">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000027"/>
        <obo:IAO_0000115>The number of subjects entered in a clinical trial.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C49692</obo:NCIT_NHC0>
        <obo:NCIT_P106>Group Attribute</obo:NCIT_P106>
        <obo:NCIT_P108>Planned Subject Number</obo:NCIT_P108>
        <obo:NCIT_P207>C1709561</obo:NCIT_P207>
        <obo:NCIT_P322>CDISC</obo:NCIT_P322>
        <obo:NCIT_P322>CDISC-GLOSS</obo:NCIT_P322>
        <obo:NCIT_P325>The number of subjects in a class or group (including the total for the entire trial) intended to be enrolled in a trial to reach the planned sample size. Target enrollments are set so that statistical and scientific objectives of a trial will have a likelihood of being met as determined by agreement, algorithm, or other specified process.</obo:NCIT_P325>
        <obo:NCIT_P325>The planned number of subjects to be entered in a clinical trial. (NCI)</obo:NCIT_P325>
        <obo:NCIT_P366>Planned_Subject_Number</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>Anticipated Enrollment</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>PLANSUB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Planned Enrollment</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Planned Number of Subjects</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Planned Subject Number</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Target Enrollment</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>target enrollment</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>target number</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>target size</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C147066"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66738"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67152"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67497"/>
        <rdfs:label>Planned Subject Number</rdfs:label>
        <rdfs:seeAlso>https://prsinfo.clinicaltrials.gov/definitions.html</rdfs:seeAlso>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/trds/en/</rdfs:seeAlso>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C52580 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C52580">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000115"/>
        <obo:IAO_0000115>The distribution of resources over various time periods, products, operations, or investments.</obo:IAO_0000115>
        <obo:IAO_0000115>The method by which participants are assigned to arms in a clinical trial.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C52580</obo:NCIT_NHC0>
        <obo:NCIT_P106>Activity</obo:NCIT_P106>
        <obo:NCIT_P108>Allocation</obo:NCIT_P108>
        <obo:NCIT_P207>C1706778</obo:NCIT_P207>
        <obo:NCIT_P322>CDISC</obo:NCIT_P322>
        <obo:NCIT_P325>The process of assigning subjects to particular treatment groups or cohorts in a clinical study.</obo:NCIT_P325>
        <obo:NCIT_P366>Allocation</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>Allocation</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Subject Allocation</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C147066"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410"/>
        <rdfs:label>Allocation</rdfs:label>
        <rdfs:seeAlso>https://www.clinicaltrials.gov/ct2/about-studies/glossary</rdfs:seeAlso>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/NCIT_C52580"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>The method by which participants are assigned to arms in a clinical trial.</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C60776 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C60776">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000300"/>
        <obo:IAO_0000115>Information regarding the means of contacting a person or group.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C60776</obo:NCIT_NHC0>
        <obo:NCIT_P106>Conceptual Entity</obo:NCIT_P106>
        <obo:NCIT_P108>Contact Information</obo:NCIT_P108>
        <obo:NCIT_P207>C1880174</obo:NCIT_P207>
        <obo:NCIT_P366>Contact_Information</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>Contact Info</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Contact Information</oboInOwl:hasExactSynonym>
        <rdfs:label>Contact Information</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C70793 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C70793">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCIT_C48355"/>
        <obo:IAO_0000115>An entity such as an individual, company, institution, group, or organization which takes responsibility for the initiation, management, and/or financing of a clinical study. The sponsor does not actually conduct the investigation unless the sponsor is a sponsor-investigator. A person other than an individual (e.g., corporation or agency) that uses one or more of its own employees to conduct research it has initiated is considered to be a sponsor, and the employees are considered to be investigators. [21 CFR P.50.3(k)] [21 CFR P.50.102(j)] [21 CFR P.312.3]</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C70793</obo:NCIT_NHC0>
        <obo:NCIT_P106>Health Care Related Organization</obo:NCIT_P106>
        <obo:NCIT_P108>Clinical Study Sponsor</obo:NCIT_P108>
        <obo:NCIT_P207>C2347796</obo:NCIT_P207>
        <obo:NCIT_P322>CDISC</obo:NCIT_P322>
        <obo:NCIT_P322>CDISC-GLOSS</obo:NCIT_P322>
        <obo:NCIT_P322>CareLex</obo:NCIT_P322>
        <obo:NCIT_P325>An entity that is responsible for the initiation, management, and/or financing of a clinical study.</obo:NCIT_P325>
        <obo:NCIT_P325>An entity that is responsible for the initiation, management, and/or financing of a clinical study.[NCI]</obo:NCIT_P325>
        <obo:NCIT_P325>An individual, company, institution, or organization that takes responsibility for the initiation, management, and/or financing of a clinical trial. NOTE: If there is also a secondary sponsor, the responsible entity would be considered the primary sponsor. A corporation or agency whose employees conduct the investigation is considered a sponsor and the employees are considered investigators. [After ICH E6, WHO, 21 CFR 50.3 (e), and after IDMP] See also secondary sponsor.</obo:NCIT_P325>
        <obo:NCIT_P366>Clinical_Study_Sponsor</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>CLINICAL STUDY SPONSOR</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Clinical Study Sponsor</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>SPONSOR</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Sponsor</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Study Sponsor</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>sponsor</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C114548"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C154681"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66738"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67152"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67497"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C78735"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C83187"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C83188"/>
        <rdfs:label>Clinical Study Sponsor</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C70817 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C70817">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000272"/>
        <obo:IAO_0000115>The formal plan of an experiment or research activity, including the objective, rationale, design, materials and methods for the conduct of the study; intervention description, and method of data analysis.</obo:IAO_0000115>
        <obo:IAO_0000115>The written description of the clinical study, including objective(s), design, and methods. It may also include relevant scientific background and statistical considerations (if the protocol document includes the statistical analysis plan, use &quot;Study Protocol with SAP and/or ICF&quot; option). Note: All amendments approved by a human subjects protection review board (if applicable), before the time of submission and that apply to all clinical trial Facility Locations must be included.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C70817</obo:NCIT_NHC0>
        <obo:NCIT_P106>Intellectual Product</obo:NCIT_P106>
        <obo:NCIT_P108>Study Protocol</obo:NCIT_P108>
        <obo:NCIT_P207>C2348563</obo:NCIT_P207>
        <obo:NCIT_P322>CDISC</obo:NCIT_P322>
        <obo:NCIT_P325>The formal plan of an experiment or research activity, including the objective, rationale, design, materials and methods for the conduct of the study, intervention description, and method of data analysis.</obo:NCIT_P325>
        <obo:NCIT_P366>Study_Protocol</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>Protocol</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Study Protocol</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132310"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410"/>
        <rdfs:label>Study Protocol</rdfs:label>
        <rdfs:seeAlso>https://prsinfo.clinicaltrials.gov/definitions.html</rdfs:seeAlso>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/NCIT_C70817"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>The written description of the clinical study, including objective(s), design, and methods. It may also include relevant scientific background and statistical considerations (if the protocol document includes the statistical analysis plan, use &quot;Study Protocol with SAP and/or ICF&quot; option). Note: All amendments approved by a human subjects protection review board (if applicable), before the time of submission and that apply to all clinical trial Facility Locations must be included.</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/results_definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C70840 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C70840">
        <rdfs:subClassOf rdf:resource="http://purl.org/net/OCRe/research.owl#Interventional_study"/>
        <obo:IAO_0000115>A clinical study that is designed using a procedure in which one or more parties to the study [subject(s), investigator(s), monitor, or/and data analyst(s)] are kept unaware of the treatment assignment(s).</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C70840</obo:NCIT_NHC0>
        <obo:NCIT_P106>Research Activity</obo:NCIT_P106>
        <obo:NCIT_P108>Blinded Clinical Study</obo:NCIT_P108>
        <obo:NCIT_P207>C2347038</obo:NCIT_P207>
        <obo:NCIT_P322>CDISC-GLOSS</obo:NCIT_P322>
        <obo:NCIT_P325>A study in which the subject, the investigator, or anyone assessing the outcome is unaware of the treatment assignment(s). NOTE: Blinding is used to reduce the potential for bias. [Modified ICH E6 Glossary] See also blinding/masking, double-blind study, single-blind study, triple-blind study; contrast with open-label or unblinded study.</obo:NCIT_P325>
        <obo:NCIT_P325>A type of study in which the patients (single-blinded) or the patients and their doctors (double-blinded) do not know which drug or treatment is being given. The opposite of a blinded study is an open label study.</obo:NCIT_P325>
        <obo:NCIT_P366>Blinded_Clinical_Study</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>Blind Clinical Study</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Blinded Clinical Study</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Blinded Clinical Trial</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Masked Clinical Study</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>blinded study</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67497"/>
        <rdfs:label>Blinded Clinical Study</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C71485 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C71485">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCIT_C147141"/>
        <obo:IAO_0000115>Clinical studies testing the efficacy of devices, techniques, procedures, or tests for the purpose of detecting the presence of disease, usually before there are any symptoms.</obo:IAO_0000115>
        <obo:IAO_0000115>One or more interventions are assessed or examined for identifying a condition, or risk factors for a condition, in people who are not yet known to have the condition or risk factor.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C71485</obo:NCIT_NHC0>
        <obo:NCIT_P106>Research Activity</obo:NCIT_P106>
        <obo:NCIT_P108>Screening Study</obo:NCIT_P108>
        <obo:NCIT_P207>C2348164</obo:NCIT_P207>
        <obo:NCIT_P322>CDISC</obo:NCIT_P322>
        <obo:NCIT_P322>CDISC-GLOSS</obo:NCIT_P322>
        <obo:NCIT_P325>A type of study designed to assess or examine methods of identifying a condition (or risk factors for a condition) in people who are not yet known to have the condition (or risk factor). (Clinicaltrials.gov)</obo:NCIT_P325>
        <obo:NCIT_P325>Trials conducted to detect persons with early, mild, and asymptomatic disease.</obo:NCIT_P325>
        <obo:NCIT_P366>Screening_Study</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>SCREENING</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Screening Study</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Screening Trial</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>screening trials</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66736"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67497"/>
        <rdfs:label>Screening Study</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/NCIT_C71485"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>One or more interventions are assessed or examined for identifying a condition, or risk factors for a condition, in people who are not yet known to have the condition or risk factor.</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C71486 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C71486">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCIT_C147141"/>
        <obo:IAO_0000115>Clinical studies intended to improve the comfort and quality of life for the patient using drugs, nutritional, dietary, behavioral or other interventions.</obo:IAO_0000115>
        <obo:IAO_0000115>One or more interventions are evaluated for maximizing comfort, minimizing side effects, or mitigating against a decline in the participant&apos;s health or function.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C71486</obo:NCIT_NHC0>
        <obo:NCIT_P106>Research Activity</obo:NCIT_P106>
        <obo:NCIT_P108>Supportive Care Study</obo:NCIT_P108>
        <obo:NCIT_P207>C2348611</obo:NCIT_P207>
        <obo:NCIT_P322>CDISC</obo:NCIT_P322>
        <obo:NCIT_P325>A type of study designed to evaluate one or more interventions where the primary intent is to maximize comfort, minimize side effects or mitigate against a decline in the subject&apos;s health or function. In general, supportive care interventions are not intended to cure a disease. (ClinicalTrials.gov)</obo:NCIT_P325>
        <obo:NCIT_P366>Supportive_Care_Study</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>SUPPORTIVE CARE</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Supportive Care Study</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Supportive Care Trial</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66736"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830"/>
        <rdfs:label>Supportive Care Study</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/NCIT_C71486"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>One or more interventions are evaluated for maximizing comfort, minimizing side effects, or mitigating against a decline in the participant&apos;s health or function.</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C82638 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C82638">
        <rdfs:subClassOf rdf:resource="http://purl.org/net/OCRe/research.owl#Interventional_study"/>
        <obo:IAO_0000115>A type of clinical study in which two or more treatments are given alone and in combination, such that all possible combinations are represented across the treatment arms, and are compared in parallel against the study control group.</obo:IAO_0000115>
        <obo:IAO_0000115>Two or more interventions, each alone and in combination, are evaluated in parallel against a control group</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C82638</obo:NCIT_NHC0>
        <obo:NCIT_P106>Research Activity</obo:NCIT_P106>
        <obo:NCIT_P108>Factorial Study</obo:NCIT_P108>
        <obo:NCIT_P207>C2826344</obo:NCIT_P207>
        <obo:NCIT_P322>CDISC</obo:NCIT_P322>
        <obo:NCIT_P325>Two or more interventions, each alone or in combination, are evaluated in parallel against a control group. This study design allows for the comparison of active drug to placebo, presence of drug-drug interactions, and comparison of active drugs against each other.</obo:NCIT_P325>
        <obo:NCIT_P366>Factorial_Study</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>FACTORIAL</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Factorial Study</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C77526"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C89967"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C99076"/>
        <rdfs:label>Factorial Study</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/NCIT_C82638"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>Two or more interventions, each alone and in combination, are evaluated in parallel against a control group</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C84336 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C84336">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCBITaxon_9606"/>
        <obo:IAO_0000115>Any of two or more parties working jointly towards a common goal.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C84336</obo:NCIT_NHC0>
        <obo:NCIT_P106>Conceptual Entity</obo:NCIT_P106>
        <obo:NCIT_P108>Collaborator</obo:NCIT_P108>
        <obo:NCIT_P207>C2827395</obo:NCIT_P207>
        <oboInOwl:hasExactSynonym>Collaborator</oboInOwl:hasExactSynonym>
        <rdfs:label>Collaborator</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C90467 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C90467">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCIT_C60776"/>
        <obo:IAO_0000115>The country in which the test is conducted.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C90467</obo:NCIT_NHC0>
        <obo:NCIT_P106>Geographic Area</obo:NCIT_P106>
        <obo:NCIT_P108>Test Facility Country</obo:NCIT_P108>
        <obo:NCIT_P207>C2983675</obo:NCIT_P207>
        <obo:NCIT_P322>CDISC</obo:NCIT_P322>
        <obo:NCIT_P325>The country of the place in which a nonclinical laboratory study takes place, i.e., actually uses the test article in a test system. Testing facility includes any establishment required to register under section 510 of the act that conducts nonclinical laboratory studies and any consulting laboratory described in section 704 of the act that conducts such studies. Testing facility encompasses only those operational units that are being or have been used to conduct nonclinical laboratory studies. (FDA)</obo:NCIT_P325>
        <oboInOwl:hasExactSynonym>TFCNTRY</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Test Facility Country</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C77526"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C90007"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C90009"/>
        <rdfs:label>Test Facility Country</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C90468 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C90468">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCIT_C60776"/>
        <obo:IAO_0000115>The geographic area in which a test is conducted.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C90468</obo:NCIT_NHC0>
        <obo:NCIT_P106>Geographic Area</obo:NCIT_P106>
        <obo:NCIT_P108>Test Facility Location</obo:NCIT_P108>
        <obo:NCIT_P207>C2983676</obo:NCIT_P207>
        <obo:NCIT_P322>CDISC</obo:NCIT_P322>
        <obo:NCIT_P325>The geographic area of the place in which a nonclinical laboratory study takes place, i.e., actually uses the test article in a test system. Testing facility includes any establishment required to register under section 510 of the act that conducts nonclinical laboratory studies and any consulting laboratory described in section 704 of the act that conducts such studies. Testing facility encompasses only those operational units that are being or have been used to conduct nonclinical laboratory studies. (FDA)</obo:NCIT_P325>
        <oboInOwl:hasExactSynonym>TSTFLOC</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Test Facility Location</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C77526"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C90007"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C90009"/>
        <rdfs:label>Test Facility Location</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C90469 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C90469">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCIT_C60776"/>
        <obo:IAO_0000115>The name of the place in which a test is conducted.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C90469</obo:NCIT_NHC0>
        <obo:NCIT_P106>Intellectual Product</obo:NCIT_P106>
        <obo:NCIT_P108>Test Facility Name</obo:NCIT_P108>
        <obo:NCIT_P207>C2983677</obo:NCIT_P207>
        <obo:NCIT_P322>CDISC</obo:NCIT_P322>
        <obo:NCIT_P325>The name of the place in which a nonclinical laboratory study takes place, i.e., actually uses the test article in a test system. Testing facility includes any establishment required to register under section 510 of the act that conducts nonclinical laboratory studies and any consulting laboratory described in section 704 of the act that conducts such studies. Testing facility encompasses only those operational units that are being or have been used to conduct nonclinical laboratory studies. (FDA)</obo:NCIT_P325>
        <oboInOwl:hasExactSynonym>TSTFNAM</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Test Facility Name</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C77526"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C90007"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C90009"/>
        <rdfs:label>Test Facility Name</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C93360 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C93360">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/PDRO_0000129"/>
        <obo:IAO_0000115>A condition that is a focus of the study.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C93360</obo:NCIT_NHC0>
        <obo:NCIT_P106>Qualitative Concept</obo:NCIT_P106>
        <obo:NCIT_P108>Study Condition</obo:NCIT_P108>
        <obo:NCIT_P207>C2985574</obo:NCIT_P207>
        <obo:NCIT_P322>BRIDG</obo:NCIT_P322>
        <obo:NCIT_P325>A condition that is a focus of the study.</obo:NCIT_P325>
        <oboInOwl:hasExactSynonym>Study Condition</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>StudyCondition</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C159501"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C159503"/>
        <rdfs:label>Study Condition</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C98714 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C98714">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000578"/>
        <obo:IAO_0000115>A sequence of letters, numbers, or other characters that uniquely identifies a clinical trial within a clinical trial registry.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C98714</obo:NCIT_NHC0>
        <obo:NCIT_P106>Intellectual Product</obo:NCIT_P106>
        <obo:NCIT_P108>Clinical Trial Registry Identifier</obo:NCIT_P108>
        <obo:NCIT_P207>C3274381</obo:NCIT_P207>
        <obo:NCIT_P322>CDISC</obo:NCIT_P322>
        <obo:NCIT_P325>Identification numbers assigned to the protocol by clinicaltrials.gov, EudraCT, or other registries.</obo:NCIT_P325>
        <oboInOwl:hasExactSynonym>Clinical Trial Registry Identifier</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>REGID</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Registry Identifier</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Trial Identifying Number</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66738"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67152"/>
        <rdfs:label>Clinical Trial Registry Identifier</rdfs:label>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/trds/en/</rdfs:seeAlso>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C98722 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C98722">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/ERO_0000015"/>
        <obo:IAO_0000115>An investigational drug product (including biological product) available through expanded access for patients who do not qualify for enrollment in a clinical trial. Expanded Access includes all expanded access types under section 561 of the Federal Food, Drug, and Cosmetic Act: (1) for individual patients, including emergency use; (2) for intermediate-size patient populations; and (3) under a treatment IND or treatment protocol.</obo:IAO_0000115>
        <obo:IAO_0000115>Studies that provide a means for obtaining an experimental drug or device for patients who are not adequately treated by existing therapy, who do not meet the eligibility criteria for enrollment, or who are otherwise unable to participate in another clinical study. Expanded Access studies include individual-patient IND, treatment IND, compassionate use, emergency use or continued access.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C98722</obo:NCIT_NHC0>
        <obo:NCIT_P106>Research Activity</obo:NCIT_P106>
        <obo:NCIT_P108>Expanded Access Study</obo:NCIT_P108>
        <obo:NCIT_P207>C3274389</obo:NCIT_P207>
        <obo:NCIT_P322>CDISC</obo:NCIT_P322>
        <obo:NCIT_P325>Studies that provide a means for obtaining an experimental drug or device for patients who are not adequately treated by existing therapy, who do not meet the eligibility criteria for enrollment, or who are otherwise unable to participate in another clinical study. Expanded Access studies include individual-patient IND, treatment IND, compassionate use, emergency use or continued access.</obo:NCIT_P325>
        <oboInOwl:hasExactSynonym>EXPANDED ACCESS</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Expanded Access Study</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C99077"/>
        <rdfs:label>Expanded Access Study</rdfs:label>
        <rdfs:seeAlso>https://prsinfo.clinicaltrials.gov/expanded_access_definitions.html</rdfs:seeAlso>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/NCIT_C98722"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>An investigational drug product (including biological product) available through expanded access for patients who do not qualify for enrollment in a clinical trial. Expanded Access includes all expanded access types under section 561 of the Federal Food, Drug, and Cosmetic Act: (1) for individual patients, including emergency use; (2) for intermediate-size patient populations; and (3) under a treatment IND or treatment protocol.</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C98747 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C98747">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000011"/>
        <obo:IAO_0000115>For each intervention studied in the clinical study, the general type of intervention.</obo:IAO_0000115>
        <obo:IAO_0000115>The kind of product or procedure studied in a trial.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C98747</obo:NCIT_NHC0>
        <obo:NCIT_P106>Functional Concept</obo:NCIT_P106>
        <obo:NCIT_P108>Intervention Type</obo:NCIT_P108>
        <obo:NCIT_P207>C3274412</obo:NCIT_P207>
        <obo:NCIT_P322>CDISC</obo:NCIT_P322>
        <obo:NCIT_P325>The kind of product or procedure studied in a trial.</obo:NCIT_P325>
        <oboInOwl:hasExactSynonym>INTTYPE</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Intervention Type</oboInOwl:hasExactSynonym>
        <oboInOwl:hasNarrowSynonym>intervention</oboInOwl:hasNarrowSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66738"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67152"/>
        <rdfs:label>Intervention Type</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/NCIT_C98747"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>For each intervention studied in the clinical study, the general type of intervention.</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/NCIT_C98747"/>
        <owl:annotatedProperty rdf:resource="http://www.geneontology.org/formats/oboInOwl#hasNarrowSynonym"/>
        <owl:annotatedTarget>intervention</owl:annotatedTarget>
        <rdfs:seeAlso>http://www.icmje.org/recommendations/ 
http://www.who.int/ictrp/network/trds/en/index.html</rdfs:seeAlso>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C98772 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C98772">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000027"/>
        <obo:IAO_0000115>The primary measurement(s) or observation(s) used to measure the effect of experimental variables in a study, or for observational studies, to describe patterns of diseases or traits or associations with exposures, risk factors or treatment. These are the outcome measures used to assess the primary objective(s).</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C98772</obo:NCIT_NHC0>
        <obo:NCIT_P106>Intellectual Product</obo:NCIT_P106>
        <obo:NCIT_P108>Primary Outcome Measure</obo:NCIT_P108>
        <obo:NCIT_P207>C3274433</obo:NCIT_P207>
        <obo:NCIT_P322>CDISC</obo:NCIT_P322>
        <obo:NCIT_P325>The primary measurement(s) or observation(s) used to measure the effect of experimental variables in a study, or for observational studies, to describe patterns of diseases or traits or associations with exposures, risk factors or treatment. These are the outcome measures used to assess the primary objective(s).</obo:NCIT_P325>
        <oboInOwl:hasExactSynonym>OUTMSPRI</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>PRIMARY OUTCOME MEASURE</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Primary Outcome Measure</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C117745"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66738"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67152"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C81222"/>
        <rdfs:label>Primary Outcome Measure</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C98781 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C98781">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000027"/>
        <obo:IAO_0000115>Other key measures that will be used to evaluate the intervention(s) or, for observational studies, that are a focus of the study. These are the outcome measures used to assess the secondary objective(s).</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C98781</obo:NCIT_NHC0>
        <obo:NCIT_P106>Intellectual Product</obo:NCIT_P106>
        <obo:NCIT_P108>Secondary Outcome Measure</obo:NCIT_P108>
        <obo:NCIT_P207>C3274440</obo:NCIT_P207>
        <obo:NCIT_P322>CDISC</obo:NCIT_P322>
        <obo:NCIT_P325>Secondary measures that will be used to evaluate the intervention(s) or, for observational studies, that are a focus of the study. These are the outcome measures used to assess the secondary objective(s).</obo:NCIT_P325>
        <oboInOwl:hasExactSynonym>OUTMSSEC</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>SECONDARY OUTCOME MEASURE</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Secondary Outcome Measure</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C117745"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66738"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67152"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C81222"/>
        <rdfs:label>Secondary Outcome Measure</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OAE_0000001 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OAE_0000001">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000061"/>
        <rdfs:subClassOf>
            <owl:Restriction>
                <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/BFO_0000062"/>
                <owl:someValuesFrom rdf:resource="http://purl.obolibrary.org/obo/OAE_0000002"/>
            </owl:Restriction>
        </rdfs:subClassOf>
        <obo:IAO_0000115>Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant’s participation in the research, whether or not considered related to the participant’s participation in the research</obo:IAO_0000115>
        <obo:IAO_0000115>a pathological bodily process that occurs after a medical intervention. An adverse event is likely caused by the medical intervention; however, such a causal association is not required to be an adverse event.</obo:IAO_0000115>
        <obo:IAO_0000116>Melanie Courtot and YH: More work is needed on how to restrict the scope of a term to be an &apos;adverse event&apos;, notably regarding temporal association. When is an appropirate time interval between a medical intervention and an adverse event observed? One week, one month, one year, or a lifetime? For some well-studied medical interventions (e.g., administration of many vaccines or drugs), we probably have a general idea. For many new interventions, we don&apos;t know much. In OAE, this issue is associated with defining the &apos;adverse event incubation time&apos;.</obo:IAO_0000116>
        <obo:IAO_0000116>YH: An adverse event is a process that has specified output of some adverse medical outcome (e.g., symptom, sign or accident) after a medical intervention (or process) (e.g., administration of drug or vaccine). The medical intervention can be an administration of a drug, a vaccine (i.e., vaccination), or a special nutritional product (for example, dietary supplement, infant formula, medical food), surgery, or usage of a medical device.</obo:IAO_0000116>
        <obo:IAO_0000116>YH: An adverse event is possibly induced by the medical intervention. It can be caused by the medical intervention, or may not be caused by the medical intervention. One ultimate goal (or the goal in clinics) of study adverse events is to assess if the adverse event outcome is due to the medical intervention.</obo:IAO_0000116>
        <obo:IAO_0000116>YH: In development of OAE, we initially use vaccine adverse event as our use case. A vaccine adverse event is associated with a vaccination (i.e. a medical intervention), regardless of whether it is considered vaccine-related, and includes any side effect, injury, toxicity, or sensitivity reaction or significant failure of immunization (i.e., a pharmacologic action).
Ref: Baylor NW and Midthum K. Regulation and testing of vaccines. In: Vaccines (Editors: Plotkin S, Orenstein W, and Offit P). 2008.  p1623.</obo:IAO_0000116>
        <obo:IAO_0000116>YH: The current term &apos;adverse event&apos; is different from the term definition shown in our paper: He Y, Xiang Z, Sarntivijai S, Toldo L, Ceusters W. OAE: a realism-based biomedical ontology for the representation of adverse events. Adverse Event Representation Workshop, International Conference on Biomedical Ontologies (ICBO), University at Buffalo, NY, July 26-30, 2011. Full lenghth conference proceeding paper.  

We  made the name changing in order to make OAE cover the broader sense of the &apos;adverse event&apos; which does not assume definite causal effect between an adverse event and a medical intervention. In current definition, the adverse event emphasizes the time association and assumes a likelihood of such a causal association. This term &apos;adverse event&apos; is stil under the OGMS:pathological bodily process.

The &apos;adverse event&apos; defined in the above paper has now been changed to a new term: &apos;causal adverse event&apos;. See more information in the new publication: Yongqun He Y, Sirarat Sarntivijai, Yu Lin, Zuoshuang Xiang, Abra Guo, Shelley Zhang, Desikan Jagannathan, Luca Toldo, Cui Tao and Barry Smith. OAE: The Ontology of Adverse Events. Journal of Biomedical Semantics. 2014, 5:29  doi:10.1186/2041-1480-5-29. PMID: 25093068.PMCID: PMC4120740.</obo:IAO_0000116>
        <obo:IAO_0000116>YH: The main scope of OAE includes: (1) represent terms and relations in the area of adverse events, (2) assess possible associations between an adverse event and a medical intervention, particularly, identify any causal effect of a medical intervention to an adverse event; and (2) understand the mechanism (including molecular mechanisms) of causal adverse events.</obo:IAO_0000116>
        <obo:IAO_0000116>YH: There has been discussion regarding whether the term &apos;side effect&apos; is an alternative term for &apos;adverse event&apos;. In AERO, the term &apos;AERO:adverse event&apos; represents a subset of those adverse events for which causality has been established. In OAE, an adverse event for which causality has been established is called &apos;causal adverse event&apos;.</obo:IAO_0000116>
        <obo:IAO_0000117>Yongqun He</obo:IAO_0000117>
        <obo:IAO_0000118>AE</obo:IAO_0000118>
        <obo:IAO_0000118>adverse reaction</obo:IAO_0000118>
        <obo:IAO_0000119>WEB: http://en.wikipedia.org/wiki/Adverse_event</obo:IAO_0000119>
        <obo:IAO_0000119>WEB: http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm</obo:IAO_0000119>
        <obo:IAO_0000119>WEB: http://www.ncbi.nlm.nih.gov/pubmed/25093068</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/oae.owl"/>
        <rdfs:comment>The OAE official website is: http://www.oae-ontology.org/.</rdfs:comment>
        <rdfs:label>adverse event</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/OAE_0000001"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant’s participation in the research, whether or not considered related to the participant’s participation in the research</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/results_definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/OAE_0000002 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OAE_0000002">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000011"/>
        <obo:IAO_0000115>A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.</obo:IAO_0000115>
        <obo:IAO_0000115>medical intervention is a planned process that has the goal of diagnosing, preventing or relieving illness or injury. </obo:IAO_0000115>
        <obo:IAO_0000116>The act of intervening, interfering or interceding with the intent of modifying the outcome. In medicine, an intervention is usually undertaken to help treat or cure a condition. For example, &quot;Acupuncture as a therapeutic intervention is widely practiced in the United States,&quot;
Reference:
http://www.medterms.com/script/main/art.asp?articlekey=34214 . Some interventions can be used for diagnosis. </obo:IAO_0000116>
        <obo:IAO_0000116>The act of intervening, interfering or interceding with the intent of modifying the outcome. In medicine, an intervention is usually undertaken to help treat or cure a condition. For example, &quot;Acupuncture as a therapeutic intervention is widely practiced in the United States,&quot; 
Reference:
http://www.medterms.com/script/main/art.asp?articlekey=34214 . Some interventions can be used for diagnosis. </obo:IAO_0000116>
        <obo:IAO_0000117>YH</obo:IAO_0000117>
        <obo:IAO_0000119>WEB: http://wiki.answers.com/Q/What_is_medical_intervention</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/oae.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/omrse.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <oboInOwl:hasExactSynonym>Intervention(s)</oboInOwl:hasExactSynonym>
        <rdfs:label>medical intervention</rdfs:label>
        <rdfs:seeAlso>https://prsinfo.clinicaltrials.gov/definitions.html</rdfs:seeAlso>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/OAE_0000002"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.</owl:annotatedTarget>
        <obo:IAO_0000119>https://www.clinicaltrials.gov/ct2/about-studies/glossary</obo:IAO_0000119>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/OAE_0000002"/>
        <owl:annotatedProperty rdf:resource="http://www.geneontology.org/formats/oboInOwl#hasExactSynonym"/>
        <owl:annotatedTarget>Intervention(s)</owl:annotatedTarget>
        <rdfs:seeAlso>http://www.icmje.org/recommendations/ 
http://www.who.int/ictrp/network/trds/en/index.html</rdfs:seeAlso>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/OAE_0000011 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OAE_0000011">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OAE_0000002"/>
        <obo:IAO_0000115>a medical intervention where a patient is administered with a drug</obo:IAO_0000115>
        <obo:IAO_0000117>YH</obo:IAO_0000117>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/oae.owl"/>
        <rdfs:label>drug administration</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OAE_0000094 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OAE_0000094">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OAE_0000002"/>
        <obo:IAO_0000115>a medical intervention that is used for therapeutic purpose</obo:IAO_0000115>
        <obo:IAO_0000117>YH</obo:IAO_0000117>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/oae.owl"/>
        <rdfs:label>therapeutic intervention</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OAE_0002807 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OAE_0002807">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OAE_0000002"/>
        <obo:IAO_0000115>a medical intervention that refers to any series of pre-defined steps that should be followed to achieve a desired result.</obo:IAO_0000115>
        <obo:IAO_0000117>YH, SS</obo:IAO_0000117>
        <obo:IAO_0000119>WEB: http://www.wisegeekhealth.com/what-is-the-difference-between-a-surgery-and-a-procedure.htm</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/oae.owl"/>
        <rdfs:label xml:lang="en">medical procedure</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OBI_0000011 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OBI_0000011">
        <owl:equivalentClass>
            <owl:Restriction>
                <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/BFO_0000055"/>
                <owl:someValuesFrom>
                    <owl:Restriction>
                        <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/RO_0000059"/>
                        <owl:someValuesFrom rdf:resource="http://purl.obolibrary.org/obo/IAO_0000104"/>
                    </owl:Restriction>
                </owl:someValuesFrom>
            </owl:Restriction>
        </owl:equivalentClass>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000015"/>
        <obo:IAO_0000111 xml:lang="en">planned process</obo:IAO_0000111>
        <obo:IAO_0000111 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">planned process</obo:IAO_0000111>
        <obo:IAO_0000112 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Injecting mice with a vaccine in order to test its efficacy</obo:IAO_0000112>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000122"/>
        <obo:IAO_0000115 xml:lang="en">A processual entity that realizes a plan which is the concretization of a plan specification.</obo:IAO_0000115>
        <obo:IAO_0000116 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">&apos;Plan&apos; includes a future direction sense. That can be problematic if plans are changed during their execution. There are however implicit contingencies for protocols that an agent has in his mind that can be considered part of the plan, even if the agent didn&apos;t have them in mind before. Therefore, a planned process can diverge from what the agent would have said the plan was before executing it, by adjusting to problems encountered during execution (e.g. choosing another reagent with equivalent properties, if the originally planned one has run out.)</obo:IAO_0000116>
        <obo:IAO_0000116 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">We are only considering successfully completed planned processes. A plan may be modified, and details added during execution. For a given planned process, the associated realized plan specification is the one encompassing all changes made during execution. This means that all processes in which an agent acts towards achieving some 
objectives is a planned process.</obo:IAO_0000116>
        <obo:IAO_0000117 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Bjoern Peters</obo:IAO_0000117>
        <obo:IAO_0000119 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">branch derived</obo:IAO_0000119>
        <obo:IAO_0000232 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">6/11/9: Edited at workshop. Used to include: is initiated by an agent</obo:IAO_0000232>
        <obo:IAO_0000232 xml:lang="en">This class merges the previously separated objective driven process and planned process, as they the separation proved hard to maintain. (1/22/09, branch call)</obo:IAO_0000232>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ero.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/oae.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <rdfs:label xml:lang="en">planned process</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OBI_0000102 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OBI_0000102">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000202"/>
        <obo:IAO_0000111 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">responsible party role</obo:IAO_0000111>
        <obo:IAO_0000112 xml:lang="en">he THERAPIST has the ability to print a separate statement for the patient and each responsible party. http://www.beaverlog.com/therapist/ez_support/billing/responsible_party_statements.htm</obo:IAO_0000112>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000120"/>
        <obo:IAO_0000115 xml:lang="en">a study personnel role played by a party who is accountable for the execution of a study component and can make decisions about the conduct of the study</obo:IAO_0000115>
        <obo:IAO_0000117 xml:lang="en">Person: Jennifer Fostel</obo:IAO_0000117>
        <obo:IAO_0000118 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">responsible party</obo:IAO_0000118>
        <obo:IAO_0000119 xml:lang="en">OBI</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <rdfs:label xml:lang="en">responsible party role</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OBI_0000115 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OBI_0000115">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0500000"/>
        <obo:IAO_0000111 xml:lang="en">intervention design</obo:IAO_0000111>
        <obo:IAO_0000111 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">intervention design</obo:IAO_0000111>
        <obo:IAO_0000112 xml:lang="en">PMID: 18208636.Br J Nutr. 2008 Jan 22;:1-11.Effect of vitamin D supplementation on bone and vitamin D status among Pakistani immigrants in Denmark: a randomised double-blinded placebo-controlled intervention study.</obo:IAO_0000112>
        <obo:IAO_0000112 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PMID: 18208636.Br J Nutr. 2008 Jan 22;:1-11.Effect of vitamin D supplementation on bone and vitamin D status among Pakistani immigrants in Denmark: a randomised double-blinded placebo-controlled intervention study.</obo:IAO_0000112>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000125"/>
        <obo:IAO_0000115>A description of the manner in which the clinical trial will be conducted.</obo:IAO_0000115>
        <obo:IAO_0000115 xml:lang="en">An intervention design is a study design in which a controlled process applied to the subjects (the intervention) serves as the independent variable manipulated by the experimentalist. The treatment (perturbation or intervention) defined can be defined as a combination of values taken by independent variable manipulated by the experimentalists are applied to the recruited subjects assigned (possibly by applying specific methods) to treatment groups. The specificity of intervention design is the fact that independent variables are being manipulated and a response of the biological system is evaluated via response variables as monitored by possibly a series of assays.</obo:IAO_0000115>
        <obo:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An intervention design is a study design in which a controlled process applied to the subjects (the intervention) serves as the independent variable manipulated by the experimentalist. The treatment (perturbation or intervention) defined can be defined as a combination of values taken by independent variable manipulated by the experimentalists are applied to the recruited subjects assigned (possibly by applying specific methods) to treatment groups. The specificity of intervention design is the fact that independent variables are being manipulated and a response of the biological system is evaluated via response variables as monitored by possibly a series of assays.</obo:IAO_0000115>
        <obo:IAO_0000117 xml:lang="en">Philppe Rocca-Serra</obo:IAO_0000117>
        <obo:IAO_0000117 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Philppe Rocca-Serra</obo:IAO_0000117>
        <obo:IAO_0000119 xml:lang="en">OBI branch derived</obo:IAO_0000119>
        <obo:IAO_0000119 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">OBI branch derived</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <oboInOwl:hasExactSynonym>Interventional Study Design</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>intervention model</oboInOwl:hasExactSynonym>
        <rdfs:label xml:lang="en">intervention design</rdfs:label>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">intervention design</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/OBI_0000115"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>A description of the manner in which the clinical trial will be conducted.</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/OBI_0000202 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OBI_0000202">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000023"/>
        <obo:IAO_0000111 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">investigation agent role</obo:IAO_0000111>
        <obo:IAO_0000112 xml:lang="en">The person perform microarray experiments and submit microarray results (including raw data, processed data) with experiment description to ArrayExpress.</obo:IAO_0000112>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000122"/>
        <obo:IAO_0000115 xml:lang="en">A role borne by an entity and that is realized in a process that is part of an investigation in which an objective is achieved. These processes include, among others: planning, overseeing, funding, reviewing.</obo:IAO_0000115>
        <obo:IAO_0000116 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Implementing a study means carrying out or performing the study and providing reagents or other materials used in the study and other tasks without which the study would not happen.</obo:IAO_0000116>
        <obo:IAO_0000116>Philly2013: Historically, this role would have been borne only by humans or organizations. However, we now also want to enable representing investigations run by robot scientists such as ADAM (King et al, Science, 2009)</obo:IAO_0000116>
        <obo:IAO_0000117 xml:lang="en">GROUP:  Role Branch</obo:IAO_0000117>
        <obo:IAO_0000118 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">investigator</obo:IAO_0000118>
        <obo:IAO_0000119 xml:lang="en">OBI</obo:IAO_0000119>
        <obo:IAO_0000232 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Feb 10, 2009.  changes after discussion at OBI Consortium Workshop Feb 2-6, 2009.  accepted as core term.</obo:IAO_0000232>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <obo:OBI_0001847 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">study person role</obo:OBI_0001847>
        <rdfs:comment>Philly2013: Historically, this role would have been borne only by humans or organizations. However, we now also want to enable investigations run by robot scientists such as ADAM (King et al, Science, 2009)</rdfs:comment>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">investigation agent role</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OBI_0000243 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OBI_0000243">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000102"/>
        <obo:IAO_0000111 xml:lang="en">sponsor role</obo:IAO_0000111>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000120"/>
        <obo:IAO_0000115 xml:lang="en">a responsible party role involved with any of the following activities:  initiating, managing and funding a study</obo:IAO_0000115>
        <obo:IAO_0000117 xml:lang="en">Person: Jennifer Fostel</obo:IAO_0000117>
        <obo:IAO_0000118 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">sponsor</obo:IAO_0000118>
        <obo:IAO_0000232 xml:lang="en">CDISC definition: sponsor. 1. An individual, company, institution, or organization that takes responsibility for the initiation, management, and/or financing of a clinical trial. 2. A corporation or agency whose employees conduct the investigation is considered a sponsor; employees are considered investigators</obo:IAO_0000232>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <rdfs:label xml:lang="en">sponsor role</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OBI_0000245 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OBI_0000245">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000040"/>
        <obo:IAO_0000111 xml:lang="en">organization</obo:IAO_0000111>
        <obo:IAO_0000112 xml:lang="en">PMID: 16353909.AAPS J. 2005 Sep 22;7(2):E274-80. Review. The joint food and agriculture organization of the United Nations/World Health Organization Expert Committee on Food Additives and its role in the evaluation of the safety of veterinary drug residues in foods.</obo:IAO_0000112>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000122"/>
        <obo:IAO_0000115 xml:lang="en">An entity that can bear roles, has members, and has a set of organization rules. Members of organizations are either organizations themselves or individual people. Members can bear specific organization member roles that are determined in the organization rules. The organization rules also determine how decisions are made on behalf of the organization by the organization members.</obo:IAO_0000115>
        <obo:IAO_0000116 xml:lang="en">BP: The definition summarizes long email discussions on the OBI developer, roles, biomaterial and denrie branches. It leaves open if an organization is a material entity or a dependent continuant, as no consensus was reached on that.  The current placement as material is therefore temporary, in order to move forward with development. Here is the entire email summary, on which the definition is based:

1) there are organization_member_roles (president, treasurer, branch
editor), with individual persons as bearers

2) there are organization_roles (employer, owner, vendor, patent holder)

3) an organization has a charter / rules / bylaws, which specify what roles
there are, how they should be realized, and how to modify the
charter/rules/bylaws themselves.

It is debatable what the organization itself is (some kind of dependent
continuant or an aggregate of people). This also determines who/what the
bearer of organization_roles&apos; are. My personal favorite is still to define
organization as a kind of &apos;legal entity&apos;, but thinking it through leads to
all kinds of questions that are clearly outside the scope of OBI.

Interestingly enough, it does not seem to matter much where we place
organization itself, as long as we can subclass it (University, Corporation,
Government Agency, Hospital), instantiate it (Affymetrix, NCBI, NIH, ISO,
W3C, University of Oklahoma), and have it play roles.

This leads to my proposal: We define organization through the statements 1 -
3 above, but without an &apos;is a&apos; statement for now. We can leave it in its
current place in the is_a hierarchy (material entity) or move it up to
&apos;continuant&apos;. We leave further clarifications to BFO, and close this issue
for now.</obo:IAO_0000116>
        <obo:IAO_0000117 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PERSON: Alan Ruttenberg</obo:IAO_0000117>
        <obo:IAO_0000117 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PERSON: Bjoern Peters</obo:IAO_0000117>
        <obo:IAO_0000117 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PERSON: Philippe Rocca-Serra</obo:IAO_0000117>
        <obo:IAO_0000117 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PERSON: Susanna Sansone</obo:IAO_0000117>
        <obo:IAO_0000119 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">GROUP: OBI</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <rdfs:label xml:lang="en">organization</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OBI_0000272 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OBI_0000272">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000104"/>
        <obo:IAO_0000111 xml:lang="en">protocol</obo:IAO_0000111>
        <obo:IAO_0000112 xml:lang="en">PCR protocol, has objective specification, amplify DNA fragment of interest, and has action specification describes the amounts of experimental reagents used (e..g. buffers, dNTPS, enzyme), and the temperature and cycle time settings for running the PCR.</obo:IAO_0000112>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000122"/>
        <obo:IAO_0000115 xml:lang="en">A plan specification which has sufficient level of detail and quantitative information to communicate it between investigation agents, so that different investigation agents will reliably be able to independently reproduce the process.</obo:IAO_0000115>
        <obo:IAO_0000117 xml:lang="en">PlanAndPlannedProcess Branch</obo:IAO_0000117>
        <obo:IAO_0000119 xml:lang="en">OBI branch derived + wikipedia (http://en.wikipedia.org/wiki/Protocol_%28natural_sciences%29)</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <obo:OBI_0001847 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">study protocol</obo:OBI_0001847>
        <rdfs:label xml:lang="en">protocol</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OBI_0000810 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OBI_0000810">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000011"/>
        <rdfs:subClassOf>
            <owl:Restriction>
                <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/OBI_0000293"/>
                <owl:someValuesFrom rdf:resource="http://purl.obolibrary.org/obo/NCBITaxon_9606"/>
            </owl:Restriction>
        </rdfs:subClassOf>
        <rdfs:subClassOf>
            <owl:Restriction>
                <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/RO_0000057"/>
                <owl:someValuesFrom>
                    <owl:Restriction>
                        <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/RO_0000087"/>
                        <owl:someValuesFrom rdf:resource="http://purl.obolibrary.org/obo/OBI_0000202"/>
                    </owl:Restriction>
                </owl:someValuesFrom>
            </owl:Restriction>
        </rdfs:subClassOf>
        <obo:IAO_0000111 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">informed consent process</obo:IAO_0000111>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000122"/>
        <obo:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A planned process in which a person or their legal representative is informed about key facts about potential risks and benefits of a process and makes a documented decision as to whether the person in question will participate.</obo:IAO_0000115>
        <obo:IAO_0000116 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">09/28/2009 Alan Ruttenberg: This is made a subclass of the higher level processual entity in BFO because I don&apos;t want to take a stand on whether it is a process aggregate. Analogous to the situation with Material entity.</obo:IAO_0000116>
        <obo:IAO_0000117 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Person:Alan Ruttenberg</obo:IAO_0000117>
        <obo:IAO_0000119 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://clinicaltrials.gov/ct2/info/glossary#informed</obo:IAO_0000119>
        <obo:IAO_0000232 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">2009/09/28 Alan Ruttenberg. Fucoidan-use-case</obo:IAO_0000232>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">informed consent process</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OBI_0000968 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OBI_0000968">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000040"/>
        <obo:IAO_0000111 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">device</obo:IAO_0000111>
        <obo:IAO_0000112 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A voltmeter is a measurement device which is intended to perform some measure function.</obo:IAO_0000112>
        <obo:IAO_0000112 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An autoclave is a device that sterlizes instruments or contaminated waste by applying high temperature and pressure.</obo:IAO_0000112>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000122"/>
        <obo:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A material entity that is designed to perform a function in a scientific investigation, but is not a reagent.</obo:IAO_0000115>
        <obo:IAO_0000116 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">2012-12-17 JAO: In common lab usage, there is a distinction made between devices and reagents that is difficult to model. Therefore we have chosen to specifically exclude reagents from the definition of &quot;device&quot;, and are enumerating the types of roles that a reagent can perform.

2013-6-5 MHB: The following clarifications are outcomes of the May 2013 Philly Workshop. Reagents are distinguished from devices that also participate in scientific techniques by the fact that reagents are chemical or biological in nature and necessarily participate in some chemical interaction or reaction during the realization of their experimental role. By contrast, devices do not participate in such chemical reactions/interactions.  Note that there are cases where devices use reagent components during their operation, where the reagent-device distinction is less clear.  For example:

(1) An HPLC machine is considered a device, but has a column that holds a stationary phase resin as an operational component.  This resin qualifies as a device if it participates purely in size exclusion, but bears a reagent role that is realized in the running of a column if it interacts electrostatically or chemically with the evaluant. The container the resin is in (“the column”) considered alone is a device. So the entire column as well as the entire HPLC machine are devices that have a reagent as an operating part.

(2) A pH meter is a device, but its electrode component bears a reagent role in virtue of its interacting directly with the evaluant in execution of an assay.

(3) A gel running  box  is a device that has a metallic lead as a component that participates in a chemical reaction with the running buffer when a charge is passed through it.  This metallic lead is considered to have a reagent role as a component of this device realized in the running of a gel.

In the examples above, a reagent is an operational component of a device, but the device itself does not realize a reagent role (as bearing a reagent role is not transitive across the part_of relation).  In this way, the asserted disjointness between a reagent and device holds, as both roles are never realized in the same bearer during execution of an assay.  </obo:IAO_0000116>
        <obo:IAO_0000117 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PERSON: Helen Parkinson</obo:IAO_0000117>
        <obo:IAO_0000118 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">instrument</obo:IAO_0000118>
        <obo:IAO_0000119 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">OBI development call 2012-12-17.</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">device</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OBI_0001627 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OBI_0001627">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000300"/>
        <obo:IAO_0000111 xml:lang="en">country name</obo:IAO_0000111>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000120"/>
        <obo:IAO_0000115 xml:lang="en">A textual entity that denotes a geographic location that is a site or part of a site that is identified as a country in the political geography.</obo:IAO_0000115>
        <obo:IAO_0000117 xml:lang="en">Person: Chris Stoeckert, Jie Zheng</obo:IAO_0000117>
        <obo:IAO_0000119 xml:lang="en">NIAID GSCID-BRC metadata working group</obo:IAO_0000119>
        <obo:IAO_0000119 xml:lang="en">Website: http://en.wikipedia.org/wiki/Country</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <obo:OBI_0001886>Specimen Collection Location - Country</obo:OBI_0001886>
        <dc:source>NIAID GSCID-BRC</dc:source>
        <rdfs:label xml:lang="en">country name</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OBI_0001755 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OBI_0001755">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000033"/>
        <obo:IAO_0000111 xml:lang="en">selection criterion</obo:IAO_0000111>
        <obo:IAO_0000112 xml:lang="en">rats should be aged between 6 and 8 weeks and weight between 180-250grams</obo:IAO_0000112>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000122"/>
        <obo:IAO_0000115 xml:lang="en">A directive information entity which defines and states a principle of standard by which selection process may take place.</obo:IAO_0000115>
        <obo:IAO_0000117 xml:lang="en">Person: Philippe Rocca-Serra</obo:IAO_0000117>
        <obo:IAO_0000118 xml:lang="en">selection rule</obo:IAO_0000118>
        <obo:IAO_0000119 xml:lang="en">OBI discussion summarized under the following tracker item : http://sourceforge.net/p/obi/obi-terms/678/</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <rdfs:label xml:lang="en">selection criterion</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OBI_0001928 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OBI_0001928">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000011"/>
        <obo:IAO_0000111 xml:lang="en">selection</obo:IAO_0000111>
        <obo:IAO_0000112 xml:lang="en">PMID: 24023800.  In this study, a set of eleven genes (VATP16, 60 S, UQCC, SMD3, EF1α, UBQ, SAND, GAPDH, ACT, PsaB, PTB2) was evaluated to identify reference genes during the first hours of interaction (6, 12, 18 and 24 hpi) between two V. vinifera genotypes and P. viticola. Two analyses were used for the selection of reference genes: direct comparison of susceptible, Trincadeira, and resistant, Regent, V. vinifera cultivars at 0 h, 6, 12, 18 and 24 hours post inoculation with P. viticola (genotype effect); and comparison of each genotype with mock inoculated samples during inoculation time-course (biotic stress effect). Three statistical methods were used, GeNorm, NormFinder, and BestKeeper, allowing to identify UBQ, EF1α and GAPDH as the most stable genes for the genotype effect.</obo:IAO_0000112>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000122"/>
        <obo:IAO_0000115 xml:lang="en">A planned process which results in the creation of group of entity from a larger group by the application of predefined criteria.</obo:IAO_0000115>
        <obo:IAO_0000116 xml:lang="en">this term refers to  a planned process and therefore is distinct from the notion of &apos;natural selection&apos;, a process covering the operation of natural causes by which those individuals of a species that are best adapted to the environment tend to be preserved and to transmit their characters, while those less adapted die out, so that in the course of generations the degree of adaptation to the environment tends progressively to increase. (as defined by Oxford English Dictionary)</obo:IAO_0000116>
        <obo:IAO_0000117 xml:lang="en">Person: Philippe Rocca-Serra</obo:IAO_0000117>
        <obo:IAO_0000118 xml:lang="en">selection process</obo:IAO_0000118>
        <obo:IAO_0000119 xml:lang="en">OBI</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <rdfs:label xml:lang="en">selection</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OBI_0001933 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OBI_0001933">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000030"/>
        <obo:IAO_0000111>value specification</obo:IAO_0000111>
        <obo:IAO_0000112>The value of &apos;positive&apos; in a classification scheme of &quot;positive or negative&quot;; the value of &apos;20g&apos; on the quantitative scale of mass.</obo:IAO_0000112>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000122"/>
        <obo:IAO_0000115>An information content entity that specifies a value within a classification scheme or on a quantitative scale.</obo:IAO_0000115>
        <obo:IAO_0000116>This term is currently a descendant of &apos;information content entity&apos;, which requires that it &apos;is about&apos; something. A value specification of &apos;20g&apos; for a measurement data item of the mass of a particular mouse &apos;is about&apos; the mass of that mouse. However there are cases where a value specification is not clearly about any particular. In the future we may change &apos;value specification&apos; to remove the &apos;is about&apos; requirement.</obo:IAO_0000116>
        <obo:IAO_0000117>PERSON:Bjoern Peters</obo:IAO_0000117>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <rdfs:label>value specification</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OBI_0002555 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OBI_0002555">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0500027"/>
        <rdfs:subClassOf>
            <owl:Class>
                <owl:intersectionOf rdf:parseType="Collection">
                    <owl:Restriction>
                        <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/BFO_0000051"/>
                        <owl:someValuesFrom rdf:resource="http://purl.obolibrary.org/obo/OBI_0002556"/>
                    </owl:Restriction>
                    <owl:Restriction>
                        <owl:onProperty rdf:resource="http://purl.obolibrary.org/obo/BFO_0000051"/>
                        <owl:someValuesFrom rdf:resource="http://purl.obolibrary.org/obo/OBI_0002557"/>
                    </owl:Restriction>
                </owl:intersectionOf>
            </owl:Class>
        </rdfs:subClassOf>
        <obo:IAO_0000111 xml:lang="en">age group inclusion criterion</obo:IAO_0000111>
        <obo:IAO_0000112 xml:lang="en">&quot;18-33 years old&quot;</obo:IAO_0000112>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000123"/>
        <obo:IAO_0000115>A type of eligibility criteria that indicates the age a person must be to participate in a clinical study. This may be indicated by a specific age or the following age groups. The age groups are: Child (birth-17), Adult (18-64), Older Adult (65+).</obo:IAO_0000115>
        <obo:IAO_0000115>An inclusion criterion that defines and states an age bracket which, if met, makes an entity suitable for a given task or participation in a given process.</obo:IAO_0000115>
        <obo:IAO_0000117>Mathias Brochhausen</obo:IAO_0000117>
        <obo:IAO_0000233>#839</obo:IAO_0000233>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <oboInOwl:hasExactSynonym>ages eligible for study</oboInOwl:hasExactSynonym>
        <rdfs:label xml:lang="en">age group inclusion criterion</rdfs:label>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/trds/en/</rdfs:seeAlso>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/OBI_0002555"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>A type of eligibility criteria that indicates the age a person must be to participate in a clinical study. This may be indicated by a specific age or the following age groups. The age groups are: Child (birth-17), Adult (18-64), Older Adult (65+).</owl:annotatedTarget>
        <obo:IAO_0000119>https://clinicaltrials.gov/ct2/about-studies/glossary</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/OBI_0002556 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OBI_0002556">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0001933"/>
        <obo:IAO_0000111 xml:lang="en">minimum age value specification</obo:IAO_0000111>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000123"/>
        <obo:IAO_0000115 xml:lang="en">A value specifcation that specifies the youngest age when specifying an age range.</obo:IAO_0000115>
        <obo:IAO_0000115>The numerical value, if any, for the minimum age a potential participant must meet to be eligible for the clinical study.</obo:IAO_0000115>
        <obo:IAO_0000117 xml:lang="en">Mathias Brochhausen</obo:IAO_0000117>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <oboInOwl:hasExactSynonym>minimum age</oboInOwl:hasExactSynonym>
        <rdfs:label xml:lang="en">minimum age value specification</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/OBI_0002556"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>The numerical value, if any, for the minimum age a potential participant must meet to be eligible for the clinical study.</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/OBI_0002557 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OBI_0002557">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0001933"/>
        <obo:IAO_0000111 xml:lang="en">maximum age value specification</obo:IAO_0000111>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000123"/>
        <obo:IAO_0000115 xml:lang="en">A value specifcation that specifies the oldest age when specifying an age range.</obo:IAO_0000115>
        <obo:IAO_0000115>The numerical value, if any, for the maximum age a potential participant can be to be eligible for the clinical study.</obo:IAO_0000115>
        <obo:IAO_0000117 xml:lang="en">Mathias Brochhausen</obo:IAO_0000117>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <oboInOwl:hasExactSynonym>maximum age</oboInOwl:hasExactSynonym>
        <rdfs:label xml:lang="en">maximum age value specification</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/OBI_0002557"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>The numerical value, if any, for the maximum age a potential participant can be to be eligible for the clinical study.</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/OBI_0002561 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OBI_0002561">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0500027"/>
        <obo:IAO_0000111 xml:lang="en">sex inclusion criterion</obo:IAO_0000111>
        <obo:IAO_0000112 xml:lang="en">&quot;included males and females&quot;, &quot;included male patients&quot;</obo:IAO_0000112>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000123"/>
        <obo:IAO_0000115>A type of eligibility criteria that indicates the sex of people who may participate in a clinical study (all, female, male). Sex is a person&apos;s classification as female or male based on biological distinctions. Sex is distinct from gender-based eligibility.</obo:IAO_0000115>
        <obo:IAO_0000115 xml:lang="en">An inclusion criterion that defines and states one or more sexes which, if met, makes an entity suitable for a given task or participation in a given process.</obo:IAO_0000115>
        <obo:IAO_0000117 xml:lang="en">Mathias Brochhausen</obo:IAO_0000117>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <oboInOwl:hasExactSynonym>sexes eligible for study</oboInOwl:hasExactSynonym>
        <rdfs:label xml:lang="en">sex inclusion criterion</rdfs:label>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/trds/en/</rdfs:seeAlso>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/OBI_0002561"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>A type of eligibility criteria that indicates the sex of people who may participate in a clinical study (all, female, male). Sex is a person&apos;s classification as female or male based on biological distinctions. Sex is distinct from gender-based eligibility.</owl:annotatedTarget>
        <obo:IAO_0000119>https://clinicaltrials.gov/ct2/about-studies/glossary</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/OBI_0300311 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OBI_0300311">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0500000"/>
        <obo:IAO_0000111 xml:lang="en">observation design</obo:IAO_0000111>
        <obo:IAO_0000112 xml:lang="en">PMID: 12387964.Lancet. 2002 Oct 12;360(9340):1144-9.Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study.</obo:IAO_0000112>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000125"/>
        <obo:IAO_0000115 xml:lang="en">observation design is a study design in which subjects are monitored in the absence of any active intervention by experimentalists.</obo:IAO_0000115>
        <obo:IAO_0000117 xml:lang="en">Philippe Rocca-Serra</obo:IAO_0000117>
        <obo:IAO_0000119 xml:lang="en">OBI branch derived</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <rdfs:label xml:lang="en">observation design</rdfs:label>
        <rdfs:seeAlso>https://prsinfo.clinicaltrials.gov/definitions.html</rdfs:seeAlso>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OBI_0500000 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OBI_0500000">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000104"/>
        <obo:IAO_0000111 xml:lang="en">study design</obo:IAO_0000111>
        <obo:IAO_0000112 xml:lang="en">a matched pairs study design describes criteria by which subjects are identified as pairs which then undergo the same protocols, and the data generated is analyzed by comparing the differences between the paired subjects, which constitute the results of the executed study design.</obo:IAO_0000112>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000122"/>
        <obo:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A plan specification comprised of protocols (which may specify how and what kinds of data will be gathered) that are executed as part of an investigation and is realized during a study design execution.</obo:IAO_0000115>
        <obo:IAO_0000116 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Editor note: there is at least an implicit restriction on the kind of data transformations that can be done based on the measured data available.</obo:IAO_0000116>
        <obo:IAO_0000117 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PERSON: Chris Stoeckert</obo:IAO_0000117>
        <obo:IAO_0000118 xml:lang="en">experimental design</obo:IAO_0000118>
        <obo:IAO_0000232 xml:lang="en">rediscussed at length (MC/JF/BP). 12/9/08). The definition was clarified to differentiate it from protocol.</obo:IAO_0000232>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <rdfs:label xml:lang="en">study design</rdfs:label>
        <rdfs:seeAlso>https://prsinfo.clinicaltrials.gov/definitions.html</rdfs:seeAlso>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/trds/en/</rdfs:seeAlso>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OBI_0500002 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OBI_0500002">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000115"/>
        <obo:IAO_0000111 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">repeated measure design</obo:IAO_0000111>
        <obo:IAO_0000112 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PMID: 10959922.J Biopharm Stat. 2000 Aug;10(3):433-45.Equivalence in test assay method comparisons for the repeated-measure, matched-pair design in medical device studies: statistical considerations.</obo:IAO_0000112>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000120"/>
        <obo:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">a study design which use the same individuals and exposure them to a set of conditions. The effect of order and practice can be confounding factor in such designs</obo:IAO_0000115>
        <obo:IAO_0000117 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PlanAndPlannedProcess Branch</obo:IAO_0000117>
        <obo:IAO_0000119 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">http://www.holah.karoo.net/experimentaldesigns.htm</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">repeated measure design</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OBI_0500003 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OBI_0500003">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0500002"/>
        <obo:IAO_0000111 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">cross over design</obo:IAO_0000111>
        <obo:IAO_0000112 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PMID: 17601993-Objective: HIV-infected patients with lipodystrophy (HIV-lipodystrophy) are insulin resistant and have elevated plasma free fatty acid (FFA) concentrations. We aimed to explore the mechanisms underlying FFA-induced insulin resistance in patients with HIV-lipodystrophy. Research Design and Methods: Using a randomized placebo-controlled cross-over design, we studied the effects of an overnight acipimox-induced suppression of FFA on glucose and FFA metabolism by using stable isotope labelled tracer techniques during basal conditions and a two-stage euglycemic, hyperinsulinemic clamp (20 mU insulin/m(2)/min; 50 mU insulin/m(2)/min) in nine patients with nondiabetic HIV-lipodystrophy. All patients received antiretroviral therapy. Biopsies from the vastus lateralis muscle were obtained during each stage of the clamp. Results: Acipimox treatment reduced basal FFA rate of appearance by 68.9% (52.6%-79.5%) and decreased plasma FFA concentration by 51.6 % (42.0%-58.9%), (both, P &lt; 0.0001). Endogenous glucose production was not influenced by acipimox. During the clamp the increase in glucose-uptake was significantly greater after acipimox treatment compared to placebo (acipimox: 26.85 (18.09-39.86) vs placebo: 20.30 (13.67-30.13) mumol/kg/min; P &lt; 0.01). Insulin increased phosphorylation of Akt (Thr(308)) and GSK-3beta (Ser(9)), decreased phosphorylation of glycogen synthase (GS) site 3a+b and increased GS-activity (I-form) in skeletal muscle (P &lt; 0.01). Acipimox decreased phosphorylation of GS (site 3a+b) (P &lt; 0.02) and increased GS-activity (P &lt; 0.01) in muscle. Conclusion: The present study provides direct evidence that suppression of lipolysis in patients with HIV-lipodystrophy improves insulin-stimulated peripheral glucose-uptake. The increased glucose-uptake may in part be explained by increased dephosphorylation of GS (site 3a+b) resulting in increased GS activity.</obo:IAO_0000112>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000120"/>
        <obo:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">a repeated measure design which ensures that experimental units receive, in sequence, the treatment (or the control), and then, after a specified time interval (aka *wash-out periods*), switch to the control (or treatment). In this design, subjects (patients in human context) serve as their own controls, and randomization may be used to determine the ordering which a subject receives the treatment and control</obo:IAO_0000115>
        <obo:IAO_0000117 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Philippe Rocca-Serra</obo:IAO_0000117>
        <obo:IAO_0000119 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">(source: http://www.sbu.se/Filer/Content0/publikationer/1/literaturesearching_1993/glossary.html)</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">cross over design</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OBI_0500004 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OBI_0500004">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0500003"/>
        <obo:IAO_0000111 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">n-to-1 design</obo:IAO_0000111>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000125"/>
        <obo:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">N-of-1 design is a cross-over design in which the same patient is repeatedly randomised to receive either the experimental treatment or its control (Senn, 1993).</obo:IAO_0000115>
        <obo:IAO_0000117 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Philippe Rocca-Serra</obo:IAO_0000117>
        <obo:IAO_0000119 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Adapted from  http://www.childrens-mercy.org/stats/definitions/crossover.htm and source:http://symptomresearch.nih.gov/chapter_6/sec1/csss1pg1.htm)</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">n-to-1 design</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OBI_0500006 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OBI_0500006">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0500000"/>
        <obo:IAO_0000111 xml:lang="en">parallel group design</obo:IAO_0000111>
        <obo:IAO_0000112 xml:lang="en">PMID: 17408389-Purpose: Proliferative vitreoretinopathy (PVR) is the most important reason for blindness following retinal detachment. Presently, vitreous tamponades such as gas or silicone oil cannot contact the lower part of the retina. A heavier-than-water tamponade displaces the inflammatory and PVR-stimulating environment from the inferior area of the retina. The Heavy Silicone Oil versus Standard Silicone Oil Study (HSO Study) is designed to answer the question of whether a heavier-than-water tamponade improves the prognosis of eyes with PVR of the lower retina. Methods: The HSO Study is a multicentre, randomized, prospective controlled clinical trial comparing two endotamponades within a two-arm parallel group design. Patients with inferiorly and posteriorly located PVR are randomized to either heavy silicone oil or standard silicone oil as a tamponading agent. Three hundred and fifty consecutive patients are recruited per group. After intraoperative re-attachment, patients are randomized to either standard silicone oil (1000 cSt or 5000 cSt) or Densiron((R)) as a tamponading agent. The main endpoint criteria are complete retinal attachment at 12 months and change of visual acuity (VA) 12 months postoperatively compared with the preoperative VA. Secondary endpoints include complete retinal attachment before endotamponade removal, quality of life analysis and the number of retina affecting re-operation within 1 year of follow-up. Results: The design and early recruitment phase of the study are described. Conclusions: The results of this study will uncover whether or not heavy silicone oil improves the prognosis of eyes with PVR.</obo:IAO_0000112>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000125"/>
        <obo:IAO_0000115 xml:lang="en">A parallel group design or independent measure design is a study design which uses unique experimental unit each experimental group, in other word no two individuals are shared between experimental groups, hence also known as parallel group design. Subjects of a treatment group receive a unique combination of independent variable values making up a treatment</obo:IAO_0000115>
        <obo:IAO_0000115>Participants are assigned to one of two or more groups in parallel for the duration of the study</obo:IAO_0000115>
        <obo:IAO_0000117 xml:lang="en">Philippe Rocca-Serra</obo:IAO_0000117>
        <obo:IAO_0000118 xml:lang="en">independent measure design</obo:IAO_0000118>
        <obo:IAO_0000119 xml:lang="en">http://www.holah.karoo.net/experimentaldesigns.htm</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <rdfs:label xml:lang="en">parallel group design</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/OBI_0500006"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>Participants are assigned to one of two or more groups in parallel for the duration of the study</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/OBI_0500014 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OBI_0500014">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0500000"/>
        <obo:IAO_0000111 xml:lang="en">factorial design</obo:IAO_0000111>
        <obo:IAO_0000112 xml:lang="en">PMID: 17582121-Our objective was to examine the effects of dietary cation-anion difference (DCAD) with different concentrations of dietary crude protein (CP) on performance and acid-base status in early lactation cows. Six lactating Holstein cows averaging 44 d in milk were used in a 6 x 6 Latin square design with a 2 x 3 factorial arrangement of treatments: DCAD of -3, 22, or 47 milliequivalents (Na + K - Cl - S)/100 g of dry matter (DM), and 16 or 19% CP on a DM basis. Linear increases with DCAD occurred in DM intake, milk fat percentage, 4% fat-corrected milk production, milk true protein, milk lactose, and milk solids-not-fat. Milk production itself was unaffected by DCAD. Jugular venous blood pH, base excess and HCO3(-) concentration, and urine pH increased, but jugular venous blood Cl- concentration, urine titratable acidity, and net acid excretion decreased linearly with increasing DCAD. An elevated ratio of coccygeal venous plasma essential AA to nonessential AA with increasing DCAD indicated that N metabolism in the rumen was affected, probably resulting in more microbial protein flowing to the small intestine. Cows fed 16% CP had lower urea N in milk than cows fed 19% CP; the same was true for urea N in coccygeal venous plasma and urine. Dry matter intake, milk production, milk composition, and acid-base status did not differ between the 16 and 19% CP treatments. It was concluded that DCAD affected DM intake and performance of dairy cows in early lactation. Feeding 16% dietary CP to cows in early lactation, compared with 19% CP, maintained lactation performance while reducing urea N excretion in milk and urine.</obo:IAO_0000112>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000125"/>
        <obo:IAO_0000115>Two or more interventions, each alone and in combination, are evaluated in parallel against a control group</obo:IAO_0000115>
        <obo:IAO_0000115 xml:lang="en">factorial design is_a study design which is used to evaluate two or more factors simultaneously. The treatments are combinations of levels of the factors. The advantages of factorial designs over one-factor-at-a-time experiments is that they are more efficient and they allow interactions to be detected. In statistics, a factorial design experiment is an experiment whose design consists of two or more factors, each with discrete possible values or levels, and whose experimental units take on all possible combinations of these levels across all such factors. Such an experiment allows studying the effect of each factor on the response variable, as well as the effects of interactions between factors on the response variable.</obo:IAO_0000115>
        <obo:IAO_0000117 xml:lang="en">Philippe Rocca-Serra</obo:IAO_0000117>
        <obo:IAO_0000119 xml:lang="en">http://www.stats.gla.ac.uk/steps/glossary/anova.html#facdes And from wikipedia (01/03/2007): http://en.wikipedia.org/wiki/Factorial_experiment)</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <rdfs:label xml:lang="en">factorial design</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/OBI_0500014"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>Two or more interventions, each alone and in combination, are evaluated in parallel against a control group</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/OBI_0500026 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OBI_0500026">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0001755"/>
        <obo:IAO_0000111 xml:lang="en">eligibility criterion</obo:IAO_0000111>
        <obo:IAO_0000112 xml:lang="en">PMID: 17579629 -Eligibility criteria included: untreated ED-SCLC; age &gt;/=70 and performance status 0-2, or age &lt;70 and PS 3.</obo:IAO_0000112>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000122"/>
        <obo:IAO_0000115>A limited list of criteria for selection of participants in the clinical study, provided in terms of inclusion and exclusion criteria and suitable for assisting potential participants in identifying clinical studies of interest.</obo:IAO_0000115>
        <obo:IAO_0000115>The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex</obo:IAO_0000115>
        <obo:IAO_0000115 xml:lang="en">an eligibility criterion (rule) is_a selection criterion which 
defines and states the requirements (positive or negative) for an entity to be considered as suitable for a given task or participation in a process.
</obo:IAO_0000115>
        <obo:IAO_0000117 xml:lang="en">Person: Philippe Rocca-Serra</obo:IAO_0000117>
        <obo:IAO_0000118 xml:lang="en">eligibility rule</obo:IAO_0000118>
        <obo:IAO_0000119 xml:lang="en">Adapted from Clinical Research Glossary Version 4.0 CDICS glossary group</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <rdfs:label xml:lang="en">eligibility criterion</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/OBI_0500026"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>A limited list of criteria for selection of participants in the clinical study, provided in terms of inclusion and exclusion criteria and suitable for assisting potential participants in identifying clinical studies of interest.</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/OBI_0500026"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex</owl:annotatedTarget>
        <obo:IAO_0000119>https://clinicaltrials.gov/ct2/about-studies/glossary</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/OBI_0500027 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OBI_0500027">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0500026"/>
        <obo:IAO_0000111 xml:lang="en">inclusion criterion</obo:IAO_0000111>
        <obo:IAO_0000112 xml:lang="en">PMID: 23979341-The major inclusion criterion was patients in whom severe cerebral embolism was diagnosed at age 75 or younger (more than 9 in the NIHSS score on day 7 after the onset of stroke) .</obo:IAO_0000112>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000125"/>
        <obo:IAO_0000115>A type of eligibility criteria. These are the reasons that a person is allowed to participate in a clinical study.</obo:IAO_0000115>
        <obo:IAO_0000115 xml:lang="en">an inclusion criterion (rule) is_a *eligibility criterion*  which defines and states a condition which, if met, makes an entity suitable for a given task or participation in a given process. For instance, in a study protocol, inclusion criteria indicate the conditions that prospective subjects MUST meet to be eligible for participation in a study.</obo:IAO_0000115>
        <obo:IAO_0000117 xml:lang="en">Person: Philippe Rocca-Serra</obo:IAO_0000117>
        <obo:IAO_0000118 xml:lang="en">inclusion condition</obo:IAO_0000118>
        <obo:IAO_0000118 xml:lang="en">inclusion rule</obo:IAO_0000118>
        <obo:IAO_0000119 xml:lang="en">Adapted from Clinical Research Glossary Version 4.0 CDICS glossary group</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <oboInOwl:hasExactSynonym>key inclusion criteria</oboInOwl:hasExactSynonym>
        <rdfs:label xml:lang="en">inclusion criterion</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/OBI_0500027"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>A type of eligibility criteria. These are the reasons that a person is allowed to participate in a clinical study.</owl:annotatedTarget>
        <obo:IAO_0000119>https://clinicaltrials.gov/ct2/about-studies/glossary</obo:IAO_0000119>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/OBI_0500027"/>
        <owl:annotatedProperty rdf:resource="http://www.geneontology.org/formats/oboInOwl#hasExactSynonym"/>
        <owl:annotatedTarget>key inclusion criteria</owl:annotatedTarget>
        <obo:IAO_0000119>http://www.icmje.org/recommendations/ 
https://www.who.int/ictrp/network/trds/en/</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/OBI_0500028 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OBI_0500028">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0500026"/>
        <obo:IAO_0000111 xml:lang="en">exclusion rule</obo:IAO_0000111>
        <obo:IAO_0000112 xml:lang="en">PMID: 17600285-Exclusion criteria included the use of any topical ophthalmic or topical oral medication and/or history of ocular or oral surgery within the past six months.</obo:IAO_0000112>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000125"/>
        <obo:IAO_0000115>A type of eligibility criteria. These are reasons that a person is not allowed to participate in a clinical study.</obo:IAO_0000115>
        <obo:IAO_0000115 xml:lang="en">an exclusion criterion (rule) is_a *eligibility criterion*  which defines and states a condition which, if met, makes an entity unsuitable for a given task or participation in a given process. For instance, in a study protocol, exclusion criteria indicate the conditions that prospective subjects SHOULD NOT meet to be eligible for participation in a study</obo:IAO_0000115>
        <obo:IAO_0000117 xml:lang="en">Person: Philippe Rocca-Serra</obo:IAO_0000117>
        <obo:IAO_0000119 xml:lang="en">Adapted from Clinical Research Glossary Version 4.0 CDICS glossary group</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <oboInOwl:hasExactSynonym>key exclusion criteria</oboInOwl:hasExactSynonym>
        <rdfs:label xml:lang="en">exclusion criterion</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/OBI_0500028"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>A type of eligibility criteria. These are reasons that a person is not allowed to participate in a clinical study.</owl:annotatedTarget>
        <obo:IAO_0000119>https://clinicaltrials.gov/ct2/about-studies/glossary</obo:IAO_0000119>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/OBI_0500028"/>
        <owl:annotatedProperty rdf:resource="http://www.geneontology.org/formats/oboInOwl#hasExactSynonym"/>
        <owl:annotatedTarget>key exclusion criteria</owl:annotatedTarget>
        <obo:IAO_0000119>http://www.icmje.org/recommendations/ 
https://www.who.int/ictrp/network/trds/en/</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/OBI_0600004 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OBI_0600004">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0001928"/>
        <obo:IAO_0000111 xml:lang="en">human subject enrollment</obo:IAO_0000111>
        <obo:IAO_0000112 xml:lang="en">enlisting familiy members of HIV patients into a study</obo:IAO_0000112>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000122"/>
        <obo:IAO_0000115 xml:lang="en">A planned process with the objective to obtain a population of human subjects to participate in an investigation by determining eligibility of subjects and obtaining informed consent.</obo:IAO_0000115>
        <obo:IAO_0000116 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">As with group assignment, should the specified output here be an organism which bears a role</obo:IAO_0000116>
        <obo:IAO_0000117 xml:lang="en">Bjoern Peters</obo:IAO_0000117>
        <obo:IAO_0000119 xml:lang="en">IEDB</obo:IAO_0000119>
        <obo:IAO_0000232 xml:lang="en">criteria come from plan / clinical trial branch</obo:IAO_0000232>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <rdfs:label xml:lang="en">human subject enrollment</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OGMS_0000014 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OGMS_0000014">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000027"/>
        <obo:IAO_0000115 xml:lang="en">A representation that is either the output of a clinical history taking or a physical examination or an image finding, or some combination thereof.</obo:IAO_0000115>
        <obo:IAO_0000117>Albert Goldfain</obo:IAO_0000117>
        <obo:IAO_0000119>http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf</obo:IAO_0000119>
        <obo:IAO_0000232>creation date: 2010-07-19T10:18:02Z</obo:IAO_0000232>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ogms.owl"/>
        <rdfs:label>clinical finding</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OGMS_0000015 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OGMS_0000015">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000027"/>
        <obo:IAO_0000115 xml:lang="en">A series of statements representing health-relevant qualities of a patient and of a patient&apos;s family.</obo:IAO_0000115>
        <obo:IAO_0000117>Albert Goldfain</obo:IAO_0000117>
        <obo:IAO_0000119>http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf</obo:IAO_0000119>
        <obo:IAO_0000232>creation date: 2010-07-19T10:18:59Z</obo:IAO_0000232>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ogms.owl"/>
        <rdfs:label>clinical history</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OGMS_0000019 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OGMS_0000019">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000027"/>
        <obo:IAO_0000115 xml:lang="en">A representation of a quality of a patient that is (1) recorded by a clinician because the quality is hypothesized to be of clinical significance and (2) refers to qualities obtaining in the patient prior to their becoming detectable in a clinical history taking or physical examination.</obo:IAO_0000115>
        <obo:IAO_0000117>Albert Goldfain</obo:IAO_0000117>
        <obo:IAO_0000119>http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf</obo:IAO_0000119>
        <obo:IAO_0000232>creation date: 2009-06-23T10:22:44Z</obo:IAO_0000232>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ogms.owl"/>
        <rdfs:label>preclinical finding</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OGMS_0000031 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OGMS_0000031">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000016"/>
        <obo:IAO_0000115 xml:lang="en">A disposition (i) to undergo pathological processes that (ii) exists in an organism because of one or more disorders in that organism.</obo:IAO_0000115>
        <obo:IAO_0000117>Albert Goldfain</obo:IAO_0000117>
        <obo:IAO_0000119>http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf</obo:IAO_0000119>
        <obo:IAO_0000232>creation date: 2009-06-23T11:21:20Z</obo:IAO_0000232>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ogms.owl"/>
        <rdfs:label>disease</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OGMS_0000060 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OGMS_0000060">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000015"/>
        <obo:IAO_0000117>Albert Goldfain</obo:IAO_0000117>
        <obo:IAO_0000232>creation date: 2009-06-23T11:53:49Z</obo:IAO_0000232>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/oae.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ogms.owl"/>
        <rdfs:label>bodily process</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OGMS_0000061 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OGMS_0000061">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000060"/>
        <obo:IAO_0000115 xml:lang="en">A bodily process that is clinically abnormal.</obo:IAO_0000115>
        <obo:IAO_0000117>Albert Goldfain</obo:IAO_0000117>
        <obo:IAO_0000119>http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf</obo:IAO_0000119>
        <obo:IAO_0000232>creation date: 2009-06-23T11:54:29Z</obo:IAO_0000232>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/oae.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ogms.owl"/>
        <rdfs:label>pathological bodily process</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OGMS_0000073 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OGMS_0000073">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000027"/>
        <obo:IAO_0000115>1. the determination of the nature of a case of disease.
2. the art of distinguishing one disease from another.</obo:IAO_0000115>
        <obo:IAO_0000115 xml:lang="en">The representation of a conclusion of a diagnostic process.</obo:IAO_0000115>
        <obo:IAO_0000117>Albert Goldfain</obo:IAO_0000117>
        <obo:IAO_0000119>http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf</obo:IAO_0000119>
        <obo:IAO_0000232>creation date: 2009-06-23T12:42:23Z</obo:IAO_0000232>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ogms.owl"/>
        <rdfs:label>diagnosis</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000073"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>1. the determination of the nature of a case of disease.
2. the art of distinguishing one disease from another.</owl:annotatedTarget>
        <obo:IAO_0000119>https://www.clinicaltrialsregister.eu/doc/EU_Clinical_Trials_Register_Glossary.pdf</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/OMRSE_00000024 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OMRSE_00000024">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000023"/>
        <obo:IAO_0000115 xml:lang="en">A role inhering in an entity realized by social interactions in human society.</obo:IAO_0000115>
        <obo:IAO_0000117 xml:lang="en">Mathias Brochhausen</obo:IAO_0000117>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/omrse.owl"/>
        <rdfs:comment xml:lang="en">Previous definition: A role played by an entity in human social processes.</rdfs:comment>
        <rdfs:label xml:lang="en">role in human social processes</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OMRSE_00000038 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OMRSE_00000038">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OMRSE_00000024"/>
        <obo:IAO_0000115 xml:lang="en">A role borne by a human individual or by a collection of humans regarded as possessing rights and duties enforeable at law.</obo:IAO_0000115>
        <obo:IAO_0000117>Mathias Brochhausen</obo:IAO_0000117>
        <obo:IAO_0000119>Malcolm N. Shaw: International Law. Cambridge University Press, Cambridge, 2008.</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/omrse.owl"/>
        <rdfs:comment xml:lang="en">We are aware of the fact that Wikipedia&apos;s definition differs from ours by saying that &quot;Legal personality (...) is the characteristic of a non-living entity regarded by law to have the status of personhood&quot; (http://en.wikipedia.org/wiki/Legal_personality) 
However, Shaw explicates:
&quot;In any legal system, certain entities, whether they be individuals or companies, will be regarded as possessing rights and duties enforceable at law. Thus an individual may prosecute or be prosecuted for assault and a company can sue for breach of contract. They are able to do this because the law recognises them as &apos;legal persons&apos; possessing the capacity to have and to maintain certain rights, and being subject to perform specific duties. (...) In municipal law individuals, limited companies and public corporations are recognized as each possessing a distinct legal personality, the terms of which are circumscribed by the relevant legislation&quot; (Shaw MN: International Law. Sixth Edition. Cambridge University Press, Cambridge, 2008).                We hold that Shaw&apos;s position is ontological more prolific since it not only allows to explain how groups of individuals become recognized as unities at law, but also how different individuals can hold different legal personality roles (always against the context of one legal system). The latter will proof useful when dealing with the representing comatous patients or minorsat law in ontologies.</rdfs:comment>
        <rdfs:label xml:lang="en">legal person role</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OPMI_0000112 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OPMI_0000112">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000030"/>
        <obo:IAO_0000115>A telephone number is a sequence of digits assigned to a fixed-line telephone subscriber station connected to a telephone line or to a wireless electronic telephony device, such as a radio telephone or a mobile telephone, or to other devices for data transmission via the public switched telephone network (PSTN) or other public and private networks.</obo:IAO_0000115>
        <obo:IAO_0000117>Oliver He</obo:IAO_0000117>
        <obo:IAO_0000118>phone number</obo:IAO_0000118>
        <obo:IAO_0000119>https://en.wikipedia.org/wiki/Telephone_number</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <rdfs:label xml:lang="en">telephone number</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OPMI_0000223 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OPMI_0000223">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCIT_C60776"/>
        <obo:IAO_0000115>The textual name of the contact person or organization</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <rdfs:label xml:lang="en">contact name</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OPMI_0000289 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OPMI_0000289">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCIT_C98714"/>
        <obo:IAO_0000115>A centrally registered identifier that is assigned for a specific clinical trial registered in  the ClinicalTrials.gov. The format for the ClinicalTrials.gov registry number is “NCT” followed by an 8-digit number, e.g.: NCT00000419.</obo:IAO_0000115>
        <obo:IAO_0000117>Qingliang Leon Li, Asiyah Yu Lin, Oliver He</obo:IAO_0000117>
        <obo:IAO_0000118>NCT identifier</obo:IAO_0000118>
        <obo:IAO_0000118>NCT number</obo:IAO_0000118>
        <obo:IAO_0000118>National Clinical Trial identifier</obo:IAO_0000118>
        <obo:IAO_0000119>https://clinicaltrials.gov/ct2/about-site/link-to</obo:IAO_0000119>
        <obo:IAO_0000119>https://www.nlm.nih.gov/bsd/policy/clin_trials.html</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <rdfs:label xml:lang="en">USA National Clinical Trial identifier</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OPMI_0000290 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OPMI_0000290">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000300"/>
        <obo:IAO_0000115>A textual entity that is the title of a clinical trial</obo:IAO_0000115>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <rdfs:label xml:lang="en">title of clinical trial</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OPMI_0000291 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OPMI_0000291">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OPMI_0000290"/>
        <obo:IAO_0000115>A title of clinical trial that is recorded as official</obo:IAO_0000115>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <oboInOwl:hasExactSynonym>full title</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>scientific title</oboInOwl:hasExactSynonym>
        <rdfs:label xml:lang="en">official title of clinical trial</rdfs:label>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/trds/en/</rdfs:seeAlso>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OPMI_0000292 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OPMI_0000292">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OPMI_0000290"/>
        <obo:IAO_0000115>A title of clinical trial that is meant for lay people understanding</obo:IAO_0000115>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <oboInOwl:hasExactSynonym>brief title</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>lay title</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>public title</oboInOwl:hasExactSynonym>
        <rdfs:label xml:lang="en">lay title of clinical trial</rdfs:label>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/trds/en/</rdfs:seeAlso>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OPMI_0000293 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OPMI_0000293">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCBITaxon_9606"/>
        <obo:IAO_0000115>A person who performs an investigation task and takes the role of an investigator role.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <rdfs:label xml:lang="en">investigator</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OPMI_0000294 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OPMI_0000294">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OPMI_0000293"/>
        <obo:IAO_0000115>An investigator who is involved in a clinical trial and is responsible for ensuring that an investigation is conducted according to the signed investigator statement, the investigational plan, and applicable regulations; for protecting the rights, safety, and welfare of subjects under the investigator&apos;s care; and for the control of drugs under investigation.</obo:IAO_0000115>
        <obo:IAO_0000117>Oliver He</obo:IAO_0000117>
        <obo:IAO_0000119>https://en.wikipedia.org/wiki/Clinical_investigator</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <rdfs:label xml:lang="en">clinical investigator</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OPMI_0000295 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OPMI_0000295">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000148"/>
        <obo:IAO_0000115>The date on which a study starts</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <rdfs:label xml:lang="en">study start date</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OPMI_0000296 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OPMI_0000296">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OPMI_0000295"/>
        <obo:IAO_0000115>The (estimated) date on which the clinical study is open for recruitment of participants, or the actual date on which the first participant is enrolled.</obo:IAO_0000115>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <oboInOwl:hasExactSynonym>date of first enrollment</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>study start</oboInOwl:hasExactSynonym>
        <rdfs:label xml:lang="en">clinical trial start date</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/OPMI_0000296"/>
        <owl:annotatedProperty rdf:resource="http://www.geneontology.org/formats/oboInOwl#hasExactSynonym"/>
        <owl:annotatedTarget>date of first enrollment</owl:annotatedTarget>
        <rdfs:seeAlso>http://www.icmje.org/recommendations/ 
http://www.who.int/ictrp/network/trds/en/index.html</rdfs:seeAlso>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/OPMI_0000297 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OPMI_0000297">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000148"/>
        <obo:IAO_0000115>The date on which a study completes</obo:IAO_0000115>
        <obo:IAO_0000115>The date the final participant was examined or received an intervention for purposes of final collection of data for the primary and secondary outcome measures and adverse events (for example, last participant’s last visit), whether the clinical study concluded according to the pre-specified protocol or was terminated.</obo:IAO_0000115>
        <obo:IAO_0000117>Oliver He</obo:IAO_0000117>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <oboInOwl:hasExactSynonym>Completion Date</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>study completion</oboInOwl:hasExactSynonym>
        <rdfs:label xml:lang="en">study completion date</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/OPMI_0000297"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>The date the final participant was examined or received an intervention for purposes of final collection of data for the primary and secondary outcome measures and adverse events (for example, last participant’s last visit), whether the clinical study concluded according to the pre-specified protocol or was terminated.</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/OPMI_0000297"/>
        <owl:annotatedProperty rdf:resource="http://www.geneontology.org/formats/oboInOwl#hasExactSynonym"/>
        <owl:annotatedTarget>Completion Date</owl:annotatedTarget>
        <rdfs:seeAlso>http://www.icmje.org/recommendations/ 
http://www.who.int/ictrp/network/trds/en/index.html</rdfs:seeAlso>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/OPMI_0000298 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OPMI_0000298">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OPMI_0000297"/>
        <obo:IAO_0000115>The date the final participant was examined or received an intervention for purposes of final collection of data for the primary and secondary outcome measures and adverse events (for example, last participant’s last visit), whether the clinical study concluded according to the pre-specified protocol or was terminated.</obo:IAO_0000115>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <oboInOwl:hasExactSynonym>completion date</oboInOwl:hasExactSynonym>
        <rdfs:label xml:lang="en">clinical trial study completion date</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/OPMI_0000298"/>
        <owl:annotatedProperty rdf:resource="http://www.geneontology.org/formats/oboInOwl#hasExactSynonym"/>
        <owl:annotatedTarget>completion date</owl:annotatedTarget>
        <rdfs:seeAlso>http://www.icmje.org/recommendations/ 
http://www.who.int/ictrp/network/trds/en/index.html</rdfs:seeAlso>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/OPMI_0000299 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OPMI_0000299">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OPMI_0000297"/>
        <obo:IAO_0000115>The date that the final participant was examined or received an intervention for the purposes of final collection of data for the primary outcome, whether the clinical study concluded according to the pre-specified protocol or was terminated. In the case of clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all of the primary outcomes.</obo:IAO_0000115>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <oboInOwl:hasExactSynonym>primary completion</oboInOwl:hasExactSynonym>
        <rdfs:label xml:lang="en">clinical trial primary completion date</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OPMI_0000300 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OPMI_0000300">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000005"/>
        <obo:IAO_0000115>The main objective of the intervention(s) being evaluated by the clinical trial.</obo:IAO_0000115>
        <obo:IAO_0000118>primary purpose of clinical trial</obo:IAO_0000118>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <rdfs:label xml:lang="en">clinical trial primary purpose specification</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OPMI_0000302 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OPMI_0000302">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000148"/>
        <obo:IAO_0000115>The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record&apos;s availability on ClinicalTrials.gov (the first posted date).</obo:IAO_0000115>
        <obo:IAO_0000115>a date when a registration occurs</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <oboInOwl:hasExactSynonym>First submitted</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>date of registration in primary registry</oboInOwl:hasExactSynonym>
        <rdfs:label xml:lang="en">date of registration</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/OPMI_0000302"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record&apos;s availability on ClinicalTrials.gov (the first posted date).</owl:annotatedTarget>
        <obo:IAO_0000119>https://www.clinicaltrials.gov/ct2/about-studies/glossary</obo:IAO_0000119>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/OPMI_0000302"/>
        <owl:annotatedProperty rdf:resource="http://www.geneontology.org/formats/oboInOwl#hasExactSynonym"/>
        <owl:annotatedTarget>date of registration in primary registry</owl:annotatedTarget>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/trds/en/</rdfs:seeAlso>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/OPMI_0000304 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OPMI_0000304">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OPMI_0000326"/>
        <obo:IAO_0000115>The current stage of a clinical study and whether it is or will be open for enrollment</obo:IAO_0000115>
        <obo:IAO_0000115>The recruitment status for the clinical study as a whole, based upon the status of the individual sites. If at least one facility in a multi-site clinical study has an Individual Site Status of &quot;Recruiting,&quot; then the Overall Recruitment Status for the study must be &quot;Recruiting.&quot;</obo:IAO_0000115>
        <obo:IAO_0000117>Oliver He</obo:IAO_0000117>
        <obo:IAO_0000119>https://clinicaltrials.gov/ct2/help/glossary/recruitment-status</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <rdfs:label xml:lang="en">recruitment status</rdfs:label>
        <rdfs:seeAlso>http://www.icmje.org/recommendations/ 
http://www.who.int/ictrp/network/trds/en/index.html</rdfs:seeAlso>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/OPMI_0000304"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>The recruitment status for the clinical study as a whole, based upon the status of the individual sites. If at least one facility in a multi-site clinical study has an Individual Site Status of &quot;Recruiting,&quot; then the Overall Recruitment Status for the study must be &quot;Recruiting.&quot;</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/OPMI_0000326 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OPMI_0000326">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000017"/>
        <obo:IAO_0000117>Oliver He, Edison Ong</obo:IAO_0000117>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <rdfs:label xml:lang="en">status</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OPMI_0000327 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OPMI_0000327">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OPMI_0000326"/>
        <obo:IAO_0000115>The current stage of a clinical study and whether it is or will be open for enrollment</obo:IAO_0000115>
        <obo:IAO_0000117>Oliver He</obo:IAO_0000117>
        <obo:IAO_0000119>https://clinicaltrials.gov/ct2/help/glossary/recruitment-status</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <rdfs:label xml:lang="en">study status</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OPMI_0000356 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OPMI_0000356">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCIT_C98714"/>
        <obo:IAO_0000117>Qingliang Leon Li, Asiyah Yu Lin, Oliver He</obo:IAO_0000117>
        <obo:IAO_0000119>https://pubchem.ncbi.nlm.nih.gov/source/NIPH%20Clinical%20Trials%20Search%20of%20Japan</obo:IAO_0000119>
        <obo:IAO_0000119>https://rctportal.niph.go.jp/en/</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <rdfs:label xml:lang="en">Japan clinical trial identifier</rdfs:label>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/jprn2/en/</rdfs:seeAlso>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OPMI_0000357 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OPMI_0000357">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OPMI_0000356"/>
        <obo:IAO_0000115>A Japan clinical trial identifier provided by the University Hospital Medical Information Network Center (UMIN-CTR)</obo:IAO_0000115>
        <obo:IAO_0000117>Qingliang Leon Li, Asiyah Yu Lin, Oliver He</obo:IAO_0000117>
        <obo:IAO_0000118>UMIN</obo:IAO_0000118>
        <obo:IAO_0000119>https://rctportal.niph.go.jp/en/</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <rdfs:label xml:lang="en">UMIN-CTR clinical trial identifier</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OPMI_0000358 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OPMI_0000358">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OPMI_0000356"/>
        <obo:IAO_0000117>Qingliang Leon Li, Asiyah Yu Lin, Oliver He</obo:IAO_0000117>
        <obo:IAO_0000118>JapicCTI</obo:IAO_0000118>
        <obo:IAO_0000119>https://rctportal.niph.go.jp/en/</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <rdfs:label xml:lang="en">JAPIC clinical trial identifier</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OPMI_0000359 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OPMI_0000359">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OPMI_0000356"/>
        <obo:IAO_0000115>A centrally registered identifier that is assigned for a specific clinical trial registered in JMACCT. The format for the JMACCT registry number is “JMA-IIA” followed by a 5-digit number, e.g., JMA-IIA00391.</obo:IAO_0000115>
        <obo:IAO_0000117>Qingliang Leon Li, Asiyah Yu Lin, Oliver He</obo:IAO_0000117>
        <obo:IAO_0000118>JMACCT</obo:IAO_0000118>
        <obo:IAO_0000119>https://rctportal.niph.go.jp/en/</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <rdfs:label xml:lang="en">JMACCT clinical trial identifier</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OPMI_0000360 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OPMI_0000360">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCIT_C98714"/>
        <obo:IAO_0000112>EudraCT Number: 2007-002422-29</obo:IAO_0000112>
        <obo:IAO_0000117>Qingliang Leon Li, Asiyah Yu Lin, Oliver He</obo:IAO_0000117>
        <obo:IAO_0000118>EudraCT identifier</obo:IAO_0000118>
        <obo:IAO_0000119>https://en.wikipedia.org/wiki/EudraCT</obo:IAO_0000119>
        <obo:IAO_0000119>https://www.clinicaltrialsregister.eu/ctr-search/search</obo:IAO_0000119>
        <obo:IAO_0000119>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <rdfs:label xml:lang="en">European clinical trial registry identifier</rdfs:label>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/primary/en/</rdfs:seeAlso>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OPMI_0000365 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OPMI_0000365">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OAE_0000002"/>
        <obo:IAO_0000115>Combining a drug and device, a biological product and device; a drug and biological product; or a drug, biological product, and device</obo:IAO_0000115>
        <obo:IAO_0000117>Leon Li, Asiyah Lin, Oliver He</obo:IAO_0000117>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <rdfs:label xml:lang="en">combinational intervention</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/OPMI_0000365"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>Combining a drug and device, a biological product and device; a drug and biological product; or a drug, biological product, and device</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/OPMI_0000367 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OPMI_0000367">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/PATO_0001236"/>
        <obo:IAO_0000115>The quality of a clinical trial that studies a drug or biological product. The phase is based on the study&apos;s objective, the number of participants, and other characteristics. According to USA FDA, there are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4.</obo:IAO_0000115>
        <obo:IAO_0000117>Leon Li, Asiyah Lin, Oliver He</obo:IAO_0000117>
        <obo:IAO_0000118>clinical trial stage</obo:IAO_0000118>
        <obo:IAO_0000119>https://www.clinicaltrials.gov/ct2/help/glossary/phase</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <oboInOwl:hasNarrowSynonym>phase</oboInOwl:hasNarrowSynonym>
        <rdfs:label xml:lang="en">clinical trial phase</rdfs:label>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/trds/en/</rdfs:seeAlso>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OPMI_0000368 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OPMI_0000368">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OPMI_0000367"/>
        <obo:IAO_0000115>A clinical trial phase that represents the first-in-man trial, which tests within a small group of people (typically 20-80) to evaluate safety, determine safe dosage ranges, and begin to identify side effects. A drug&apos;s side effects could be subtle or long term, or may only happen with a few people, so phase 1 trials are not expected to identify all side effects.</obo:IAO_0000115>
        <obo:IAO_0000117>Leon Li, Asiyah Lin, Oliver He</obo:IAO_0000117>
        <obo:IAO_0000118>Phase 1</obo:IAO_0000118>
        <obo:IAO_0000118>Phase I</obo:IAO_0000118>
        <obo:IAO_0000119>http://purl.obolibrary.org/obo/NCIT_C15600</obo:IAO_0000119>
        <obo:IAO_0000119>https://en.wikipedia.org/wiki/Clinical_trial</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <obo:NCIT_P207>C0920321</obo:NCIT_P207>
        <obo:OPMI_0000364>C15600</obo:OPMI_0000364>
        <rdfs:label xml:lang="en">clinical trial phase 1</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OPMI_0000369 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OPMI_0000369">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OPMI_0000367"/>
        <obo:IAO_0000115>A clinical trial phase that is designed to study a biomedical or behavioral intervention in a larger group of people (several hundred), to evaluate the drug&apos;s effectiveness for a particular indication in patients with the disease or condition under study, and to determine the common short-term side effects and risks associated with the intervention. [def-source: NCI]</obo:IAO_0000115>
        <obo:IAO_0000117>Leon Li, Asiyah Lin, Oliver He</obo:IAO_0000117>
        <obo:IAO_0000118>Phase II</obo:IAO_0000118>
        <obo:IAO_0000119>http://purl.obolibrary.org/obo/NCIT_C15601</obo:IAO_0000119>
        <obo:IAO_0000119>https://en.wikipedia.org/wiki/Clinical_trial</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <obo:NCIT_P207>C0282460</obo:NCIT_P207>
        <obo:OPMI_0000364>C15601</obo:OPMI_0000364>
        <rdfs:label xml:lang="en">clinical trial phase 2</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OPMI_0000370 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OPMI_0000370">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OPMI_0000367"/>
        <obo:IAO_0000115>A clinical trial phase that is designed to investigate the efficacy of the biomedical or behavioral intervention in large groups of human subjects (from several hundred to several thousand), to confirm efficacy, to monitor adverse reactions to the new medication or treatment regimen with respect to long-term use and by comparing the intervention to other standard or experimental interventions as well as to a placebo. [def-source: NCI]</obo:IAO_0000115>
        <obo:IAO_0000117>Leon Li, Asiyah Lin, Oliver He</obo:IAO_0000117>
        <obo:IAO_0000118>Phase III</obo:IAO_0000118>
        <obo:IAO_0000119>http://purl.obolibrary.org/obo/NCIT_C15602</obo:IAO_0000119>
        <obo:IAO_0000119>https://en.wikipedia.org/wiki/Clinical_trial</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <obo:NCIT_P207>C0282461</obo:NCIT_P207>
        <obo:OPMI_0000364>C15602</obo:OPMI_0000364>
        <rdfs:label xml:lang="en">clinical trial phase 3</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OPMI_0000371 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OPMI_0000371">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OPMI_0000367"/>
        <obo:IAO_0000115>A clinical trial phase that is designed for a randomized, controlled trial to evaluate the long-term safety and efficacy of a drug for a given indication. Often they are designed to study side effects that may have become apparent after the phase III study was completed. [def-source: NCI]</obo:IAO_0000115>
        <obo:IAO_0000117>Leon Li, Asiyah Lin, Oliver He</obo:IAO_0000117>
        <obo:IAO_0000118>Phase IV</obo:IAO_0000118>
        <obo:IAO_0000119>https://en.wikipedia.org/wiki/Clinical_trial</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <obo:NCIT_P207>C0282462</obo:NCIT_P207>
        <obo:OPMI_0000364>C15603</obo:OPMI_0000364>
        <rdfs:label xml:lang="en">clinical trial phase 4</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OPMI_0000372 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OPMI_0000372">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OPMI_0000367"/>
        <obo:IAO_0000115>A clinical trial phase that is designed to use an investigational agent that is available only in very limited quantities and which has never previously given to humans or for which there is extremely limited human experience. Phase 0 clinical trials are intended to enable researchers to understand the path of the drug in the body and its efficacy. Adverse event reporting in Phase 0 trials is expedited. [def-source: NCI]</obo:IAO_0000115>
        <obo:IAO_0000117>Leon Li, Asiyah Lin, Oliver He</obo:IAO_0000117>
        <obo:IAO_0000118></obo:IAO_0000118>
        <obo:IAO_0000118>Early Phase 1</obo:IAO_0000118>
        <obo:IAO_0000118>Pre-Clinical Phase</obo:IAO_0000118>
        <obo:IAO_0000118 xml:lang="en">clinical trial phase 0</obo:IAO_0000118>
        <obo:IAO_0000119>http://purl.obolibrary.org/obo/NCIT_C54721</obo:IAO_0000119>
        <obo:IAO_0000119>https://en.wikipedia.org/wiki/Clinical_trial</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <obo:NCIT_P207>C1882358</obo:NCIT_P207>
        <obo:OPMI_0000364>C54721</obo:OPMI_0000364>
        <rdfs:label>clinical trial early phase 1</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OPMI_0000376 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OPMI_0000376">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OAE_0000002"/>
        <obo:IAO_0000115>A medical intervention that involves a behavioral process to control, prevent, or treat a behavior problem.</obo:IAO_0000115>
        <obo:IAO_0000117>Leon Li, Asiyah Lin, Oliver He</obo:IAO_0000117>
        <obo:IAO_0000119>https://www.understood.org/en/learning-attention-issues/treatments-approaches/educational-strategies/behavior-intervention-plans-what-you-need-to-know</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <oboInOwl:hasExactSynonym>behavioral</oboInOwl:hasExactSynonym>
        <rdfs:label xml:lang="en">behavioral intervention</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/OPMI_0000376"/>
        <owl:annotatedProperty rdf:resource="http://www.geneontology.org/formats/oboInOwl#hasExactSynonym"/>
        <owl:annotatedTarget>behavioral</owl:annotatedTarget>
        <rdfs:seeAlso>https://prsinfo.clinicaltrials.gov/definitions.html</rdfs:seeAlso>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/OPMI_0000390 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OPMI_0000390">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000202"/>
        <obo:IAO_0000115>An investigation agent role that is taken by a human individual</obo:IAO_0000115>
        <obo:IAO_0000117>Leon Li, Asiyah Lin, Oliver He</obo:IAO_0000117>
        <obo:IAO_0000118>human investigator role</obo:IAO_0000118>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <rdfs:label xml:lang="en">investigator role</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OPMI_0000398 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OPMI_0000398">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000243"/>
        <obo:IAO_0000115>A sponsor role taken by an individual, organization, group or other legal entity which takes responsibility for initiating, managing and/or financing a study. The Primary Sponsor is responsible for ensuring that the trial is properly registered. The Primary Sponsor may or may not be the main funder.</obo:IAO_0000115>
        <obo:IAO_0000117>Leon Li, Asiyah Lin, Oliver He</obo:IAO_0000117>
        <obo:IAO_0000119>https://www.who.int/ictrp/network/trds/en/</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <rdfs:label xml:lang="en">primary sponsor role</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OPMI_0000399 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OPMI_0000399">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0000243"/>
        <obo:IAO_0000115>A sponsor role taken by an additional individual, organization or another legal person, if any, that has agreed with the primary sponsor to take on responsibilities of sponsorship.</obo:IAO_0000115>
        <obo:IAO_0000117>Leon Li, Asiyah Lin, Oliver He</obo:IAO_0000117>
        <obo:IAO_0000118>collaborator role</obo:IAO_0000118>
        <obo:IAO_0000119>https://www.who.int/ictrp/network/trds/en/</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <rdfs:comment>A secondary sponsor may have agreed to:
- take on all the responsibilities of sponsorship jointly with the primary sponsor; or
- form a group with the Primary Sponsor in which the responsibilities of sponsorship are allocated among the members of the group; or
- act as the Primary Sponsor’s legal representative in relation to some or all of the trial sites.
by WHO (https://www.who.int/ictrp/network/trds/en/)</rdfs:comment>
        <rdfs:comment>In clinicaltrials.gov, the secondary sponsor role can be taken by a project collaborator (Reference: https://prsinfo.clinicaltrials.gov/trainTrainer/WHO-ICMJE-ClinTrialsgov-Cross-Ref.pdf). However, a secondary sponsor may serve as a collaborator role, but a collaborator may not serve as a secondary sponsor role.</rdfs:comment>
        <rdfs:label xml:lang="en">secondary sponsor role</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OPMI_0000400 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OPMI_0000400">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OPMI_0000390"/>
        <obo:IAO_0000115>An investigator role taken by an individual who is designated as responsible party by the sponsor</obo:IAO_0000115>
        <obo:IAO_0000117>Leon Li, Asiyah Lin, Oliver He</obo:IAO_0000117>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <rdfs:label xml:lang="en">principal investigator role</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OPMI_0000401 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OPMI_0000401">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OPMI_0000390"/>
        <obo:IAO_0000115>An investigator role taken by an individual who both initiates and conducts the study</obo:IAO_0000115>
        <obo:IAO_0000117>Leon Li, Asiyah Lin, Oliver He</obo:IAO_0000117>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <rdfs:label xml:lang="en">sponsor investigator role</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OPMI_0004508 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/OPMI_0004508">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/ERO_0000016"/>
        <obo:IAO_0000115>A clinical trial that is at Early Phase 1 or Phase 0</obo:IAO_0000115>
        <obo:IAO_0000115>A clinical trial that is at an Early Phase i or Phase 0, which is designed to use an investigational agent that is available only in very limited quantities and which has never previously given to humans or for which there is extremely limited human experience. Phase 0 clinical trials are intended to enable researchers to understand the path of the drug in the body and its efficacy. Adverse event reporting in Phase 0 trials is expedited. [def-source: NCI]</obo:IAO_0000115>
        <obo:IAO_0000115>Exploratory trials, involving very limited human exposure, with no therapeutic or diagnostic intent (e.g., screening studies, microdose studies). (Formerly listed as &quot;Phase 0&quot;)</obo:IAO_0000115>
        <obo:IAO_0000117>Leon Li, Asiyah Lin, Oliver He</obo:IAO_0000117>
        <obo:IAO_0000118>Phase 0 clinical trial</obo:IAO_0000118>
        <obo:IAO_0000118>Phase 0 trial</obo:IAO_0000118>
        <obo:IAO_0000118>Pre-Clinical Trial</obo:IAO_0000118>
        <obo:IAO_0000119>http://purl.obolibrary.org/obo/NCIT_C54721</obo:IAO_0000119>
        <obo:IAO_0000119>https://en.wikipedia.org/wiki/Clinical_trial</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <rdfs:label xml:lang="en">Early Phase 1 clinical trial</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.obolibrary.org/obo/OPMI_0004508"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>Exploratory trials, involving very limited human exposure, with no therapeutic or diagnostic intent (e.g., screening studies, microdose studies). (Formerly listed as &quot;Phase 0&quot;)</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- http://purl.obolibrary.org/obo/PATO_0000047 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/PATO_0000047">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/PATO_0001995"/>
        <obo:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An organismal quality inhering in a bearer by virtue of the bearer&apos;s ability to undergo sexual reproduction in order to differentiate the individuals or types involved.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/pato.owl"/>
        <oboInOwl:hasOBONamespace rdf:datatype="http://www.w3.org/2001/XMLSchema#string">quality</oboInOwl:hasOBONamespace>
        <oboInOwl:id rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PATO:0000047</oboInOwl:id>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/pato#attribute_slim"/>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">biological sex</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/PATO_0000383 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/PATO_0000383">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/PATO_0001894"/>
        <obo:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A biological sex quality inhering in an individual or a population that only produces gametes that can be fertilised by male gametes.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/pato.owl"/>
        <oboInOwl:hasOBONamespace rdf:datatype="http://www.w3.org/2001/XMLSchema#string">quality</oboInOwl:hasOBONamespace>
        <oboInOwl:id rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PATO:0000383</oboInOwl:id>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/pato#mpath_slim"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/pato#value_slim"/>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">female</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/PATO_0000384 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/PATO_0000384">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/PATO_0001894"/>
        <obo:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A biological sex quality inhering in an individual or a population whose sex organs contain only male gametes.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/pato.owl"/>
        <oboInOwl:hasOBONamespace rdf:datatype="http://www.w3.org/2001/XMLSchema#string">quality</oboInOwl:hasOBONamespace>
        <oboInOwl:id rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PATO:0000384</oboInOwl:id>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/pato#mpath_slim"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/pato#value_slim"/>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">male</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/PATO_0001236 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/PATO_0001236">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000019"/>
        <obo:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A quality which inheres in an process.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/oae.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/pato.owl"/>
        <oboInOwl:hasAlternativeId rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PATO:0001239</oboInOwl:hasAlternativeId>
        <oboInOwl:hasAlternativeId rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PATO:0001240</oboInOwl:hasAlternativeId>
        <oboInOwl:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">quality of a process</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">quality of occurrent</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">quality of process</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">relational quality of occurrent</oboInOwl:hasExactSynonym>
        <oboInOwl:hasOBONamespace rdf:datatype="http://www.w3.org/2001/XMLSchema#string">quality</oboInOwl:hasOBONamespace>
        <oboInOwl:id rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PATO:0001236</oboInOwl:id>
        <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">See comments of relational quality of a physical entity.</rdfs:comment>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">process quality</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/PATO_0001241 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/PATO_0001241">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000019"/>
        <obo:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A quality which inheres in a continuant.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/pato.owl"/>
        <oboInOwl:hasAlternativeId rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PATO:0001237</oboInOwl:hasAlternativeId>
        <oboInOwl:hasAlternativeId rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PATO:0001238</oboInOwl:hasAlternativeId>
        <oboInOwl:hasDbXref rdf:datatype="http://www.w3.org/2001/XMLSchema#string">snap:Quality</oboInOwl:hasDbXref>
        <oboInOwl:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">monadic quality of a continuant</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">multiply inhering quality of a physical entity</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">quality of a continuant</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">quality of a single physical entity</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">quality of an object</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">quality of continuant</oboInOwl:hasExactSynonym>
        <oboInOwl:hasNarrowSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">monadic quality of an object</oboInOwl:hasNarrowSynonym>
        <oboInOwl:hasNarrowSynonym rdf:datatype="http://www.w3.org/2001/XMLSchema#string">monadic quality of continuant</oboInOwl:hasNarrowSynonym>
        <oboInOwl:hasOBONamespace rdf:datatype="http://www.w3.org/2001/XMLSchema#string">quality</oboInOwl:hasOBONamespace>
        <oboInOwl:id rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PATO:0001241</oboInOwl:id>
        <rdfs:comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Relational qualities are qualities that hold between multiple entities. Normal (monadic) qualities such as the shape of a eyeball exist purely as a quality of that eyeball. A relational quality such as sensitivity to light is a quality of that eyeball (and connecting nervous system) as it relates to incoming light waves/particles.</rdfs:comment>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">physical object quality</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/PATO_0001894 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/PATO_0001894">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/PATO_0000047"/>
        <obo:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An organismal quality inhering in a bearer by virtue of the bearer&apos;s physical expression of sexual characteristics.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/pato.owl"/>
        <oboInOwl:hasOBONamespace rdf:datatype="http://www.w3.org/2001/XMLSchema#string">quality</oboInOwl:hasOBONamespace>
        <oboInOwl:id rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PATO:0001894</oboInOwl:id>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/pato#attribute_slim"/>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">phenotypic sex</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/PATO_0001995 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/PATO_0001995">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/PATO_0001241"/>
        <obo:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A quality that inheres in an entire organism or part of an organism.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/pato.owl"/>
        <oboInOwl:hasOBONamespace rdf:datatype="http://www.w3.org/2001/XMLSchema#string">quality</oboInOwl:hasOBONamespace>
        <oboInOwl:id rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PATO:0001995</oboInOwl:id>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">organismal quality</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/PDRO_0000129 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/PDRO_0000129">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000030"/>
        <obo:IAO_0000114 rdf:resource="http://purl.obolibrary.org/obo/IAO_0000123"/>
        <obo:IAO_0000115 xml:lang="en">An information content entity that describes some relationships between some entities and whose truthfullness is a prerequisite for something.</obo:IAO_0000115>
        <obo:IAO_0000115 xml:lang="fr">Une entité de contenu informationnel qui décrit des relations entre certaines entités et dont la véracité est un prérequis pour quelque chose.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/pdro.owl"/>
        <rdfs:label xml:lang="en">condition</rdfs:label>
        <rdfs:label xml:lang="fr">condition</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/VO_0000002 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/VO_0000002">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OAE_0000002"/>
        <obo:IAO_0000115>a medical intervention that involves in adding vaccine into a host (e.g., human, mouse) in vivo with the intent to invoke an adaptive immune response.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/oae.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/vo.owl"/>
        <rdfs:label>vaccination</rdfs:label>
        <rdfs:seeAlso>https://prsinfo.clinicaltrials.gov/definitions.html</rdfs:seeAlso>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/VO_0000427 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/VO_0000427">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/VO_0000596"/>
        <obo:IAO_0000115>A vaccine clinical trial that investigates the safety profile of a vaccine in a small group (10-50) of healthy volunteers.</obo:IAO_0000115>
        <obo:IAO_0000117>YH</obo:IAO_0000117>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/vo.owl"/>
        <rdfs:label>phase 1 vaccine trial</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/VO_0000428 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/VO_0000428">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/VO_0000596"/>
        <obo:IAO_0000115>A vaccine clinical trial that studies vaccine efficacy with a target population (numbering 50-100). Different dosage levels will also be explored at this stage to determine the optimum dose.</obo:IAO_0000115>
        <obo:IAO_0000117>YH</obo:IAO_0000117>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/vo.owl"/>
        <rdfs:label>phase 2 vaccine trial</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/VO_0000429 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/VO_0000429">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/VO_0000596"/>
        <obo:IAO_0000115>A vaccine clinical trial that takes the trial to a large-scale safety and efficacy study in a relevant patient population, usually in excess of 3,000.</obo:IAO_0000115>
        <obo:IAO_0000117>YH</obo:IAO_0000117>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/vo.owl"/>
        <rdfs:label>phase 3 vaccine trial</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/VO_0000430 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/VO_0000430">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/VO_0000596"/>
        <obo:IAO_0000115>The final stage of vaccine clinical evaluation. Phase IV occurs after a vaccine or therapy is licensed and is being used by large numbers of people. These studies are not always required or completed.</obo:IAO_0000115>
        <obo:IAO_0000117>YH</obo:IAO_0000117>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/vo.owl"/>
        <rdfs:label>phase 4 vaccine trial</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/VO_0000596 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/VO_0000596">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/ERO_0000015"/>
        <obo:IAO_0000115>A processual entity by which a vaccine is tested clinically for safety and effectiveness. Clinical trials are conducted in phases. Classically, clinical trials unfold in three phases in order to gather data and information about a vaccine and its performance. This will form the basis of a dossier submitted to regulatory authorities by way of an application for licensure. After a vaccine is licensed and is being used by large numbers of people, a Phase IV study may or may not be taken for vaccine clinical evaluation.</obo:IAO_0000115>
        <obo:IAO_0000116>Most vaccines against a pathogen (e.g., HIV) are not tested by vaccinating people and then deliberately exposing them to virulent pathogen (e.g., HIV). This strategy is never for a vaccine against a disease as serious as HIV.
The best way to determine if a vaccine is effective is to test it in a randomized, controlled, double-blind clinical trial. This type of trial is often referred to as the gold standard in medical research and provides the strongest evidence for the efficacy of a vaccine.</obo:IAO_0000116>
        <obo:IAO_0000117>YH</obo:IAO_0000117>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/vo.owl"/>
        <rdfs:label>vaccine clinical trial</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.org/net/OCRe/research.owl#Case_control_study -->

    <owl:Class rdf:about="http://purl.org/net/OCRe/research.owl#Case_control_study">
        <rdfs:subClassOf rdf:resource="http://purl.org/net/OCRe/research.owl#Observational_study"/>
        <obo:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A case control study is an observational study that compares people with a specific disease or outcome of interest (cases) to people from the same population without that disease or outcome (controls), and which seeks to find associations between the outcome and prior exposure to particular risk factors. [Glossary of Terms in The Cochrane Collaboration]</obo:IAO_0000115>
        <obo:IAO_0000115>Group of individuals with specific characteristics (for example, conditions or exposures) compared to group(s) with different characteristics, but otherwise similar.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ero.owl"/>
        <statistics:curator rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Simona</statistics:curator>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Case-control study</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.org/net/OCRe/research.owl#Case_control_study"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>Group of individuals with specific characteristics (for example, conditions or exposures) compared to group(s) with different characteristics, but otherwise similar.</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- http://purl.org/net/OCRe/research.owl#Case_crossover_study -->

    <owl:Class rdf:about="http://purl.org/net/OCRe/research.owl#Case_crossover_study">
        <rdfs:subClassOf rdf:resource="http://purl.org/net/OCRe/research.owl#Observational_study"/>
        <obo:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A case-crossover study is an observational study that aims to answer the question, “Was this event triggered by something unusual that happened just before?” The key feature of the design is that each case serves as its own control. The method is analogous to a crossover experiment viewed retrospectively, except that the investigator does not control when a patient starts and stops being exposed to the potential trigger. Also, the exposure frequency is typically measured in only a sample of the total time when the patient was at risk of the injury or disease onset. Thus it usually resembles a case-control study more than a retrospective cohort study. 
The simplest case-crossover design is closely analogous to a traditional matched-pair case-control design. In both designs, each case has a matched control. In a traditional matched-pair case-control study, the control is a different person at a similar time. In the matched-pair case-crossover design, the control is the same person at a different time [Annu Rev Public Health. 2000;21:193-221.]</obo:IAO_0000115>
        <obo:IAO_0000115>Characteristics of case immediately prior to disease onset (sometimes called the hazard period) compared to characteristics of same case at a prior time (that is, control period).</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ero.owl"/>
        <statistics:curator rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Simona</statistics:curator>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Case-crossover study</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.org/net/OCRe/research.owl#Case_crossover_study"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>Characteristics of case immediately prior to disease onset (sometimes called the hazard period) compared to characteristics of same case at a prior time (that is, control period).</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- http://purl.org/net/OCRe/research.owl#Cohort_study -->

    <owl:Class rdf:about="http://purl.org/net/OCRe/research.owl#Cohort_study">
        <rdfs:subClassOf rdf:resource="http://purl.org/net/OCRe/research.owl#Observational_study"/>
        <obo:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A cohort study is an observational study in which a defined group of people (the cohort) is followed over time. The outcomes of people in subsets of this cohort are compared, to examine people who were exposed or not exposed (or exposed at different levels) to a particular intervention or other factor of interest. A prospective cohort study assembles participants and follows them into the future. A retrospective (or historical) cohort study identifies subjects from past records and follows them from the time of those records to the present. [Glossary of Terms in The Cochrane Collaboration]</obo:IAO_0000115>
        <obo:IAO_0000115>Group of individuals, initially defined and composed, with common characteristics (for example, condition, birth year), who are examined or traced over a given time period.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ero.owl"/>
        <statistics:curator rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Simona</statistics:curator>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Cohort study</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.org/net/OCRe/research.owl#Cohort_study"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>Group of individuals, initially defined and composed, with common characteristics (for example, condition, birth year), who are examined or traced over a given time period.</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- http://purl.org/net/OCRe/research.owl#Cross-sectional_study -->

    <owl:Class rdf:about="http://purl.org/net/OCRe/research.owl#Cross-sectional_study">
        <rdfs:subClassOf rdf:resource="http://purl.org/net/OCRe/research.owl#Observational_study"/>
        <obo:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A cross-sectional study is an observational study measuring the distribution of some characteristic(s) in a population at a particular point in time. (Also called survey.) [adapted from: Glossary of Terms in The Cochrane Collaboration]</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ero.owl"/>
        <statistics:curator rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Simona</statistics:curator>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Cross-sectional study</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.org/net/OCRe/research.owl#Interventional_study -->

    <owl:Class rdf:about="http://purl.org/net/OCRe/research.owl#Interventional_study">
        <rdfs:subClassOf rdf:resource="http://purl.org/net/OCRe/research.owl#Quantitative_human_study"/>
        <obo:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An interventional study is a quantitative study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes. Interventions include but are not restricted to drugs, cells and other biological products, surgical procedures, radiologic procedures, devices, behavioural treatments, process-of-care changes, preventive care, etc. [adapted from: WHO, available at: http://www.who.int/ictrp/en/]</obo:IAO_0000115>
        <obo:IAO_0000115>Participants are assigned prospectively to an intervention or interventions according to a protocol to evaluate the effect of the intervention(s) on biomedical or other health related outcomes.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ero.owl"/>
        <statistics:curator rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Simona</statistics:curator>
        <study_protocol:develop_comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Simona: to be reviewed</study_protocol:develop_comment>
        <oboInOwl:hasExactSynonym>clinical trail</oboInOwl:hasExactSynonym>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Interventional study</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.org/net/OCRe/research.owl#Interventional_study"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>Participants are assigned prospectively to an intervention or interventions according to a protocol to evaluate the effect of the intervention(s) on biomedical or other health related outcomes.</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.org/net/OCRe/research.owl#Interventional_study"/>
        <owl:annotatedProperty rdf:resource="http://www.geneontology.org/formats/oboInOwl#hasExactSynonym"/>
        <owl:annotatedTarget>clinical trail</owl:annotatedTarget>
        <rdfs:seeAlso>https://clinicaltrials.gov/ct2/about-studies/glossary</rdfs:seeAlso>
    </owl:Axiom>
    


    <!-- http://purl.org/net/OCRe/research.owl#Observational_study -->

    <owl:Class rdf:about="http://purl.org/net/OCRe/research.owl#Observational_study">
        <rdfs:subClassOf rdf:resource="http://purl.org/net/OCRe/research.owl#Quantitative_human_study"/>
        <obo:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An observational study is a quantitative study in which the investigators do not seek to intervene, and simply observe the course of events. [adapted from: Glossary of Terms in The Cochrane Collaboration]</obo:IAO_0000115>
        <obo:IAO_0000115>Studies in human beings in which biomedical and/or health outcomes are assessed in pre-defined groups of individuals. Participants in the study may receive diagnostic, therapeutic, or other interventions, but the investigator does not assign specific interventions to the study participants. This includes when participants receive interventions as part of routine medical care, and a researcher studies the effect of the intervention.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ero.owl"/>
        <statistics:curator rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Simona</statistics:curator>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Observational study</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.org/net/OCRe/research.owl#Observational_study"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>Studies in human beings in which biomedical and/or health outcomes are assessed in pre-defined groups of individuals. Participants in the study may receive diagnostic, therapeutic, or other interventions, but the investigator does not assign specific interventions to the study participants. This includes when participants receive interventions as part of routine medical care, and a researcher studies the effect of the intervention.</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- http://purl.org/net/OCRe/research.owl#Parallel_group_study -->

    <owl:Class rdf:about="http://purl.org/net/OCRe/research.owl#Parallel_group_study">
        <rdfs:subClassOf rdf:resource="http://purl.org/net/OCRe/research.owl#Interventional_study"/>
        <obo:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A parallel group study is an interventional study that compares across at least two allocation groups concurrently, each receiving a regimen of interventions (which can be &quot;no intervention&quot;).</obo:IAO_0000115>
        <obo:IAO_0000115>Participants are assigned to one of two or more groups in parallel for the duration of the study</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ero.owl"/>
        <statistics:curator rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Simona</statistics:curator>
        <study_protocol:develop_comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Simona: to be reviewed.</study_protocol:develop_comment>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Parallel group study</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.org/net/OCRe/research.owl#Parallel_group_study"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>Participants are assigned to one of two or more groups in parallel for the duration of the study</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- http://purl.org/net/OCRe/research.owl#Qualitative_human_study -->

    <owl:Class rdf:about="http://purl.org/net/OCRe/research.owl#Qualitative_human_study">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/ERO_0000015"/>
        <obo:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A qualitative study is an individual-human study whose primary mode of inquiry is qualitative.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ero.owl"/>
        <statistics:curator rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Simona</statistics:curator>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Qualitative human study</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.org/net/OCRe/research.owl#Quantitative_human_study -->

    <owl:Class rdf:about="http://purl.org/net/OCRe/research.owl#Quantitative_human_study">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/ERO_0000015"/>
        <obo:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A quantitative study is an individual-human study whose primary mode of inquiry is quantitative.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ero.owl"/>
        <statistics:curator rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Simona</statistics:curator>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Quantitative human study</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.org/net/OCRe/study_design.owl#Crossover_study -->

    <owl:Class rdf:about="http://purl.org/net/OCRe/study_design.owl#Crossover_study">
        <rdfs:subClassOf rdf:resource="http://purl.org/net/OCRe/research.owl#Interventional_study"/>
        <obo:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A crossover study is an interventional study where the population is a more than a single human subject, in which at least two regimens of interventions are given alternatingly. Upon completion of one regimen, participants are switched to the other. For example, for a comparison of regimens A and B, the participants are randomly allocated to receive them in either the order A, B or the order B, A. 
Regimens are assigned to and data are analyzed within more than one participant at a time.</obo:IAO_0000115>
        <obo:IAO_0000115>Participants receive one of two (or more) alternative interventions during the initial phase of the study and receive the other intervention during the second phase of the study</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ero.owl"/>
        <statistics:curator rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Simona</statistics:curator>
        <study_protocol:develop_comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Simona: to be reviewed</study_protocol:develop_comment>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Crossover study</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.org/net/OCRe/study_design.owl#Crossover_study"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>Participants receive one of two (or more) alternative interventions during the initial phase of the study and receive the other intervention during the second phase of the study</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- http://purl.org/net/OCRe/study_design.owl#N-of-1_crossover_study -->

    <owl:Class rdf:about="http://purl.org/net/OCRe/study_design.owl#N-of-1_crossover_study">
        <rdfs:subClassOf rdf:resource="http://purl.org/net/OCRe/research.owl#Interventional_study"/>
        <obo:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An N-of-1 crossover study is an interventional study where the population is a single human subject and in which at least two regimens of interventions are given alternatingly. Regimens are assigned to and data are analyzed within one participant at a time.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ero.owl"/>
        <statistics:curator rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Simona</statistics:curator>
        <study_protocol:develop_comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Simona: to be reviewed</study_protocol:develop_comment>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">N-of-1 crossover study</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.org/net/OCRe/study_design.owl#Single_group_study -->

    <owl:Class rdf:about="http://purl.org/net/OCRe/study_design.owl#Single_group_study">
        <rdfs:subClassOf rdf:resource="http://purl.org/net/OCRe/research.owl#Interventional_study"/>
        <obo:IAO_0000115 rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A single group study is an interventional study that has only a single allocation group and no contemporaneuos comparison group.

A study in which an individual acts has his/her own comparison does not fall into this category, since an individual is not a group.</obo:IAO_0000115>
        <obo:IAO_0000115>Clinical trials with a single arm</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ero.owl"/>
        <statistics:curator rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Simona</statistics:curator>
        <study_protocol:develop_comment rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Simona: to be reviewed</study_protocol:develop_comment>
        <rdfs:label rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Single group study</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="http://purl.org/net/OCRe/study_design.owl#Single_group_study"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>Clinical trials with a single arm</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- http://www.w3.org/2002/07/owl#Thing -->

    <owl:Class rdf:about="http://www.w3.org/2002/07/owl#Thing">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ico.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/opmi.owl"/>
    </owl:Class>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000001 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000001">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000030"/>
        <obo:IAO_0000115>An identifier(s) (ID), if any, other than the organization&apos;s Unique Protocol Identification Number or the NCT number that is assigned to the clinical study. This includes any unique clinical study identifiers assigned by other publicly available clinical trial registries. If the clinical study is funded in whole or in part by a U.S. Federal Government agency, the complete grant or contract number must be submitted as a Secondary ID.</obo:IAO_0000115>
        <obo:IAO_0000115>Other identifiers besides the Trial Identifying Number allocated by the Primary Registry, if any.</obo:IAO_0000115>
        <rdfs:label>secondary identifier</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="https://bio.scai.fraunhofer.de/ontology/CTO_0000001"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>An identifier(s) (ID), if any, other than the organization&apos;s Unique Protocol Identification Number or the NCT number that is assigned to the clinical study. This includes any unique clinical study identifiers assigned by other publicly available clinical trial registries. If the clinical study is funded in whole or in part by a U.S. Federal Government agency, the complete grant or contract number must be submitted as a Secondary ID.</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="https://bio.scai.fraunhofer.de/ontology/CTO_0000001"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>Other identifiers besides the Trial Identifying Number allocated by the Primary Registry, if any.</owl:annotatedTarget>
        <obo:IAO_0000119>https://www.who.int/ictrp/network/trds/en/</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000002 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000002">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCIT_C98714"/>
        <obo:IAO_0000115>A centrally registered identifier that is assigned for a specific clinical trial registered in the Australian New Zealand clinical trials registry (ANZCTR). The format for the registry number is “ACTRN” followed by a 14-digit number, e.g., ACTRN12620000457943.</obo:IAO_0000115>
        <oboInOwl:hasExactSynonym>ANZCTR identifier</oboInOwl:hasExactSynonym>
        <rdfs:label>Australian New Zealand clinical trials registry identifier</rdfs:label>
        <rdfs:seeAlso>http://www.anzctr.org.au/</rdfs:seeAlso>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/primary/en/</rdfs:seeAlso>
    </owl:Class>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000003 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000003">
        <rdfs:subClassOf rdf:resource="https://bio.scai.fraunhofer.de/ontology/CTO_0000073"/>
        <obo:IAO_0000115>Australian New Zealand Clinical Trials Registry  is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.</obo:IAO_0000115>
        <oboInOwl:hasExactSynonym>ANZCTR</oboInOwl:hasExactSynonym>
        <rdfs:label>Australian New Zealand clinical trials registry</rdfs:label>
        <rdfs:seeAlso>http://www.anzctr.org.au/</rdfs:seeAlso>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/primary/en/</rdfs:seeAlso>
    </owl:Class>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000004 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000004">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCIT_C98714"/>
        <obo:IAO_0000115>A centrally registered identifier that is assigned for a specific clinical trial registered in the Peruvian clinical trial registry  (REPEC). The format for the registry number is “PER-” followed by a 3-digit number, followed by a hyphen, followed by a 2-digit number e.g., PER-010-20.</obo:IAO_0000115>
        <oboInOwl:hasExactSynonym>REPEC identifier</oboInOwl:hasExactSynonym>
        <rdfs:label>Peruvian clinical trial registry identifier</rdfs:label>
        <rdfs:seeAlso>https://ensayosclinicos-repec.ins.gob.pe/en/</rdfs:seeAlso>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/primary/en/</rdfs:seeAlso>
    </owl:Class>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000005 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000005">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0500000"/>
        <obo:IAO_0000115>The party or parties involved in the clinical trial who are prevented from having knowledge of the interventions assigned to individual participants.</obo:IAO_0000115>
        <oboInOwl:hasRelatedSynonym>blinding</oboInOwl:hasRelatedSynonym>
        <oboInOwl:hasRelatedSynonym>masking</oboInOwl:hasRelatedSynonym>
        <rdfs:label>masking design</rdfs:label>
        <rdfs:seeAlso>http://www.icmje.org/recommendations/</rdfs:seeAlso>
        <rdfs:seeAlso>http://www.who.int/ictrp/network/trds/en/index.html</rdfs:seeAlso>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="https://bio.scai.fraunhofer.de/ontology/CTO_0000005"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>The party or parties involved in the clinical trial who are prevented from having knowledge of the interventions assigned to individual participants.</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000006 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000006">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCIT_C52580"/>
        <obo:IAO_0000115>Participants are expressly assigned to intervention groups through a non-random method, such as physician choice</obo:IAO_0000115>
        <oboInOwl:hasExactSynonym>non-randomized</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>nonrandomized</oboInOwl:hasExactSynonym>
        <rdfs:label>non-random allocation</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="https://bio.scai.fraunhofer.de/ontology/CTO_0000006"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>Participants are expressly assigned to intervention groups through a non-random method, such as physician choice</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000007 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000007">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000088"/>
        <obo:IAO_0000115>A study record that includes the summary results posted in the ClinicalTrials.gov results database. Summary results information includes participant flow, baseline characteristics, outcome measures, and adverse events (including serious adverse events).</obo:IAO_0000115>
        <oboInOwl:hasExactSynonym>summary results</oboInOwl:hasExactSynonym>
        <rdfs:label>study summary result</rdfs:label>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/trds/en/</rdfs:seeAlso>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="https://bio.scai.fraunhofer.de/ontology/CTO_0000007"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>A study record that includes the summary results posted in the ClinicalTrials.gov results database. Summary results information includes participant flow, baseline characteristics, outcome measures, and adverse events (including serious adverse events).</owl:annotatedTarget>
        <obo:IAO_0000119>https://clinicaltrials.gov/ct2/about-studies/glossary</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000008 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000008">
        <rdfs:subClassOf rdf:resource="https://bio.scai.fraunhofer.de/ontology/CTO_0000051"/>
        <obo:IAO_0000115>A description of each secondary outcome measure (or for observational studies, specific secondary measurement[s] or observation[s] used to describe patterns of diseases or traits or associations with exposures, risk factors or treatment).
Each secondary outcome measure information includes title, description and time frame.</obo:IAO_0000115>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
        <oboInOwl:hasRelatedSynonym>key secondary outcome</oboInOwl:hasRelatedSynonym>
        <rdfs:label>secondary outcome measure information</rdfs:label>
        <rdfs:seeAlso>https://clinicaltrials.gov/ct2/about-studies/glossary</rdfs:seeAlso>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="https://bio.scai.fraunhofer.de/ontology/CTO_0000008"/>
        <owl:annotatedProperty rdf:resource="http://www.geneontology.org/formats/oboInOwl#hasRelatedSynonym"/>
        <owl:annotatedTarget>key secondary outcome</owl:annotatedTarget>
        <rdfs:isDefinedBy>https://www.who.int/ictrp/network/trds/en/</rdfs:isDefinedBy>
    </owl:Axiom>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000009 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000009">
        <rdfs:subClassOf rdf:resource="https://bio.scai.fraunhofer.de/ontology/CTO_0000073"/>
        <obo:IAO_0000115>The Iranian registry of clinical trials is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.</obo:IAO_0000115>
        <oboInOwl:hasExactSynonym>IRCT</oboInOwl:hasExactSynonym>
        <rdfs:label>Iranian registry of clinical trials</rdfs:label>
        <rdfs:seeAlso>http://www.irct.ir/</rdfs:seeAlso>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/primary/en/</rdfs:seeAlso>
    </owl:Class>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000010 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000010">
        <rdfs:subClassOf rdf:resource="https://bio.scai.fraunhofer.de/ontology/CTO_0000051"/>
        <obo:IAO_0000115>Any other measurements, excluding post-hoc measures, that will be used to evaluate the intervention(s) or, for observational studies, that are a focus of the study.
Each primary outcome measure information includes title, description and time frame.</obo:IAO_0000115>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
        <oboInOwl:hasExactSynonym>other pre-specified outcome measures</oboInOwl:hasExactSynonym>
        <rdfs:label>other outcome measure information</rdfs:label>
    </owl:Class>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000011 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000011">
        <rdfs:subClassOf rdf:resource="https://bio.scai.fraunhofer.de/ontology/CTO_0000073"/>
        <obo:IAO_0000115>The Indian clinical trials registry is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.</obo:IAO_0000115>
        <oboInOwl:hasExactSynonym>CTRI</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>clinical trials registry - India</oboInOwl:hasExactSynonym>
        <rdfs:label>Indian clinical trials registry</rdfs:label>
        <rdfs:seeAlso>http://ctri.nic.in/</rdfs:seeAlso>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/primary/en/</rdfs:seeAlso>
    </owl:Class>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000012 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000012">
        <rdfs:subClassOf rdf:resource="https://bio.scai.fraunhofer.de/ontology/CTO_0000073"/>
        <obo:IAO_0000115>The Netherlands national trial register is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.</obo:IAO_0000115>
        <oboInOwl:hasExactSynonym>NTR</oboInOwl:hasExactSynonym>
        <rdfs:label>The Netherlands national trial register</rdfs:label>
        <rdfs:seeAlso>http://www.trialregister.nl/</rdfs:seeAlso>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/primary/en/</rdfs:seeAlso>
    </owl:Class>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000013 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000013">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCIT_C98714"/>
        <obo:IAO_0000115>A centrally registered identifier that is assigned for a specific clinical trial registered in the Iranian registry of clinical trials (IRCT). The format for the registry number is “IRCT” followed by a 14-digit number, one letter and again one or  two numbers, e.g., IRCT20100228003449N29.</obo:IAO_0000115>
        <oboInOwl:hasExactSynonym>IRCT identifier</oboInOwl:hasExactSynonym>
        <rdfs:label>Iranian registry of clinical trials identifier</rdfs:label>
        <rdfs:seeAlso>http://www.irct.ir/</rdfs:seeAlso>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/primary/en/</rdfs:seeAlso>
    </owl:Class>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000014 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000014">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCIT_C98714"/>
        <obo:IAO_0000115>A centrally registered identifier that is assigned for a specific clinical trial registered in the German clinical trials register (DRKS). The format for the registry number is “DRKS” followed by a 8-digit number, e.g., DRKS00000494.</obo:IAO_0000115>
        <oboInOwl:hasExactSynonym>DRKS identifier</oboInOwl:hasExactSynonym>
        <rdfs:label>German clinical trials register identifier</rdfs:label>
        <rdfs:seeAlso>https://www.drks.de/drks_web/</rdfs:seeAlso>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/primary/en/</rdfs:seeAlso>
    </owl:Class>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000015 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000015">
        <rdfs:subClassOf rdf:resource="https://bio.scai.fraunhofer.de/ontology/CTO_0000073"/>
        <obo:IAO_0000115>The Cuban public registry of clinical trials is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.</obo:IAO_0000115>
        <oboInOwl:hasExactSynonym>RPCEC</oboInOwl:hasExactSynonym>
        <rdfs:label>Cuban public registry of clinical trials</rdfs:label>
        <rdfs:seeAlso>http://registroclinico.sld.cu/en/home</rdfs:seeAlso>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/primary/en/</rdfs:seeAlso>
    </owl:Class>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000016 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000016">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/BFO_0000015"/>
        <obo:IAO_0000115>For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.</obo:IAO_0000115>
        <rdfs:label>outcome measure</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="https://bio.scai.fraunhofer.de/ontology/CTO_0000016"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.</owl:annotatedTarget>
        <obo:IAO_0000119>https://clinicaltrials.gov/ct2/about-studies/glossary</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000017 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000017">
        <rdfs:subClassOf rdf:resource="https://bio.scai.fraunhofer.de/ontology/CTO_0000073"/>
        <obo:IAO_0000115>The Pan African clinical trial registry is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.</obo:IAO_0000115>
        <oboInOwl:hasExactSynonym>PACTR</oboInOwl:hasExactSynonym>
        <rdfs:label>Pan African clinical trial registry</rdfs:label>
        <rdfs:seeAlso>http://www.pactr.org/</rdfs:seeAlso>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/primary/en/</rdfs:seeAlso>
    </owl:Class>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000018 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000018">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCIT_C98714"/>
        <obo:IAO_0000115>A centrally registered identifier that is assigned for a specific clinical trial registered in the The Netherlands national trial register (NTR). The format for the registry number is “NTR” followed by a 1 to 4-digit number, e.g., NL8498.</obo:IAO_0000115>
        <oboInOwl:hasExactSynonym>NTR identifier</oboInOwl:hasExactSynonym>
        <rdfs:label>The Netherlands national trial register identifier</rdfs:label>
        <rdfs:seeAlso>https://www.trialregister.nl/</rdfs:seeAlso>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/primary/en/</rdfs:seeAlso>
    </owl:Class>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000019 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000019">
        <rdfs:subClassOf rdf:resource="https://bio.scai.fraunhofer.de/ontology/CTO_0000073"/>
        <obo:IAO_0000115>The JAPIC (Japan Pharmaceutical Information Center) clinical trials registry is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.</obo:IAO_0000115>
        <oboInOwl:hasExactSynonym>JapicCTI</oboInOwl:hasExactSynonym>
        <rdfs:label>JAPIC clinical trials registry</rdfs:label>
        <rdfs:seeAlso>https://rctportal.niph.go.jp/en/</rdfs:seeAlso>
        <rdfs:seeAlso>https://www.japic.or.jp/</rdfs:seeAlso>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/primary/en/</rdfs:seeAlso>
    </owl:Class>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000020 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000020">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCIT_C98714"/>
        <obo:IAO_0000115>A centrally registered identifier that is assigned for a specific clinical trial registered in the Pan African clinical trial register. The format for the registry number is “KCT” followed by a 15-digit number, e.g., PACTR202004893013257.</obo:IAO_0000115>
        <oboInOwl:hasExactSynonym>PACTR identifier</oboInOwl:hasExactSynonym>
        <rdfs:label>Pan African clinical trial registry identifier</rdfs:label>
        <rdfs:seeAlso>https://pactr.samrc.ac.za/</rdfs:seeAlso>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/primary/en/</rdfs:seeAlso>
    </owl:Class>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000022 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000022">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCIT_C98714"/>
        <obo:IAO_0000115>A centrally registered identifier that is assigned for a specific clinical trial registered in the Chinese clinical trials register (ChiCTR). The format for the registry number is “ChiCTR” followed by a 10-digit number, e.g., ChiCTR2000031589.</obo:IAO_0000115>
        <obo:IAO_0000118>ChiCTR identifier</obo:IAO_0000118>
        <oboInOwl:hasExactSynonym>Chinese Clinical Trial Register number</oboInOwl:hasExactSynonym>
        <rdfs:label>Chinese clinical trail registry identifier</rdfs:label>
        <rdfs:seeAlso>http://www.chictr.org.cn/enIndex.aspx</rdfs:seeAlso>
    </owl:Class>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000023 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000023">
        <rdfs:subClassOf rdf:resource="https://bio.scai.fraunhofer.de/ontology/CTO_0000073"/>
        <obo:IAO_0000115>The Lebanese clinical trials registry  is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.</obo:IAO_0000115>
        <oboInOwl:hasExactSynonym>LBCTR</oboInOwl:hasExactSynonym>
        <rdfs:label>Lebanese clinical trials registry</rdfs:label>
        <rdfs:seeAlso>http://lbctr.emro.who.int/</rdfs:seeAlso>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/primary/en/</rdfs:seeAlso>
    </owl:Class>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000024 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000024">
        <rdfs:subClassOf rdf:resource="https://bio.scai.fraunhofer.de/ontology/CTO_0000073"/>
        <obo:IAO_0000115>German clinical trials register is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.</obo:IAO_0000115>
        <oboInOwl:hasExactSynonym>DRKS</oboInOwl:hasExactSynonym>
        <rdfs:label>German clinical trials register</rdfs:label>
        <rdfs:seeAlso>http://www.germanctr.de/</rdfs:seeAlso>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/primary/en/</rdfs:seeAlso>
    </owl:Class>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000025 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000025">
        <rdfs:subClassOf rdf:resource="https://bio.scai.fraunhofer.de/ontology/CTO_0000073"/>
        <obo:IAO_0000115>The JMACCT (Japan Medical Association, Center for Clinical Trials) clinical trials registry is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.</obo:IAO_0000115>
        <oboInOwl:hasExactSynonym>JMACCT</oboInOwl:hasExactSynonym>
        <rdfs:label>JMACCT clinical trials registry</rdfs:label>
        <rdfs:seeAlso>https://dbcentre3.jmacct.med.or.jp/jmactr/Default_Eng.aspx</rdfs:seeAlso>
        <rdfs:seeAlso>https://rctportal.niph.go.jp/en/</rdfs:seeAlso>
    </owl:Class>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000026 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000026">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCIT_C25150"/>
        <oboInOwl:hasExactSynonym>adult (18-64)</oboInOwl:hasExactSynonym>
        <rdfs:label>age_between_18_and_64</rdfs:label>
        <rdfs:seeAlso>https://clinicaltrials.gov/ct2/about-studies/glossary</rdfs:seeAlso>
    </owl:Class>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000028 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000028">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000027"/>
        <obo:IAO_0000115>The actual total number of participants that are enrolled in a clinical study</obo:IAO_0000115>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
        <oboInOwl:hasRelatedSynonym>enrollment</oboInOwl:hasRelatedSynonym>
        <oboInOwl:hasRelatedSynonym>sample size</oboInOwl:hasRelatedSynonym>
        <rdfs:label>number of participants</rdfs:label>
        <rdfs:seeAlso>http://www.icmje.org/recommendations/</rdfs:seeAlso>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="https://bio.scai.fraunhofer.de/ontology/CTO_0000028"/>
        <owl:annotatedProperty rdf:resource="http://www.geneontology.org/formats/oboInOwl#hasRelatedSynonym"/>
        <owl:annotatedTarget>enrollment</owl:annotatedTarget>
        <rdfs:isDefinedBy>https://prsinfo.clinicaltrials.gov/definitions.html</rdfs:isDefinedBy>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="https://bio.scai.fraunhofer.de/ontology/CTO_0000028"/>
        <owl:annotatedProperty rdf:resource="http://www.geneontology.org/formats/oboInOwl#hasRelatedSynonym"/>
        <owl:annotatedTarget>sample size</owl:annotatedTarget>
        <rdfs:isDefinedBy>http://www.who.int/ictrp/network/trds/en/index.html</rdfs:isDefinedBy>
    </owl:Axiom>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000030 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000030">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCIT_C98714"/>
        <obo:IAO_0000115>A centrally registered identifier that is assigned for a specific clinical trial registered in  Brazilian Registry of Clinical Trials (ReBEC). The format for the ReBEC registry number is “RBR-” followed by  6 characters, e.g., RBR-4hb9qs.</obo:IAO_0000115>
        <oboInOwl:hasExactSynonym>Brazilian Registry of Clinical Trials identifier</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>ReBEC identifier</oboInOwl:hasExactSynonym>
        <rdfs:label>Brazilian clinical trial registry identifier</rdfs:label>
        <rdfs:seeAlso>http://www.ensaiosclinicos.gov.br/</rdfs:seeAlso>
    </owl:Class>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000031 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000031">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OPMI_0000367"/>
        <obo:IAO_0000115>Clinical trial phase that is a combination of phases 2 and 3.</obo:IAO_0000115>
        <oboInOwl:hasExactSynonym>Phase 2/3</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Phase 2/Phase 3</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Phase I/II</oboInOwl:hasExactSynonym>
        <rdfs:label>clinical trial phase 2/3</rdfs:label>
        <rdfs:seeAlso>https://prsinfo.clinicaltrials.gov/definitions.html</rdfs:seeAlso>
    </owl:Class>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000032 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000032">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000027"/>
        <obo:IAO_0000115>data item ....</obo:IAO_0000115>
        <rdfs:label>study result</rdfs:label>
    </owl:Class>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000033 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000033">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0500027"/>
        <obo:IAO_0000115>A type of eligibility criteria that indicates whether people who do not have the condition/disease being studied can participate in that clinical study.</obo:IAO_0000115>
        <obo:IAO_0000115>Indication that participants who do not have a disease or condition, or related conditions or symptoms, under study in the clinical study are permitted to participate in the clinical study.</obo:IAO_0000115>
        <oboInOwl:hasExactSynonym>accepts healthy volunteers</oboInOwl:hasExactSynonym>
        <rdfs:label>healthy volunteer criterion</rdfs:label>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/trds/en/</rdfs:seeAlso>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="https://bio.scai.fraunhofer.de/ontology/CTO_0000033"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>A type of eligibility criteria that indicates whether people who do not have the condition/disease being studied can participate in that clinical study.</owl:annotatedTarget>
        <obo:IAO_0000119>https://clinicaltrials.gov/ct2/about-studies/glossary</obo:IAO_0000119>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="https://bio.scai.fraunhofer.de/ontology/CTO_0000033"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>Indication that participants who do not have a disease or condition, or related conditions or symptoms, under study in the clinical study are permitted to participate in the clinical study.</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000034 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000034">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCIT_C25150"/>
        <oboInOwl:hasExactSynonym>child (birth-17)</oboInOwl:hasExactSynonym>
        <rdfs:label>age_between_birth_and_17_years</rdfs:label>
    </owl:Class>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000035 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000035">
        <rdfs:subClassOf rdf:resource="https://bio.scai.fraunhofer.de/ontology/CTO_0000051"/>
        <obo:IAO_0000115>A description of each primary outcome measure (or for observational studies, specific key measurement[s] or observation[s] used to describe patterns of diseases or traits or associations with exposures, risk factors or treatment).
Each primary outcome measure information includes title, description and time frame.</obo:IAO_0000115>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
        <oboInOwl:hasRelatedSynonym>primary end point</oboInOwl:hasRelatedSynonym>
        <oboInOwl:hasRelatedSynonym>primary outcome(s)</oboInOwl:hasRelatedSynonym>
        <rdfs:label>primary outcome measure information</rdfs:label>
        <rdfs:seeAlso>https://clinicaltrials.gov/ct2/about-studies/glossary</rdfs:seeAlso>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="https://bio.scai.fraunhofer.de/ontology/CTO_0000035"/>
        <owl:annotatedProperty rdf:resource="http://www.geneontology.org/formats/oboInOwl#hasRelatedSynonym"/>
        <owl:annotatedTarget>primary end point</owl:annotatedTarget>
        <rdfs:seeAlso>https://www.clinicaltrialsregister.eu/doc/EU_Clinical_Trials_Register_Glossary.pdf</rdfs:seeAlso>
    </owl:Axiom>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="https://bio.scai.fraunhofer.de/ontology/CTO_0000035"/>
        <owl:annotatedProperty rdf:resource="http://www.geneontology.org/formats/oboInOwl#hasRelatedSynonym"/>
        <owl:annotatedTarget>primary outcome(s)</owl:annotatedTarget>
        <rdfs:isDefinedBy>https://www.who.int/ictrp/network/trds/en/</rdfs:isDefinedBy>
    </owl:Axiom>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000036 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000036">
        <rdfs:subClassOf rdf:resource="https://bio.scai.fraunhofer.de/ontology/CTO_0000073"/>
        <obo:IAO_0000115>The EU clinical trials register is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.</obo:IAO_0000115>
        <oboInOwl:hasExactSynonym>EU-CTR</oboInOwl:hasExactSynonym>
        <rdfs:label>EU clinical trials register</rdfs:label>
        <rdfs:seeAlso>https://eudract.ema.europa.eu/</rdfs:seeAlso>
        <rdfs:seeAlso>https://www.clinicaltrialsregister.eu</rdfs:seeAlso>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/primary/en/</rdfs:seeAlso>
    </owl:Class>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000037 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000037">
        <rdfs:subClassOf rdf:resource="https://bio.scai.fraunhofer.de/ontology/CTO_0000073"/>
        <obo:IAO_0000115>The UMIN (University Hospital Medical Information Network Center) clinical trials registry is a Japanese primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.</obo:IAO_0000115>
        <oboInOwl:hasExactSynonym>UMIN CTR</oboInOwl:hasExactSynonym>
        <rdfs:label>UMIN clinical trials registry</rdfs:label>
        <rdfs:seeAlso>https://rctportal.niph.go.jp/en/</rdfs:seeAlso>
        <rdfs:seeAlso>https://www.umin.ac.jp/ctr/</rdfs:seeAlso>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/primary/en/</rdfs:seeAlso>
    </owl:Class>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000038 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000038">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCIT_C25150"/>
        <oboInOwl:hasExactSynonym>older adult (65+)</oboInOwl:hasExactSynonym>
        <rdfs:label>age_older_than_64</rdfs:label>
        <rdfs:seeAlso>https://clinicaltrials.gov/ct2/about-studies/glossary</rdfs:seeAlso>
    </owl:Class>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000039 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000039">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000088"/>
        <obo:IAO_0000115>Data generated from measurement of experimental variables in a study, or for observational studies, from descriptions of patterns of diseases or traits or associations with exposures, risk factors or treatment.</obo:IAO_0000115>
        <rdfs:label>outcome measure result</rdfs:label>
    </owl:Class>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000040 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000040">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OPMI_0000326"/>
        <obo:IAO_0000115>Indicate whether a clinical study has been reviewed and approved by at least one human subjects protection review board or such review is not required per applicable law (for example, 21 CFR Part 56, 45 CFR Part 46, or other applicable regulation).</obo:IAO_0000115>
        <rdfs:label>human subjects protection review board status</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="https://bio.scai.fraunhofer.de/ontology/CTO_0000040"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>Indicate whether a clinical study has been reviewed and approved by at least one human subjects protection review board or such review is not required per applicable law (for example, 21 CFR Part 56, 45 CFR Part 46, or other applicable regulation).</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000041 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000041">
        <rdfs:subClassOf rdf:resource="https://bio.scai.fraunhofer.de/ontology/CTO_0000073"/>
        <obo:IAO_0000115>ClinicalTrials.gov is a registry of clinical trials.</obo:IAO_0000115>
        <obo:IAO_0000115>The Korean clinical trials registry (Clinical Research Information Service (CRiS), Republic of Korea) is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.</obo:IAO_0000115>
        <oboInOwl:hasExactSynonym>CRiS</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Clinical Research Information Service, Republic of Korea</oboInOwl:hasExactSynonym>
        <rdfs:label>Korean clinical trials registry</rdfs:label>
        <rdfs:seeAlso>http://cris.nih.go.kr/cris/en/use_guide/cris_introduce.jsp</rdfs:seeAlso>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/primary/en/</rdfs:seeAlso>
    </owl:Class>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000043 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000043">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OPMI_0000367"/>
        <obo:IAO_0000115>Trials without phases (for example, studies of devices or behavioral interventions).</obo:IAO_0000115>
        <oboInOwl:hasExactSynonym>N/A</oboInOwl:hasExactSynonym>
        <rdfs:label>phase not applicable</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="https://bio.scai.fraunhofer.de/ontology/CTO_0000043"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>Trials without phases (for example, studies of devices or behavioral interventions).</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000044 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000044">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0500000"/>
        <obo:IAO_0000115>Look back using observations collected predominantly prior to subject selection and enrollment</obo:IAO_0000115>
        <rdfs:label>retrospective study design</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="https://bio.scai.fraunhofer.de/ontology/CTO_0000044"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>Look back using observations collected predominantly prior to subject selection and enrollment</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000045 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000045">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCIT_C98714"/>
        <obo:IAO_0000115>A centrally registered identifier that is assigned for a specific clinical trial registered in the international standard randomised controlled trial register  (ISRCT). The format for the registry number is “ISRCTN” followed by a 8-digit number, e.g., ISRCTN14966673.</obo:IAO_0000115>
        <oboInOwl:hasExactSynonym>ISRCTN</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>International Standard Randomised Controlled Trial Number</oboInOwl:hasExactSynonym>
        <rdfs:label>International standard randomised controlled trial register identifier</rdfs:label>
        <rdfs:seeAlso>http://www.isrctn.com/</rdfs:seeAlso>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/primary/en/</rdfs:seeAlso>
    </owl:Class>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000046 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000046">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OPMI_0000367"/>
        <obo:IAO_0000115>Clinical trial phase that is a combination of phases 1 and 2.</obo:IAO_0000115>
        <oboInOwl:hasExactSynonym>Phase 1/2</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Phase 1/Phase 2</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Phase I/II</oboInOwl:hasExactSynonym>
        <rdfs:label>clinical trial phase 1/2</rdfs:label>
        <rdfs:seeAlso>https://prsinfo.clinicaltrials.gov/definitions.html</rdfs:seeAlso>
    </owl:Class>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000047 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000047">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OBI_0500000"/>
        <obo:IAO_0000115>Look forward using periodic observations collected predominantly following subject enrollment</obo:IAO_0000115>
        <rdfs:label>prospective study design</rdfs:label>
    </owl:Class>
    <owl:Axiom>
        <owl:annotatedSource rdf:resource="https://bio.scai.fraunhofer.de/ontology/CTO_0000047"/>
        <owl:annotatedProperty rdf:resource="http://purl.obolibrary.org/obo/IAO_0000115"/>
        <owl:annotatedTarget>Look forward using periodic observations collected predominantly following subject enrollment</owl:annotatedTarget>
        <obo:IAO_0000119>https://prsinfo.clinicaltrials.gov/definitions.html</obo:IAO_0000119>
    </owl:Axiom>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000048 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000048">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCIT_C98714"/>
        <obo:IAO_0000115>A centrally registered identifier that is assigned for a specific clinical trial registered in the Thai clinical trials registry  (TCTR). The format for the registry number is “TCTR” followed by a 11-digit number, e.g., TCTR20200405001</obo:IAO_0000115>
        <oboInOwl:hasExactSynonym>TCTR identifier</oboInOwl:hasExactSynonym>
        <rdfs:label>Thai clinical trials registry identifier</rdfs:label>
        <rdfs:seeAlso>http://www.clinicaltrials.in.th/</rdfs:seeAlso>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/primary/en/</rdfs:seeAlso>
    </owl:Class>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000049 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000049">
        <rdfs:subClassOf rdf:resource="https://bio.scai.fraunhofer.de/ontology/CTO_0000073"/>
        <obo:IAO_0000115>The Chinese clinical trial registry is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.</obo:IAO_0000115>
        <oboInOwl:hasExactSynonym>ChiCTR</oboInOwl:hasExactSynonym>
        <rdfs:label>Chinese clinical trial registry</rdfs:label>
        <rdfs:seeAlso>http://www.chictr.org.cn/</rdfs:seeAlso>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/primary/en/</rdfs:seeAlso>
    </owl:Class>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000050 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000050">
        <rdfs:subClassOf rdf:resource="https://bio.scai.fraunhofer.de/ontology/CTO_0000073"/>
        <obo:IAO_0000115>The Thai clinical trials registry  is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.</obo:IAO_0000115>
        <oboInOwl:hasExactSynonym>TCTR</oboInOwl:hasExactSynonym>
        <rdfs:label>Thai clinical trials registry</rdfs:label>
        <rdfs:seeAlso>http://www.clinicaltrials.in.th/</rdfs:seeAlso>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/primary/en/</rdfs:seeAlso>
    </owl:Class>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000051 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000051">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IAO_0000033"/>
        <obo:IAO_0000115>A description of the outcome measure in an interventional study or for observational studies, specific key measurement[s] or observation[s] used to describe patterns of diseases or traits or associations with exposures, risk factors or treatment.</obo:IAO_0000115>
        <rdfs:label>outcome specification</rdfs:label>
        <rdfs:seeAlso>https://clinicaltrials.gov/ct2/about-studies/glossary</rdfs:seeAlso>
    </owl:Class>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000052 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000052">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCIT_C98714"/>
        <obo:IAO_0000115>A centrally registered identifier that is assigned for a specific clinical trial registered in the Indian clinical trial register. The format for the registry number is “CRTI/” followed  by a 4-digit number, followed by a slash, followed a 2-digit number, followed by a slash, followed a 6-digit number, e.g., CTRI/2020/03/024402.</obo:IAO_0000115>
        <oboInOwl:hasExactSynonym>CRTI identifier</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Clinical Trials Registry - India identifier</oboInOwl:hasExactSynonym>
        <rdfs:label>Indian clinical trial registry identifier</rdfs:label>
        <rdfs:seeAlso>http://ctri.nic.in/Clinicaltrials/login.php</rdfs:seeAlso>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/primary/en/</rdfs:seeAlso>
    </owl:Class>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000053 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000053">
        <rdfs:subClassOf rdf:resource="https://bio.scai.fraunhofer.de/ontology/CTO_0000073"/>
        <obo:IAO_0000115>The Brazilian clinical trials registry is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.</obo:IAO_0000115>
        <oboInOwl:hasExactSynonym>ReBec</oboInOwl:hasExactSynonym>
        <rdfs:label>Brazilian clinical trials registry</rdfs:label>
        <rdfs:seeAlso>http://www.ensaiosclinicos.gov.br/</rdfs:seeAlso>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/primary/en/</rdfs:seeAlso>
    </owl:Class>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000054 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000054">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OPMI_0000356"/>
        <obo:IAO_0000115>A centrally registered identifier that is assigned for a specific clinical trial registered in the Japan Registry of Clinical Trials (jRCT). The format for the registry number is “jRCTs” followed by a 9-digit number, e.g., JPRN-jRCTs031190227</obo:IAO_0000115>
        <oboInOwl:hasExactSynonym>Japan registry of clinical trials identifier</oboInOwl:hasExactSynonym>
        <rdfs:label>jRCT clinical trial identifier</rdfs:label>
        <rdfs:seeAlso>https://jrct.niph.go.jp/</rdfs:seeAlso>
        <rdfs:seeAlso>https://rctportal.niph.go.jp/en/</rdfs:seeAlso>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/primary/en/</rdfs:seeAlso>
    </owl:Class>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000055 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000055">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCIT_C98714"/>
        <obo:IAO_0000115>A centrally registered identifier that is assigned for a specific clinical trial registered in the Cuban public registry of clinical trials (RPCEC). The format for the registry number is “RPCEC” followed by a 8-digit number, e.g., RPCEC00000306.</obo:IAO_0000115>
        <oboInOwl:hasExactSynonym>RPCEC identifier</oboInOwl:hasExactSynonym>
        <rdfs:label>Cuban public registry of clinical trials identifier</rdfs:label>
        <rdfs:seeAlso>http://registroclinico.sld.cu/en/home</rdfs:seeAlso>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/primary/en/</rdfs:seeAlso>
    </owl:Class>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000056 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000056">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/NCIT_C98714"/>
        <obo:IAO_0000115>A centrally registered identifier that is assigned for a specific clinical trial registered in the Lebanese clinical trials registry  (LBCTR). The format for the registry number is “LBCTR” followed by a 10-digit number, e.g., LBCTR2020043459.</obo:IAO_0000115>
        <rdfs:label>Lebanese clinical trials registry identifier</rdfs:label>
        <rdfs:seeAlso>LBCTR identifier</rdfs:seeAlso>
        <rdfs:seeAlso>http://lbctr.emro.who.int/</rdfs:seeAlso>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/primary/en/</rdfs:seeAlso>
    </owl:Class>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000073 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000073">
        <rdfs:subClassOf rdf:resource="https://bio.scai.fraunhofer.de/ontology/CTO_0000076"/>
        <obo:IAO_0000115>A primary registry is clinical trial registry in the WHO registry network that meet specific criteria for content, quality and validity, accessibility, unique identification, technical capacity and administration. Primary registries also meet the requirements of the International Clinical Trials Registry Platform (ICMJE).</obo:IAO_0000115>
        <rdfs:label xml:lang="en">primary registry</rdfs:label>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/primary/en/</rdfs:seeAlso>
    </owl:Class>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000074 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000074">
        <rdfs:subClassOf rdf:resource="https://bio.scai.fraunhofer.de/ontology/CTO_0000073"/>
        <obo:IAO_0000115>The Peruvian clinical trial registry is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.</obo:IAO_0000115>
        <oboInOwl:hasExactSynonym>REPEC</oboInOwl:hasExactSynonym>
        <rdfs:label xml:lang="en">Peruvian clinical trial registry</rdfs:label>
        <rdfs:seeAlso>https://ensayosclinicos-repec.ins.gob.pe/en/</rdfs:seeAlso>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/primary/en/</rdfs:seeAlso>
    </owl:Class>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000075 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000075">
        <rdfs:subClassOf rdf:resource="https://bio.scai.fraunhofer.de/ontology/CTO_0000073"/>
        <obo:IAO_0000115>The Sri Lanka clinical trials registry is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.</obo:IAO_0000115>
        <oboInOwl:hasExactSynonym>SLCTR</oboInOwl:hasExactSynonym>
        <rdfs:label xml:lang="en">Sri Lanka clinical trials registry</rdfs:label>
        <rdfs:seeAlso>http://www.slctr.lk/</rdfs:seeAlso>
        <rdfs:seeAlso>https://www.who.int/ictrp/network/primary/en/</rdfs:seeAlso>
    </owl:Class>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000076 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000076">
        <rdfs:subClassOf rdf:resource="https://bio.scai.fraunhofer.de/ontology/CTO_0000077"/>
        <obo:IAO_0000115>ClinicalTrials.gov is a registry for clinical trials.</obo:IAO_0000115>
        <oboInOwl:hasExactSynonym>ClinicalTrials.gov</oboInOwl:hasExactSynonym>
        <rdfs:label xml:lang="en">ClinicalTrial.gov registry</rdfs:label>
        <rdfs:seeAlso>https://clinicaltrials.gov/</rdfs:seeAlso>
    </owl:Class>
    


    <!-- https://bio.scai.fraunhofer.de/ontology/CTO_0000077 -->

    <owl:Class rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000077">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/ERO_0001843"/>
        <obo:IAO_0000115>A clinical trials registry is a specifc registry type that enables the registration and documentation of clinical trials.</obo:IAO_0000115>
        <rdfs:label xml:lang="en">clinical trials registry</rdfs:label>
    </owl:Class>
    


    <!-- 
    ///////////////////////////////////////////////////////////////////////////////////////
    //
    // Individuals
    //
    ///////////////////////////////////////////////////////////////////////////////////////
     -->

    


    <!-- http://purl.obolibrary.org/obo/IAO_0000122 -->

    <owl:Thing rdf:about="http://purl.obolibrary.org/obo/IAO_0000122">
        <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#NamedIndividual"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/IAO_0000078"/>
        <rdfs:label xml:lang="en">ready for release</rdfs:label>
    </owl:Thing>
    


    <!-- http://purl.obolibrary.org/obo/IAO_0000123 -->

    <owl:Thing rdf:about="http://purl.obolibrary.org/obo/IAO_0000123">
        <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#NamedIndividual"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/IAO_0000078"/>
        <rdfs:label xml:lang="en">metadata incomplete</rdfs:label>
    </owl:Thing>
    


    <!-- http://purl.obolibrary.org/obo/IAO_0000125 -->

    <owl:Thing rdf:about="http://purl.obolibrary.org/obo/IAO_0000125">
        <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#NamedIndividual"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/IAO_0000078"/>
        <rdfs:label xml:lang="en">pending final vetting</rdfs:label>
    </owl:Thing>
    


    <!-- http://purl.obolibrary.org/obo/iao.owl -->

    <owl:NamedIndividual rdf:about="http://purl.obolibrary.org/obo/iao.owl"/>
    


    <!-- http://purl.obolibrary.org/obo/obi.owl -->

    <owl:NamedIndividual rdf:about="http://purl.obolibrary.org/obo/obi.owl"/>
    <rdf:Description>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/obi.owl"/>
    </rdf:Description>
    <rdf:Description>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/omrse.owl"/>
    </rdf:Description>
    


    <!-- 
    ///////////////////////////////////////////////////////////////////////////////////////
    //
    // Annotations
    //
    ///////////////////////////////////////////////////////////////////////////////////////
     -->

    <rdf:Description rdf:about="http://purl.obolibrary.org/obo/omrse.owl">
        <rdfs:label xml:lang="en">The Ontology of Medically Related Social Entities</rdfs:label>
    </rdf:Description>
    <rdf:Description rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000021">
        <obo:IAO_0000115>A centrally registered identifier that is assigned for a specific clinical trial registered in the Korean Clinical Research Information Service (CRIS). The format for the registry number is “KCT” followed by a 7-digit number, e.g., KCT0004537.</obo:IAO_0000115>
        <rdfs:label>Korean clinical trial registry identifier</rdfs:label>
        <oboInOwl:hasExactSynonym>CRIS identifier</oboInOwl:hasExactSynonym>
        <rdfs:seeAlso>http://cris.nih.go.kr/cris/en/use_guide/cris_introduce.jsp</rdfs:seeAlso>
    </rdf:Description>
    <rdf:Description rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000027">
        <rdfs:seeAlso>https://slctr.lk/</rdfs:seeAlso>
        <rdfs:label>Sri Lanka clinical trials registry identifier</rdfs:label>
        <obo:IAO_0000115>A centrally registered identifier that is assigned for a specific clinical trial registered in the Sri Lanka clinical trials registry (SLCTR ). The format for the registry number is “SLCTR /” followed  by a 4-digit number, followed by a slash, followed a 3-digit number, e.g., SLCTR/2020/010</obo:IAO_0000115>
        <oboInOwl:hasExactSynonym>SLCTR identifier</oboInOwl:hasExactSynonym>
    </rdf:Description>
    <rdf:Description rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000029">
        <rdfs:label>jRTC clinical trials register</rdfs:label>
        <obo:IAO_0000115>The jRTC (Japan Registry of Clinical Trials) clinical trial registry is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.</obo:IAO_0000115>
        <rdfs:seeAlso>https://jrct.niph.go.jp/</rdfs:seeAlso>
        <oboInOwl:hasExactSynonym>Japan Registry of Clinical Trials</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>jRTC</oboInOwl:hasExactSynonym>
        <rdfs:seeAlso>https://rctportal.niph.go.jp/en/</rdfs:seeAlso>
    </rdf:Description>
    <rdf:Description rdf:about="https://bio.scai.fraunhofer.de/ontology/CTO_0000042">
        <oboInOwl:hasExactSynonym>ISRCTN</oboInOwl:hasExactSynonym>
        <rdfs:seeAlso>http://www.isrctn.com/</rdfs:seeAlso>
        <rdfs:label>International standard randomised controlled trial register</rdfs:label>
        <obo:IAO_0000115>The international standard randomised controlled trial register is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.</obo:IAO_0000115>
    </rdf:Description>
</rdf:RDF>



<!-- Generated by the OWL API (version 4.5.6) https://github.com/owlcs/owlapi -->

